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Gastric cancer (GC) is second only to lung cancer as a leading cause of cancer 
deaths globally. Of the estimated 1 million newly diagnosed patients 
annually1, up to 80% have advanced incurable disease. Even after surgery with 
curative intent, 60% progress to locoregional and/or distant metastatic 
disease2. As only surgery is potentially curative for GC, other treatments, 
including molecularly targeted agents, are urgently needed for the majority 
who are beyond surgical cure. One strategy for developing new curative 
treatment is to identify genetic and genomic aberrations that are causal in the 
initiation and/or progression of specific cancer types. Discoveries of druggable 
cytogenetic signatures have advanced prognostication and extended the 
survival of several hematologic malignancies3
The notable lack of reliable karyotypic data in most solid cancers has 
encouraged the view that translocations are rarely associated with epithelial 
cancer development. Fortunately, molecular cytogenetic techniques (e.g. 
comparative genomic hybridization, spectral karyotyping, multicolor 
fluorescence in situ hybridization (FISH), high resolution copy number and 
tiling arrays, genome annotations and bioinformatics) have made solid tumor 
cytogenetics more tractable, as demonstrated by recent discoveries of recurrent 
translocations in human prostate adenocarcinomas
.  
4 and non-small cell lung 
cancer5. These signature translocations impute shared oncogenic mechanisms 
among solid cancers and hematopoetic malignancies6
Our exploration of this dreaded disease begins with a broad survey of the 
current state of knowledge in five chapters. Chapter 1 reviews the current 




discussion of current management and treatment options. Chapter 2 explores 
the interplay of various environmental as well as host and/or bacterial 
susceptibility factors that may be associated with GC initiation and 
progression. In Chapter 3, we examine the African and Asian enigmas – 
apparent paradoxes in which high H. pylori infectivity coexists with low GC 
prevalence. As cancer is caused and accompanied by structural and functional 
genomic alterations, Chapter 4 summarizes and evaluates current 
understanding of the molecular pathogenesis of GC. In Chapter 5, we review 
signature chromosomal rearrangements in malignant disorders and particularly 
note recent discoveries of such translocations in prostate and lung cancers.  
 
Chapter 6 details all methods, materials and resources employed in this 
project.  
 
Data generated in this project appear in Chapters 7 – 14.  Our work was 
directed at five primary goals:  
1) To characterize the chromosomal rearrangements, copy number 
alterations, differentially expressed mRNAs and miRNAs in a survey 
of 17 GC cell lines as a means of documenting the genomic 
complexities of GC. These datasets enabled identification of unique 
GC signatures based on copy number aberrations and mRNA 
expression profiles compared to a well known panel of non-GC cell 




2) To explore the utility of integrating different molecular cytogenetic 
techniques to fully characterize the fusion breakpoints in a simple 
rearranged GC cell line, SNU-1, and to propose a translocation 
mechanism (Chapter 9).  
3) To distinguish “driver” (pathogenic) from “passenger” (collateral) 
rearrangements.  Data in Chapters 10 and 11 showed that the novel and 
recurrent 18q translocation breakpoint in cell lines was also mirrored in 
primary GC tumors (but not in non-GC tumors) via a custom-designed 
break-apart FISH assay.  
4) To ascertain clinico-pathological features of 18q breakpoint-positive 
GCs and to determine chromosome 18 status in pre-malignant lesions 
(Chapter 12). These include analysis of the expression of two 
candidate proteins, Serpin B8 and CD226 antigen by 
immunohistochemistry (Chapter 13).   
5) To molecularly define junctional DNA of candidate chromosomal 
fusions, pure fractions of translocated chromosomes were flow-sorted 
and their breakpoints accurately determined using oligo-based array 
painting techniques (Chapter 14).  
 
In short, this project highlights the value of integrating a suite of molecular 
cytogenetic techniques with other genome-wide analyses in discovering 
genomic signatures of GC. This integrated approach makes solid tumor 
cytogenetics more tractable, is generalizable and could help to discover 
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1.1.1 Global incidence and mortality   
Adenocarcinomas account for close to 95% of all malignant gastric tumors, 
the remaining being stromal cell tumors, lymphomas, leiomyosarcomas, other 
rare sarcomas and carcinoids. Being by far the most common type of 
malignant stomach tumor, gastric adenocarcinomas are generally referred to as 
gastric cancer (GC) in the research literature, a usage that will be adopted in 
this thesis. GC is a significant global health burden. It is the fourth most 
common cancer after breast, lung and prostate but the second leading cause of 
cancer mortality (after lung cancer). Globally, an estimated 1 million new 
cases are diagnosed each year (Figure 1-1), and more than 800,000 deaths 












Figure 1-1 Global incidence and mortality of the most common cancers. The 
bar chart shows estimates of age-specific cancer rates (Adapted from ref. 2).    
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There is great geographical variation in GC incidence. The highest rates (> 40 
per 100,000) are in East Asia (Japan, China and Korea), South and Central 
America (Colombia, Costa Rica and El Salvador). North America and most of 
Western Europe, in contrast, have low incidence rates (< 10 per 100,000)3
 
 


































Figure 1-2 Global geographic variation in age-standardized incidence rates of 
GC among males (upper panel) and females (lower panel), (Adapted from ref. 
2).  
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GC incidence rates are 1.8 to 2.0 times higher in males than in females2. Apart 
from gender, ethnicity appears to be associated with differences in GC 
incidence. For example, in the United States, Asians and Pacific Islanders 
(APIs) and black men have high age-standardized rates (ASR) of 18.6 and 
17.4 cases per 100,000, respectively, compared to 10.0 per 100,000 in 
Caucasian men (Table 1-1).  Similarly, ASR of API and black women are 
almost twice as high at 10.5 and 8.9 per 100,000, respectively versus 4.7 per 
100,000 in Caucasian women. Native and Hispanic Americans are also twice 
as likely to develop GC compared to the white population3-5
Table 1-1 Age-adjusted incidence and mortality rates of GC by ethnicity 
(2001-2005) based on cancer registries in 17 designated SEER (Surveillance, 
Epidemiology and End Results Program) geographic areas in the USA 
(Adapted from ref. 3). 
. The higher ASR 
in African-Americans, Hispanics and Asians may be partly due to their 
relatively lower socio-economic status, poor access to healthcare and possibly, 







In the early 20
1.1.2 Chronological trends 
th
Race/Ethnicity Male Female Male Female
All Races 11.3 5.5 5.7 2.9
White 10.0 4.7 5.0 2.5
Black 17.4 8.9 11.5 5.5
Asian/Pacific Islander 18.6 10.5 10.1 5.9
American Indian/Alaska Native 16.8 7.7 9.9 5.2





 century, GC was the leading cause of cancer mortality among 
men and second after uterine cancer among women in the USA. Since the 
1930’s, Western nations have experienced a steady and substantial decline in 
GC incidence rates.  This striking reduction in GC incidence, especially 
among the white population in the US, has been characterized as an 
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“unplanned triumph” insofar as it was an unintended but welcomed benefit of 
refrigeration technology, improved food hygiene, increased availability and 
consumption of fresh vegetables (all of which reduced exposure to putative 
gastrointestinal carcinogens), and possibly to lower H. pylori infections rates 
in the developed countries6
 
. This pattern of decline has also occurred, albeit to 
a lesser extent, in high risk countries such as Japan and China (Figure 1-3) 













Figure 1-3 Stomach cancer incidence rates (1973-1997) obtained from 18 
cancer registries in Asia, Europe and the USA (Adapted from ref. 7). 
The foregoing epidemiologic data does not detail the occurrence of GCs in 
different anatomic regions within the stomach but rather group all GCs 
together regardless of their intra-gastric location. The stomach is a relatively 
large organ which extends from the gastroesophageal junction to the pylorus. 
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It is divided into five regions (named from proximal to distal): cardia, fundus, 










Figure 1-4 The anatomic divisions of the human stomach (Illustration from 
ref. 8).  
 
Since the mid-1970s, GCs of the cardia have increased in incidence especially 
among white males in North America and Europe9-11. Proximal GCs are 
biologically more aggressive and have a poorer prognosis. In high risk Asian 
nations, reports of increasing proximal GC incidence are mixed. Data from 
Korea showed no apparent increase in a 10-year study12. A marginal increase 
of less than 6% in proximal GCs in Japan was recorded among 843 patients 
during the period 1981-200513. A recent analysis of 65,284 cases of upper 
gastrointestinal endoscopies in a high incidence region of China, Gansu 
province, also showed a steady rise in the incidence of proximal GCs (cardia 
and body) over a 12-year period (1993-2004)14. Despite these trends, it is 
important to note that GCs of the distal stomach remain predominant in East 
Asia as reported in these three studies. However, as obesity becomes more 
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prevalent among Asian populations, the rising trend of cardia cancers may be 
replicated in Asia in the future. 
 
GC is the 5
1.1.3 Singapore incidence and mortality   
th most frequent cancer among males and 7th among females in 
Singapore (Figure 1-5). It ranks fourth as a cause of cancer mortality, having 




















Figure 1-5 Age-standardized cancer incidence and mortality rates of common 
cancers in Singapore (Adapted from ref. 15). 
As in other countries, GC incidence rates are higher in males than females 
(1.5:1) (Figure 1-6a). In tandem with declining global rates, Singapore has 
also seen a steady decrease in age-standardized incidence rates from 37 per 
100,000 persons in the late 1960’s to < 20 per 100,000 among males at the 
turn of the new millennium. GC is more common in older patients, with 
incidence rates rising sharply after age 50 (Figure 1-6b).  Notwithstanding the 
declining incidence, longer life expectancy in Singapore as in other newly 
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emerging Asian countries, suggests that the clinical burden of GC is unlikely 
























Figure 1-6 Age-standardized GC incidence rates in males and females by (a) 
quinquennia (1968-2002); and (b) age (1998-2002), (Adapted from ref. 16). 
 
Singapore is an island nation with a multi-ethnic resident population of 3.6 
million comprising 75.2% Chinese, 13.6% Malays, 8.8% Indians and 2.4% 
Eurasians and other minority groups. The remaining 0.88 million are 
temporary residents (mainly Asians). Local GC incidence shows a clear ethnic 
pattern (Table 1-2). Chinese males and females have the highest incidence 
compared to Indians and Malays. Males of the latter group have a relative risk 
(RR < 0.4) of developing GC that is almost three times lower than Chinese 
males (RR = 1.0). Having attained developed country status, socio-economic 
conditions and access to healthcare are comparable among Singapore’s three 
major ethnic groups. These highly disparate GC risks thus implicate host 
(a) (b) 
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genetic differences or polymorphisms and possible culture-specific practices 
as factors that contribute to this interesting ethnicity-associated incidence 
pattern.     
 
Table 1-2 Age-standardized incidence data of GC in the major ethnic groups 

















As with most other Asian nations, the increase in incidence of cardia tumors is 
said to be less pronounced in Singapore17,18 although reliable epidemiologic 
data are not available to confirm this impression. However, crude incidence 
rates of distally located GCs are reportedly > 3-fold higher than proximal 
GCs18
 
.   
1.2 Clinical features, prognosis and treatment 
Despite a general global decline in GC incidence, overall mortality rates are 
still alarming. This dismal state of affairs is mainly due to the fact that, 
whereas early stage GC has an excellent prognosis, the majority of 
symptomatic stomach cancer patients have already progressed to advanced 
incurable disease at the time of presentation. These are usually sporadic (i.e. 
1.2.1 Lethality of GC  
Race/Ethinicity ASR RR (95% CI) ASR RR (95% CI)
All residents 18.0 - 9.9 -
Chinese 21.4 1.0 10.8 1.0
Malays 6.6 0.3(0.3-0.4) 3.8 0.4(0.3-0.6)





ASR: age-standardized (to ‘World’ population) rate per 100,000/year 
RR: age-adjusted relative risk and 95% confidence interval for Malays and 
Indians (Chinese as the reference group) 
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non-familial) tumors that are locally invasive. In many cases, regional 
(abdominal lymph nodes, peritoneum, liver) and/or distant (lung, bone 
marrow) metastases are present at initial diagnosis. Early symptoms are nearly 
always non-specific, and hence more likely to be mistaken for functional 
dyspepsia, benign gastritis or peptic ulcer disease. Alarm symptoms associated 
with late stage disease include weight loss (62% of patients) and persistent 
abdominal pain (52%). Other less frequent symptoms are nausea, vomiting, 
dysphagia, anorexia, early satiety, fatigue, melena, and ulcer-like symptoms. 
Presenting symptoms may also reflect the location and type of tumor. For 
example, patients with cancers of the proximal stomach or gastoesophageal 
junction are likely to develop dysphagia. An advanced distal tumor is liable to 
cause gastric outlet obstruction. Scirrhous-type (linitis plastica) lesions tend to 





1.2.2 Prognosis and survival 
Prognostic assessment and critical treatment decisions of individual patients 
are guided by pathological stage classifications21. There are two major 
clinicopathological staging systems for GC. The Japanese staging system is 
more detailed and complex as it requires rigorous pathologic assessment of 
abdominal lymph nodes, considers peritoneal cytology and distinguishes 
clinical, surgical, pathologic and final stages22. Western and most other Asian 
countries use the simpler staging system jointly developed by the American 
Joint Committee on Cancer (AJCC) 23 and the International Union Against 
Cancer (UICC)24 in 2002. Stage grouping is based on 3 clinicopathologic 
categories:  1) Tumor(T): depth and extent of tumor invasion; 2) Node(N): 
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number of metastatic regional lymph nodes; and 3) Metastases (M): presence 
or absence of distant metastases. The TNM classification and stage grouping 
of stomach cancer is detailed in Table 1-3. Lymph node metastatic status (N) 
is a reliable prognostic indicator25. Five-year survival rates for N1, N2 and N3 
disease were reported to be 43%, 21% and 13%, respectively26. The overall 
prognosis and survival of GC by TNM staging is dismal for patients with late 
stage tumors (Figure 1-7). For example, 5-year survival rates for stage IIIa, 
IIIb and IV patients were 20, 8 and 7%, respectively. In the United States, 
overall 5-year survival was 23% in 20013. Similarly, analysis of pan-European 
data from 22 countries and 53 cancer registries reported an overall 5-year 
survival of just 21% in the period 1991-199427
Case control studies in Japan have shown that detection of early gastric cancer 
is enhanced through population screening of high-risk individuals and in turn, 
contributes to overall higher survival rates
. 
27-29 (> 50%, compared to < 21% in 
Europe).  The high cost of such screening programs, however, makes it 
difficult to implement in less affluent high risk countries30
Another factor that adversely affects GC prognosis is the high recurrence rate, 
usually occurring within 2-3 years of surgery, even after R0 resections 
(complete resections with histologically negative surgical margins). Adjuvant 
chemotherapy may be administered to eradicate micrometastases
.  
31. However, 
most high risk GC patients respond poorly to systemic adjuvant 
chemotherapy. Clinical trials using treatment regimens based on 5-fluorouracil 
in combination with anthracyclines and cisplatin have not markedly improved 
survival rates33-35. Toxicity can be significant in the elderly among whom GC 
is more common31.  
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Table 1-3 TNM classification and stage grouping (AJCC/UICC), (adapted 









































































Figure 1-7 Survival statistics by TNM stages (Adapted from ref. 21). 
 
 
1.2.3 Treatment strategies 
Surgical resection with curative intent remains the only treatment among 
current options with proven prospects for long-term survival. However even in 
specialized centers, surgery had managed to improved 5-year survival rates 
marginally to between 33-47%, depending on surgical skills and patient 
selection36,37.  While there are ongoing trials of non-surgical therapies, chemo-
, biologic and radiotherapy are not, on present evidence, curative.  
Nevertheless, there is good evidence to support the use of neoadjuvant 
perioperative chemotherapy in patients with locally advanced GC as a means 
of improving R0 resection rates38,39
Accurate pathologic staging of the disease i.e. the extent of tumor invasion 
and metastatic spread to regional lymph nodes, is critical to the assignment of 
. 
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appropriate treatment strategies. Availability of CT (computerized 
tomography) and FDG-PET (fluoro-deoxyglucose positron emission 
tomography) scans will, for example, enable the T stage and status of local 
and regional lymph nodes to be assessed more accurately40.  Improvements in 
staging techniques and fitness assessment have led to stage migration and 
better patient selection. This has ironically resulted in fewer than 20% of all 
GC patients being offered curative surgery in the UK28
 
. Thus, although 
reported post-operative survival has improved by 2- to 3-fold in major centers 
that practice careful patient selection, many older GC patients are less likely to 
meet stringent pre-surgical criteria. Table 1-4 summarizes the treatment 
options that are generally considered most appropriate for different pathologic 

















: Treatment strategies with reference to pathological stage of GC 
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In summary, GC is still a significant global health burden especially when 
multiple factors conspire to make its lethality rather intractable to 
improvement. These factors are mainly the absence of reliable (sensitive and 
specific) diagnostic methods for early gastric cancer, advanced disease stage 
in a majority of newly diagnosed patients, lack of effective targeted cytotoxic 
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2. Gastric cancer etiology 
 
GCs were classified into 2 main histological types by Lauren in 19651. The 
more common well-differentiated intestinal type typically evolves from 
precursor lesions such as gastric atrophy or intestinal metaplasia and has 
recognizable glandular epithelium composed of absorptive and globlet cells. 
Intestinal type GCs are predominant in older males in high risk regions, 
suggesting a close association with environmental factors.  Histopathological 
observations led Correa to propose a model of carcinogenesis for intestinal 
type GC in 1975. He suggested that GC arises through progressive evolution 
of gastric epithelium from chronic gastritis to chronic multifocal atrophic 
gastritis, intestinal metaplasia, dysplasia and finally, to adenocarcinoma2
 
. 
Diffuse type GC is poorly differentiated, with characteristic small, non-
cohesive cells. It is more frequent in younger patients, some of whom have a 
history of familial GC suggesting a genetic etiology or predisposition. Mixed 
GCs have features of both intestinal and diffuse types.  
The etiology of GC is almost certainly multifactorial. Significant global 
geographical variation exists. Seventy percent of new cases are estimated to 
occur in developing countries3. Demographic features of GC incidence also 
indicate that older males are at higher risk. Its association with socio-economic 
status has led some to regard GC as a “poor man’s” disease – with Japan being 
an exception to this coinage. Poor hygiene standards, diets rich in preserved 
food, alcohol, smoking, exposure to infectious agents have all been implicated 
as culpable environmental factors associated gastric oncogenesis. On the other 
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hand, host factors such as gender, blood group A and genetic polymorphisms 
may influence susceptibility to GC. Taken together, there is a considerable 




2.1 Environmental factors 
 
Low socio-economic status is associated with increased GC risk
2.1.1 Socio-economic status 
4-6. As shown 
in Figure 2-1, more than two-thirds (70%) of estimated new GC cases were 
contributed by developing countries. China alone made up to 42% of these 
cases, comprised mostly of non-cardia GCs. A recent large-scale European 
prospective study found that socio-economic status was inversely correlated 























Figure 2-1 Estimated number of new GC cases and deaths (‘000s) in 
developing (purple) and developed countries (beige). (Adapted from ref. 3). 
Estimated number of new cases and deaths in developed 
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Data correlating socio-economic status with cardia GC are mixed. A Dutch 
study demonstrated that increased of cardia cancer were predominant in the 
higher professional class8 but could not be confirmed in a similar investigation 
performed in Scotland9
A noteworthy feature of data shown in Figure 2-1 is the high mortality of GC 
i.e. the number of deaths from GC almost equals the number of newly 
diagnosed cases, especially in developing countries with suboptimal standards 
of medical care.  
. Confounding factors such as living conditions, 
variable composition of diets (e.g. availability of fresh fruits and vegetables), 
exposure to H. pylori, smoking health education and public health policies are 
difficult to “normalize” among different populations and make meaningful 
interpretation of observational data problematic. Hence, a direct association of 
the economic well-being of a country with GC incidence is challenging to 
establish as it is highly dependent on multiple variables that operate within the 
broad ambit of socio-economic status.  
 
Migrants of Asian descent in various countries have experienced a dramatic 
decrease in incidence rates by which each successive generation had rates 
closer to those of their host countries. This is illustrated by comparing GC 
mortality data of Japanese in Japan with 1
2.1.2 Migration 
st (Issei) and 2nd (Nisei) generation 
Japanese immigrants in California (Table 2-1). Using mortality rates of 
Californian whites as the reference, a remarkable decrease in GC death rates 
was evident among 1st generation Japanese immigrants compared with non-
immigrant Japanese. This declining trend continued in the 2nd generation to 
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reach levels similar to the white population in California10. Migrant Japanese 
residents of Sao Paulo, Brazil and Hawaii have also experienced a significant 
decrease in GC incidence compared to their country of origin11,12
Table 2-1 Mortality rates (1956-1962) of Japanese men from Japan, 1
. 
st 
generation ‘Issei’ and 2nd
 
 generation ‘Nisei’ Japanese migrants to California 














Adoption of a western lifestyle and diet is probably associated with this steep 
decline13-15
 
. These findings reiterate the influence of environmental factors 
early in life on the later risk of GC development. 
Rising affluence, energy availability and industrialization translated to 
increased affordability and availability of refrigeration, enabling food to be 
kept fresh for longer periods of time. The declining incidence of GC globally 
coincided with the widespread availability of domestic refrigerators along with 
the provision of fresh fruits and vegetables. A direct association between GC 
etiology and refrigeration is shrouded by conflicting reports. Studies from 
England, Germany and Venezuela showed an inverse relationship of GC risk 
to refrigeration when used for 29 years or longer











Stomach 8.4 3.8 2.8 1.0
Colon 0.2 0.4 0.9 1.0
Liver 4.1 2.7 2.2 1.0
Japanese
or in the first two decades 
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of life17. However, a large cohort study of 120,852 men and women conducted 




There is a substantial body of evidence showing the association of dietary 
factors to GC development. Several prospective studies and meta-analyses 
showed that high consumption of fruits and vegetables has an inverse 
relationship to GC risk
2.1.4 Diet 
20-22.  Case-control studies further supported this 
association23-25. However, data from two recent large cohort prospective 
investigations from Europe and the USA refuted the association of fruit and 
vegetable intake with reduction of GC risk26,27. The active ingredients in fruits 
and vegetables and their mechanistic effects, if any, in moderating gastric 
oncogenesis are unclear but have been suggested to involve antioxidants such 
as ascorbic acid, carotenoids and tocophenols. Ascorbic acid was shown to 
reduce formation of nitrites from nitrates28. Although supplementation with 
micronutrients such as vitamin C or vitamin E protected Mongolian gerbils 
against H. pylori-induced gastritis29, human trials conducted in Venezuela30 
and China31 concluded that vitamin supplementation had no beneficial effects 
for preventing GC. Reiterating an earlier study32, Bjelakovic et al. concluded 
in a recent systematic meta-analysis involving 20 studies, that antioxidant 
supplementation did not reduce GC risk33
Likewise, conflicting conclusions with regards to salt intake and GC risk were 
reported. Prospective studies from Japan suggested that high dietary salt intake 
was significantly associated with increased GC risk
.  
34-36. Conversely, two 
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studies from the Netherlands19 and Norway37 showed, respectively, weak or no 
association to salt intake. However, the method of evaluating salt intake is still 
much debated as it is notably difficult to assess the amounts of salt used during 
cooking or at the table. Although a slightly more accurate measurement using 
24-hour urinary sodium excretion was suggested, it was also considered to be 
prone to bias and error38
The carcinogenic effect of N-nitroso compounds such as N-ethyl-N’-nitro-N-
nitrosoguanidine has been demonstrated in several animal models
.  
39-41. N-
nitroso compounds may be generated after consumption of certain foods such 
as cheese, salted fish, smoked or cured meat. Dietary nitrates are absorbed by 
the stomach and can be concentrated in the saliva. Oral bacteria then convert it 
to nitrites that react with amines, amides and amino acids to form N-nitroso 
compounds42,43. Increased levels of N-nitroso compounds correlated positively 
with the clinical presence of advanced precancerous gastric lesions44. N-
nitroso compounds are also found naturally in leafy vegetables and potatoes. 
Therefore, cautious application of nitrogenenous fertilizers45 and better food 
storage conditions46
 
 may aid in lowering the naturally abundant amounts of 
nitrates in leafy vegetables such as spinach. Reduced consumption of 
preserved food may also help to lower GC risk. 
Tobacco smoking has been shown to be consistently associated with increased 
GC risk in many cohort and case-control studies
2.1.5 Tobacco smoking and alcohol consumption 
47-53. A 10-year follow-up 
study in Japan involving 19,657 men showed that adjusted rate ratios for 
development of GC in past and current smokers were 2.0 (95% CI: 1.1-3.7) 
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and 2.1 (95% CI: 1.2-3.6), respectively, compared to non-smokers51. In 
Malaysia, Goh et al. reported in a case-control study a 2.5-fold higher GC risk 
in smokers52. While a large European systematic review of 42 studies 
concluded that smoking was significantly associated with GC of the non-
cardia (RR = 1.60; 95% CI: 1.41-1.80) as well as the cardia (RR = 1.87; 95% 
CI: 1.31-2.67) 53. The IARC Monograph on Tobacco Smoke and Involuntary 
Smoking in 2004 presented strong evidence showing that tobacco smoking 
increases GC risk 54
In contrast to smoking, there is little evidence for an association between 
alcohol intake and GC risk
.  
55. Only 1 in 10 of the evaluated cohorts in a 
Japanese systematic review showed a positive association of alcohol 
consumption with increased risk of cardia GCs56. Limited evidence from a 




Occupational factors leading to development of GC are not well-defined. 
Continual exposure to certain environmental carcinogens such as mineral and 
metal dust, coal dust, wood dust, rubber manufacturing and N-nitroso 
compounds
2.1.6 Occupational exposures 
57 may increase GC risk. Certain occupations, in particular mine 
workers and quarrymen, carpenters, workers in the steel, chemical, rubber 
manufacturing and food industries have been associated with an increased GC 
risk58. However, there is no direct evidence of causality from these 
occupations and it remains possible that non-occupational incidental risk 
factors may have confounded the associations. 
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2.1.7 Exposure to infectious agents 
Helicobacter pylori  
 
In 2005, Australian physicians Barry J. Marshall and J. Robin Warren were 
awarded the Nobel Prize in Physiology or Medicine “for their discovery of H. 
pylori and its role in gastritis and peptic ulcer disease”. The IARC declared H. 
pylori a class I carcinogen eleven years59 after the discovery of this bacterium 
in 198360. Many studies have been conducted ever since to investigate the 
nature of the relationship between H. pylori and GC etiology 61-65. To date, the 
best evidence is that H. pylori infection does not lead inexorably to GC66-68. 
The consensus strongly points to H. pylori-induced chronic gastritis, although 
only a small proportion of infected individuals eventually progress to gastric 
cancer69-71. Evidence for the association of H. pylori infection to GC risk has 
come from epidemiologic studies correlating H. pylori and GC prevalence 
rates72
 
. A more detailed discussion on H. pylori and its link to GC is presented 
in Chapter 3, page 47. 
Epstein-Barr virus (EBV) 
 
EBV-associated GC is a distinct subgroup representing approximately 10% of 
newly diagnosed GC cases annually73. EBV-associated carcinoma was 
observed as a monoclonal expansion of EBV-infected epithelial cells74. EBV-
associated GC was observed to be histologically similar to non-EBV GC but 
resistant to apoptosis75. A carcinogenic role has been suggested for EBV-
encoded small RNA (EBER) found in EBV-GC cells76, 77. Uozaki et al. also 
suggested involvement of epigenetic mechanisms such as virus-driven 
hypermethylation in EBV-GC development75. EBV-transformed cells could 
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also secrete a latent protein, LMP2A, believed to trigger the NF-κB-survivin 
pathway. Increased expression of survivin in EBV-infected epithelial cells 




2.2 Host factors 
Men are twice as likely to develop GC compared to women. This has raised 
speculations that higher levels of endogenous sex hormones such as estrogens 
in pre-menopausal women may have a protective effect
2.2.1 Gender  
79. Chadanos et al. 
proposed that gastric estrogen receptors may be involved in preventing or 
delaying the development of the intestinal type of GC80. It was hypothesized 
that estrogen up-regulates trefoil factor expression which is protective to the 
mucosal epithelium. It may also curb ERBB2 oncogene expression81
 
. 
Individuals with blood group A, in comparison to groups O, B or AB, have a 
20% increased risk of developing GC
2.2.2 Blood group A and pernicious anemia 
82. This was reported as early as the 
1950’s by Aird et al.83. The underlying mechanisms are unclear but may be 
the effect of a risk-conferring haplotype. Wu et al. reported that blood group A 
patients are associated with GC of the diffuse type84
Individuals with pernicious anemia are also known to have an increased GC 
risk
.  
85. Whilst an earlier study showed that pernicious anemia conferred an 
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Several studies have reported an increased risk of GC among patients with a 
history of prior gastric surgery for benign diseases
2.2.3 Previous gastric surgery  
88-90. A meta-analysis 
estimated a two- to four-fold increase in GC risk in patients ≥ 15 years after 
gastric surgery89. Likewise, a large cohort study reported by Fisher et al. 
showed that gastrectomy for benign conditions, e.g. gastric ulcer disease, 
increased the risk for developing GC90
 
. 
H. pylori infection is one of the major causes of gastric and duodenal ulcers. 
Whether benign gastric ulcers per se have a propensity for malignant change 
leading to gastric adenocarcinoma is controversial
2.2.4 Gastric ulcer  
91-94. A large Swedish cohort 
study involving 60,000 patients observed over 9.1 years showed a higher GC 
risk for patients with benign gastric ulcers compared to prepyloric ulcers94. Set 
against this is the fact that some GCs are ulcerating lesions and may be 




Ninety percent of GCs are sporadic, with 5-10% of cases occurring in familial 
clusters
2.2.5 Familial predisposition and hereditary diffuse gastric cancer  
95. The underlying predisposing factors are not wholly understood but 
some risk factors had been identified96-99. Familial exposure to H. pylori 
infection was associated with corpus cancer among siblings but was 
independent of cardia cancer98. Predisposition to precancerous lesions such as 
chronic atrophic gastritis may be associated with some familial cases100. Ohata 
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et al. suggested that in intestinal type of GC, H. pylori infection increased GC 
risk by causing chronic atrophic gastritis101. He noted that although exposure 
to H. pylori alone did not directly associate with gastric carcinogenesis, having 
a familial predisposition to chronic atrophic gastritis may promote stomach 
carcinogenesis101. Among familial GCs, only 1-3% are hereditary. Hereditary 
diffuse gastric cancer (HDGC) is the most well-studied inherited GC. The 
International Gastric Cancer Linkage Consortium defined HDGC families are 
those with: 1) at least two cases of diffuse GC in first/second degree relatives 
diagnosed before the age of 50; or 2) if > 3 cases of diffuse GC are reported in 
first/second degree relatives, regardless of age102. One-third of HDGC patients 
have inactivating germline mutations of the E-cadherin gene (CDH1)103. This 
inherited cancer syndrome was first discovered in a Maori kindred in New 
Zealand104 followed by HDGC families in Europe105. Kindreds that transmit 
CDH1 mutations show an autosomal dominant pattern of GC inheritance. 
Lifetime cumulative risk for these families was 40% in men and 63% in 
women in a study conducted in Canada106. In a separate study from the U.K., 
Pharoah et al. showed a higher cumulative risk of 67% for men (95% CI: 39-
99) and 83% for women (95% CI: 58-99)107. HDGC individuals develop GC 
at an average age of 38 but had been diagnosed as early as age 16 years106
 
. 
Advances in genotyping technologies employed in many large scale genome 
wide-association studies have yielded increasing evidence for genetic 
polymorphisms as significant modulators of disease susceptibility in 
individuals
2.2.6 Genetic polymorphisms  
108. In the context of gastric adenocarcinoma, several genetic 
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polymorphism studies have been reported in the last decade. El-Omar et al. 
demonstrated that polymorphisms in the human interleukin 1 beta (IL-1B) 
gene was associated with an increased risk of hypochlorhydria induced by H. 
pylori 109. IL-1B is a pro-inflammatory cytokine that is involved in a variety of 
cellular functions, including cell proliferation, differentiation, apoptosis and 
inhibition of gastric acid secretion110. Polymorphisms in IL-IB, for example 
carriers of the IL-1B-511*T genotype and also of the IL-1 receptor antagonist 
IL-1RN*2/*2 genotype were associated with increased GC risk109,111. 
However, a meta-analysis by Vincenzi et al., of IL-1B polymorphisms in 
Caucasian and Asian populations, showed that IL1B-511T polymorphism in 
association with GC risk was statistically significant only in Caucasians (OR 
of 1.56, 95% CI: 1.32-1.84, p < 0.00001), but not in Asians (OR of 1, 95% CI: 
0.85-1.16, p = 0.95)112. In the same vein, meta-analysis of a CDH1 
polymorphism, CDH1-160 C>A, revealed a positive association with tumor 
invasion among Caucasians (OR of 1.40; 95% CI: 0.95-2.04) but was 
negatively correlated in Asian patients (OR of 0.76; 95% CI: 0.55-1.05) 113. 
Associations with polymorphisms of other genes that mediate inflammation 
include interferon gamma receptor 1 gene (IFNGR1), in which the IFNGR1-
56*C/*T polymorphism is reportedly a significant risk factor for GC114. On a 
separate note, specific polymorphisms of IL-1B namely, IL-1B-511*T/*T or 
IL-1B-511*T/*C were associated with enhanced susceptibility to Vacuolating 
cytotoxin, vacAs1-, vacAm1- and Cytotoxin-associated gene A (CagA)- 
positive H. pylori strains111
 
. A more detailed discussion on the H. pylori 
virulence factors (VacA & CagA) will be discussed in Chapter 3, page 50. 
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3. Interplay of host and environmental factors 
Since the IARC declaration of H. pylori as a class I carcinogen, many studies 
have focused on the infectious process of this bacterium. Almost half the 
world population is estimated to be infected by H. pylori115. It is known that 
H. pylori induces chronic gastritis. Epidemiological studies strongly indicate 
that H. pylori exposure during childhood increases the likelihood of infection 
and progression from chronic gastric atrophy to probable carcinoma116. 
Modifying the interplay of environmental and host factors may thus help to 
mitigate the risk of GC development. The age of exposure to H. pylori is 
fundamental to the stimulation of the inflammatory response. Poor hygiene 
and low socio-economic status promotes exposure to H. pylori, while familial 
clustering especially within infected poor families greatly enhances infection 
rates101. High dietary salt content possibly accentuates infection by H. pylori. 
Studies have demonstrated that the onslaught of high sodium chloride on the 
gastric mucosa encourages bacterial overgrowth117
However, H. pylori strain variations and host genotypes are critical in 
determining the clinical outcome and hence the risk of developing GC. H. 
pylori strains that harbor virulence factors such as CagA modulate gastric 
epithelial cell proliferation and apoptosis.  Other virulence factors such as 
VacA and BabA also increase the risk of GC development. Hence, individuals 
who are susceptible carriers of the IL-1B-511*T/*T or IL-1B-511*T/*C 
polymorphisms for example, are at increased GC risk when exposed to 
virulent bacterial strains
. Bacterial conversion of 
nitrites to carcinogenic nitrosamines may induce intestinal metaplasia. The 
same can be expected of diets laden with nitroso compounds.  
112.  
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This interplay of bacterial, host and environmental factors may account for the 
huge geographical variation in global GC incidence. Migrants from high risk 
regions moving to low risk countries, for example, have a reduced GC risk. 
Individuals bearing a susceptible polymorphism, if exposed to virulent H. 
pylori strains, especially at an early age, will likely have a greater risk of 
developing GC. An understanding of these intricate relationships may provide 
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3. The African and Asian Enigma 
 
Despite being declared a class I carcinogen by the IARC in 19941, only a 
small percentage of H. pylori infected subjects will eventually develop GC (3 
cases per 10,000 infected persons)2
 
. The GLOBOCAN database estimates that 
there are approximately 1 million new GC cases per year which represents 
only a fraction of the 3.25 billion people or almost half of the world’s 
population believed to be infected with H. pylori. These discrepant figures 
obscure a direct causal relationship between H. pylori and GC development. It 
is thought that H. pylori strain diversity may play a role, which can be further 
modulated by host genetic differences such as SNP polymorphisms and/or 
other possible etiological factors. In this chapter, we shall discuss a striking 
paradox, initially observed in Africa and subsequently noted also in some 
Asian countries. We examine the relationship between the prevalence of H. 
pylori and GC in Singapore’s multi-ethnic population and suggest a possible 
‘Singapore enigma’. The chapter ends with a discussion on the hotly debated 
subject of H. pylori eradication programs that may only be effective in 
selected high risk populations. 
3.1 Infection 
H. pylori is a spiral, Gram-negative, microaerophilic bacterium that is highly 
prevalent in humans. Through the action of its flagella, H. pylori traverses the 
mucous layer of the stomach, attaches to and colonizes the apical membrane 
of host cells where it secretes factors that are both directly injurious and also 
attract inflammatory cells to its habitat3. The bacterium is rarely found inside 
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epithelial cells4. As an acid tolerant neutralophile, it has highly adaptive 
mechanisms that allow it to survive in low pH environments. H. pylori can 
synthesize large amounts of urease to degrade urea, normally produced in the 
stomach, to ammonia and carbon dioxide. Ammonia in turn neutralizes gastric 
acid and forms ammonium. This layer of protective ‘ammonia armor’ assures 
the eventual success in gastric colonization4,5. Infections are typically acquired 




3.2 Establishing an epidemiological link to GC  
It is estimated that H. pylori infects about half the world’s population and 90% 
of people in developing countries. The decision of IARC to classify H. pylori 
as a class I carcinogen was based solely on epidemiological data. The 
EUROGAST study of 17 populations from 11 European nations, the United 
States and Japan showed that GC risk increases 6-fold in H. pylori infected 
individuals7. Uemura et al. conducted a prospective study of 1,526 Japanese 
subjects with active gastroduodenal disease8. Upper gastrointestinal endoscopy 
with standard gastric biopsies was performed on study enrollment and between 
1–3 years. After a mean follow-up period of 7.8 years, 36 (2.9%) of 1,246 H. 
pylori seropositive patients had developed GC. Strikingly, none of the 
uninfected patients had GC. Some of the strongest epidemiological data came 
from a nested analysis from 12 case-control studies9. Patient blood samples, 
collected either at time of GC diagnosis or years before, were assayed using H. 
pylori specific antibodies. This study showed that H. pylori infected non-
cardia GC patients had an overall relative risk (RR) of 3.0 (95% CI: 2.3–3.8). 
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However, RR was 5.9 (95% CI: 3.4–10.3) for patients who were seropositive 
years before GC was diagnosed.  
 
Data from studies of Mongolian gerbils, an animal model of GC may lend 
some support to the oncogenic effects of H. pylori infection10. However, an 
independent study reported by Elfvin et al. failed to replicate GC in the same 
model. These authors showed that H. pylori only induced the appearance of 
atypical glands that infiltrated the muscularis propria but not beyond the 
submucosa11
 
. They considered these changes to be insufficiently diagnostic of 
gastric adenocarcinoma, but conceded that Mongolian gerbils were still a good 
animal model for H. pylori induced gastritis, gastric ulcer and metaplasia. 
It is well known that H. pylori colonizes the gastric epithelium and induces 
histologic gastritis12 in humans yet only a fraction of infected subjects are 
clinically symptomatic. In a recent review, Amieva & El-Omar noted that H. 
pylori infection typically has three clinical outcomes13. Eighty to ninety 
percent of all infected subjects are asymptomatic or have mild pan-gastritis 
with negligible change in gastric acid secretion. Up to 15% of patients develop 
duodenal or prepyloric ulcers without increased GC risk. In these patients, 
antral gastritis develops with some increase in acid secretion but little or no 
muscosal atrophy. The third possible outcome is multifocal atrophic gastritis 
and GC that affects about 1% of infected patients. It is clear that H. pylori 
infection can result in divergent clinical outcomes and it has become more 
apparent that the probable outcome is influenced by bacterial virulence 
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factors, host susceptibility factors and environmental exposures (Chapter 2, 
Page 32).   
 
The oncogenic potential of H. pylori is highly dependent on virulence factors 
expressed by specific strains or subtypes. Many studies have shown that 
virulent strains of H. pylori induce severe chronic inflammation, leading to 
atrophic gastritis, hypo or achlorhydria
3.2.1 Modifying factors: strain virulence  
14. The two best studied virulence 
factors are the vacuolating cytotoxic VacA gene and cytotoxin-associated gene 
A (CagA)13
The CagA gene is part of the cag pathogenicity island (cag PAI), a 
chromosomal segment comprising about 30 genes. cag PAI encodes proteins 
such as CagE, an ATPase that drives a type IV secretion system. Following 
attachment to the epithelium, the type IV secretion apparatus allows bacterial 
macromolecules such as the CagA protein to be injected into epithelial cells 
where it disrupts the cytoskeleton, affecting its adherence to adjacent cells, 
modulates intracellular signaling and other cellular activities. The injected 
. VacA is a pore-forming cytotoxin which causes epithelial cells to 
vacuolate in vitro and strains with the s1 subtype at the amino terminus, 
secretes an active toxin. Infection with s1 subtypes more likely lead to gastric 
ulcers and GC. The middle region of this gene encodes the ‘m’ region and m1 
subtypes are reported to have increased vacuolating activity. VacA molecules 
form a flower-like ring complex between adhered bacterial surface and host 
cells (hence its pore-forming properties). VacA has several toxigenic 
properties such as stimulating epithelial host-cell apoptosis through pore 
formation in mitochondrial membranes and signaling of pro-apoptotic factors.   
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CagA protein is first phosphorylated by the Src family kinases, followed by 
activation through the SHP2 tyrosine phosphatase and extracellular signal-
regulated kinase, ERK5. Downstream signal transduction of growth factors 
and cytokine receptors responsible for cellular proliferation, morphogenesis 
and cell motility are also altered. Interestingly, 50-70% of H. pylori strains in 
Western countries are of the CagA+ subtypes15. Patients infected with these 
strains mount a stronger inflammatory response and are at greater risk of 
developing peptic ulcers or GC than those infected with strains lacking the 
island6. Retrospective analyses also gave supportive evidence that infected GC 
patients are more likely associated with CagA+/VacA+ serotypes16
  
.  
As mentioned in Chapter 2, Page 31, polymorphisms in cytokine genes such as 
interleukin-1β (IL-1B) may govern a host’s susceptibility to GC development 
after infection with virulent H. pylori strains. El-Omar reported that 38% of 
GC patients positive for H. pylori infection had a susceptible IL-1B 
polymorphism
3.2.2 Modifying factors: host genotypes 
17. Individuals with polymorphisms (IL-1B-31*C or -511*T and 
IL-1RN*2/*2) were more likely to be predispose to hypochlorhydria, gastric 
atrophy, and have a 2- to 3-fold increased risk of developing non-cardia GCs 
than those with non-inflammatory IL-1 genotypes13. However, not all 
populations showed similar trends. For example, 1L1B-511*T polymorphisms 
were more significantly associated with Caucasians than with Asians18
Pro-inflammatory cytokines such as tumor necrosis factor α (TNF-A) have 
also been implicated in GC risk. Meta-analysis involving 23 studies on TNF-
A-308 G>A polymorphism associating with GC predisposition was conducted 
. 
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recently19. Similar to the conclusions from IL1B-, the effect of TNF-A 
polymorphism was limited only to Caucasian populations. No significant 




3.3 The enigmas 
Holcombe noted the discordance between high H. pylori seropositivity and 
low prevalence of GCs in African countries22. He coined the term ‘African 
enigma’ to describe this phenomenon. However, naysayers suggested that this 
apparent phenomenon was attributable to unreliable data from African cancer 
registries. Given the shortage of diagnostics facilities such as endoscopy in 
Africa, Wabinga also argued that the extent and prevalence of GC in Africa 
cannot be reliably determined23. The discordance in Africa had also been 
noted in Asia by Miwa et al. who observed that the high prevalence of H. 
pylori infection in India and Thailand (67-81% and 54-74%, respectively) 
coexisted with low GC incidence rates (< 10 and < 7.5 per 100,000, 
respectively), thus describing the ‘Asian enigma’24. The Asian enigma is 
unlikely to be the result of under-diagnosed GC as Miwa et al. collated 
reliable and standardized information on GC incidence and H. pylori 
seropositivity from curated publications and statistical data from the World 
Health Organization. The meta-analysis first revealed that there was 
significant variability in VacA genotypes in H. pylori strains prevalent in 
Asian countries. Japanese patients were infected with a strain that was positive 
for CagA and VacA genotype s1/m1. Korean patients were reportedly infected 
with a similar strain. Most people in the Indian sub-continent were infected 
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with the VacA S1/m1 subtype while 35% of them had the m2 subtype. This 
latter subtype, VacA s1a/m2, was also more common in Taiwan. On the other 
hand, van Doorn et al. reported an s1c subtype in 80% of clinical isolates from 
Asia25. The diversity of bacterial strains in the Asian continent was postulated 
as a possible reason for the varied geographical incidence of GC. Even in a 
high incidence country like Japan, disparities between GC incidence and H. 
pylori seropositivity have been found. Specifically, GC is considerably less 




Asia as a continent is composed of diverse ethnic populations. Singapore’s 
multi-ethnic population may serve as a microcosm of the Asian enigma. A 
study by Ang et al. best describes this paradox in documenting the association 
of H. pylori seropositivity and virulence with GC incidence among 
Singapore’s resident ethnic populations
3.3.1 The Singapore enigma 
26
Table 3-1 Cumulative (0-74 years) GC incidence and H. pylori seropositivity 
(Adapted from ref. 26). 
. In line with data presented in 
Chapter 1, page 8, ethnic Chinese showed the highest GC incidence in both 







Country Region/Ethnicity Male(%) Female(%) Male(%) Female(%)
Japan Miyagi 9.9 4.0 71.5 75.5
Portugal Gaia 5.3 2.6 65.0 61.0
Italy Florence 3.8 1.9 27.5 35.5
Iceland S region 3.2 1.2 43.5 51.0
Slovenia Ljubljana 2.9 1.1 61.0 48.5
UK Oxford 2.6 0.9 28.5 25.0
Stoke 3.4 1.3 38.0 25.5
Algeria Algiers 1.6 0.7 45.5 56.5
Denmark Copenhagen 1.4 0.9 28.5 16.0
Belgium Ghent 1.2 0.6 40.0 32.0
USA Minneapolis-St-Paul 0.9 0.3 24.5 24.0
Singapore Chinese 3.3 1.5 46.8 45.8
Malay 0.8 0.5 30.1 26.1
Indian 0.7 0.7 51.1 45.1
Average H.pylori seropositivityIncidence rate
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GC incidence rates also showed Singapore’s Chinese population ranks 
moderately high in world statistics (Table 3-1). Despite a high prevalence of 
H. pylori seropositivity (~50%), the GC incidence rates of ethnic Indians are 
low in comparison. These figures are comparable with data of Indians living in 
the Indian subcontinent. Ang et al. also showed that local Indians are as likely 
to be infected with the virulent CagA/VacA strain as the Chinese. Moreover, 
as there is little disparity in living and sanitary standards between the races, 
environmental factors are probably not the main determinants of GC 
development. Paradoxically, local Indians had low pepsinogen I and low 
pepsinogen I to II ratios. These profiles suggest that Indians have a greater 
propensity for developing atrophic gastritis but many do not progress to GC. 
In contrast, Chinese could develop GC in the absence of atrophic gastritis. 
Gastric acid secretion levels were also reported to be comparable in all three 
ethnic groups27. Echoing these findings was a study of a Malaysian population 
by Goh et al. showing Chinese ethnicity to be a GC risk factor independent of 
other known risk factors (Table 3-2)28
 
. Similarly, despite a high prevalence of 
H. pylori seropositivity, the Indian population in Malaysia had lower GC 
incidence rates. Diverse ethnic populations, as shown in these loco-regional 
contexts, are likely to be distinguished by subtle genetic differences that 
predispose or protect against development of GC from precursor lesions such 
as gastric atrophy. Taken together, the higher incidence of GC in certain ethnic 
populations e.g. Chinese, is suggestive of polygenic and environmental 
predisposition factors that are additional to the complex interaction of host 
genetic polymorphisms and bacterial virulence factors. 
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Table 3-2 Univariate analysis of ethnicity as a predictive factor in a 
prospective case control study of 3 major populations in Malaysia. (Table 






3.4 Eradication of H. pylori: is it still feasible? 
The fundamental question for many epidemiologists is whether treatment of 
H. pylori infection will significantly reduce GC incidence. Population-based 
intervention could in theory reduce GC risk. It has been proposed that 
eradication of H. pylori may moderate the inflammatory response to infection, 
normalize cell proliferation and apoptosis, suppress development of 
hyperplastic polyps and regress gastric atrophy and intestinal metaplasia29-33. 
However conclusions from prospective trials on the long-term effects of H. 
pylori eradication, to date, have remained unclear. In one of the largest studies 
conducted in Linqu, China, You et al. showed that H. pylori eradication 
therapy (amoxicillin and omeprazole) was able to reduce the prevalence of 
precancerous gastric lesions after a seven year follow-up, but the overall 
reduction in GC incidence was not significant (2.4% placebo vs. 1.7% 
eradication; p = 0.14)34
At least three other prospective studies concluded with sobering results that 
premalignant lesions could not be regressed through H. pylori eradication. van 










Chinese 66/124(53.2%) 13.66 (4.36–47.61) <0.001 78.8%
Indian 17/85 (20%) 3 ((0.87–11.31) 0.09 82.3%
Malay 4/52 (7.7%) 75.0%
. Although there was a marked improvement of gastritis and 
superficial epithelial damage after eradication, the extent of intestinal 
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metaplasia and atrophy remained unaltered35. A similar randomized control 
trial was conducted in Yantai County, China36. Biopsy specimens of 587 
volunteers were screened for presence of H. pylori. Infected patients received 
either a 7-day triple-therapy course of omeprazole, amoxicillin, and 
clarithromycin (OAC) or placebo, and then followed-up for 1 year. 
Reminiscent of the van der Hulst study, Sung et al. concluded that eradication 
improved acute and chronic gastritis but intestinal metaplasia remained 
unchanged36. Another large scale randomized controlled trial of 1,630 healthy 
H. pylori carriers conducted in Fujian Province, China reported that the overall 
GC risk of H. pylori eradicated carriers was no different from the placebo 
group over a mean follow-up of 7.5 years37
Taken together, the trials seemed to suggest that beyond a probable "point of 
no return", intervention to achieve H. pylori eradication will not significantly 
reduce GC risk, especially in patients who already developed pre-neoplastic 
lesions.  
. However, eradication 
significantly reduced GC incidence in a subgroup of patients who had no pre-
cancerous lesions on presentation.  
In a recent Asia-Pacific consensus meeting, representatives from 18 
institutions in 13 countries presented guidelines for GC prevention. They 
recommended screening and eradication of H. pylori be performed only in 
high risk populations, despite strong epidemiological evidence implicating H. 
pylori infection as a risk factor for non-cardia GC38. In the absence of 
supporting data, population-based eradication was not recommended for 
countries and populations with intermediate or low GC risk. These 
recommendations found concurrence in a review by Lee et al. that raised 
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concerns that there is little evidence of the long-term benefits of H. pylori 
eradication39. Even if treatment does reduce GC risk, logistical and economic 
challenges with screening and treatment need to be addressed. The costs 
involved may be too high given the high worldwide prevalence of H. pylori 
infection. Poor primary healthcare and infrastructure in developing countries 
are likely to hinder the efficacy of eradication programs. Patients’ non-
compliance to drug administration is a major consideration especially in 
asymptomatic individuals who may be less inclined to complete the course of 
treatment. Furthermore, the risk of antimicrobial resistance has not been 
adequately addressed. A more unresolved problem is the possibility that H. 
pylori infection may paradoxically protect individuals against esophageal 
adenocarcinoma and adolescent asthma. Prospective studies conducted for 5-
35 years in 129,000 patients showed the inverse association between H. pylori 
infection and esophageal adenocarcinoma40
Nevertheless, the cost-effectiveness of an eradication program could still be 
beneficial if directed at high risk populations. A US study modeled the cost of 
screening per year of life saved in selected populations such as Japanese-
Americans. It concluded that serologic screening for H. pylori beginning at 





Overall, persuasive evidence to support worldwide screening of asymptomatic 
subjects for H. pylori infection or carrier status to prevent gastric cancer is still 
lacking. However, it is reasonable to recommend that gastric surveillance and 
H. pylori eradication programs in high risk populations, such as Japan and 
Korea, be continued42.  
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4. Possible molecular pathogenetic attributes of gastric cancer 
 
We have reviewed epidemiological characteristics and probable 
etiological factors of GC in the preceding chapters. In aggregate, there is 
much evidence to suggest that GC initiation and progression are likely to 
involve multi-faceted events.  
Cancer can be defined as a disease driven by genetic and genomic alterations. 
It is well recognized that GCs are characterized by extensive genomic 
abnormalities such as copy number amplifications, deletions, inter- and intra-
chromosomal rearrangements e.g. translocations, para- and peri-centric 
inversions. Few and largely futile attempts had been made to investigate such 
structurally abnormal chromosomes in primary GC tumors since the early 
1970s. Karyotypic data informative of genomic alterations in GC are scarce, 
due largely to major technical difficulties in obtaining metaphase spreads of 
decent quality from primary GC tumor samples. The turning point came with 
the development of molecular cytogenetic techniques beginning with 
fluorescence in situ hybridization (FISH). This technique rapidly evolved to 
multicolor spectral karyotyping. In parallel, high throughput DNA and RNA 
microarray platform technologies were developed and refined in short order. 
These techniques enabled accrual of large pan-genomic datasets of genome 
copy number, transcriptomes (mRNA and microRNA) and characterization of 
chromosomal rearrangements. In this chapter, we review some of these genetic 
and genomic alterations in GCs and the methodological advances that are 
useful to our work. 
 
Literature Review- Chapter 4 
 
                                                                                                                                     
             67 
4.1 Conventional and molecular cytogenetics 
Most cancers, with rare exceptions, harbor some form of chromosomal 
numerical and/or structural alterations. Chromosomal karyotyping serves as a 
good entry point in attempts to identify and understand driver genes of 
pathogenic significance in the cancer type of interest, as these genes are likely 
to be dysregulated by recurrent “signature” rearrangements. For example, 
discovery of the BCR/ABL translocation (Philadelphia chromosome) has had 
great impact on clinical diagnosis, prognosis and treatment of patients with 
chronic myelogenous and acute lymphoblastic leukemias1
 
. Prompted by these 
successes, chromosomal rearrangements in many solid cancers including GCs 
were sought. However, solid tumor cytogenetics using classical techniques is 
notoriously challenging. Decent metaphase spreads are rarely obtained 
because of an exceptionally low mitotic index and the tendency of stromal 
cells to overgrow in vitro. Even when the occasional metaphase of acceptable 
quality is available, the chromosome structures are often characterized by 
many complex rearrangements that exceed the resolving limits of conventional 
G-banding techniques. Figure 4-1 is an example of an attempt to analyze G-
banded chromosomes from an aneuploid GC cell line. It shows multiple 
complex chromosomal rearrangements and many marker chromosomes of 
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Figure 4-1 Giemsa-stained chromosomal preparations of GC cell line, Hs 
746T. Mar denotes unidentified marker chromosomes.  
 
Owing to these technical difficulties, fewer than 30 GC cytogenetic studies, 
archived and maintained at the US National Cancer Institute's Cancer Genome 
Anatomy Project website (http://cgap.nci.nih.gov/Chromosomes), have been 
published in the past three decades or so (Table 4-1).  
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Table 4-1 Classical G-banding chromosomal analysis of GC tumors and cell 
lines. Multi-color chromosomal FISH and spectral karyotyping were 






















This database collated 32 studies (including 3 multicolor FISH studies) with a 
combined total of 157 primary and metastatic GC tumors and 21 GC cell lines. 










2 1973 1 - - -
3 1975 1 - - -
4 1979 1 - - -
5 1981 1 - - -
6 1984 - 1 - -
7 1985 2 - - -
8 1986 4 1 - -
9 1987 4 1 - -
10 1989 1 - - -
11 1990 6 - - -
12 1990
6 - - 11p13-15 breakpoints (in 3/6); 
partners 2q, 3p & 3q
13 1991 - 2 - -
14 1991 1 1 -
15 1992 1 4 - -
16 1992 1 - -
17 1992 7 1 - -
18 1992 - 1 -
19 1993 6 8 - -
20 1993 9 2 - -
21 1995 8 1 - t(3;5) in 2/9
22 1995 2 3 1 -
23 1996 4 - - -
24 1996 1 - - -
25 1996 3 - 1 -
26 1998 - 1 -
27 1998 8 2 - -
28 1999 13 7 - t(Y;14) in 2/19
29* 2000 - 6 t(17;19) in 2/6
30* 2002 2 - -
31 2004 12 2 - t(1;7) in 2/12
32 2006 - 10 - -
33* 2005
7 - 10 8q24 breakpoints in 3/10 lines 
and 2/7 GCs; partners 13q and 
11q
TOTAL: 112 45 21
*Used selected painting probes, M-FISH or SKY. 
Ref. 19: includes 1 lymph node 
Ref. 33: all primary tumors aspirated from ascitic fluid 
Reference Year
Primary GCs or Metastatic tumors
Recurrent translocations
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were reported. As a result of the severe technical limitations of G-banded 
classical chromosome analysis, most of the foregoing karyotypes were, at best, 
only partially described. Hence, only 2 cases were reported to have a balanced 
translocation t(3;5)(q21;q31), the remaining aberrations being unbalanced 
structural rearrangements such as additions and/or deletions of whole and 
partial chromosomal regions. Whole chromosomal gains (trisomies) and losses 
(monosomies) were reported in all cases. Trisomies of chromosome 8 (29 
cases), chromosome 20 (26) and chromosome 7 (20), were the most frequent. 
Monosomies were observed more commonly in chromosomes 18 (36 cases), 
Y (32 cases) and 22 (30 cases) (Appendix Table 1, page 304). In summary, 
cumulative data to date using suboptimal techniques nonetheless clearly 
indicate that GC chromosomes are highly altered both structurally and 
numerically.  
 
Overall, the foregoing studies indicate that diffuse type GCs tended to be near- 
or hyper-diploid with relatively few chromosomal rearrangements. In contrast, 
intestinal type GCs had modal chromosome numbers that ranged from near-
triploid to hyper-tetraploid34,35
 
. Some chromosomal rearrangements were 
reported to be complex rearrangements involving 3 or more partner 
chromosomes. It was impossible to completely characterize many of these 
complex rearrangements accurately from G-banded metaphases.  
The development of molecular cytogenetics marked an important milestone 
and began with the rapid application of FISH probes to detect translocations, 
fusions and other chromosomal aberrations. FISH analysis can be performed 
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on non-dividing interphase nuclei, and is often used to independently confirm 
abnormalities identified by other methods. However, selection of informative 
FISH probes requires detailed characterization of aberrations in the genomic 
region of interest. For example, a translocation fusion is documented when 
two probes that are normally completely separate, become juxtaposed in either 
metaphase or interphase nuclei.  However, FISH applications in GC tissues 
have been restricted to the use of alpha-satellite centromeric FISH probes36-38 
mainly to document aneuploidy or gains and losses of whole chromosomes. 
Except for the translocations, t(11;18)(q21;q21) and t(1;14)(p22;q32), found in 
about 35% of gastric MALT lymphomas39
With the benefit of hindsight, FISH methodologies led to another technical 
breakthrough - the development of multi-color karyotyping (details of this 
technique will be presented in Chapter 7). The seminal papers by Schrock et 
al.
, there is a complete absence of 
information on signature chromosomal translocations in GC.  
40 and Speicher et al.41 encouraged extensive application of spectral 
karyotyping to many solid tumors where classical cytogenetic methods had 
failed to fully characterize complex and cryptic aberrations, such as marker 
chromosomes. Unfortunately, difficulties in obtaining suitable metaphases 
from GCs hindered the widespread utilization of multi-color FISH analyses. 
To date, only three studies have been reported. Chun et al. characterized the 
breakpoints in six GC cell lines using custom-labeled band-specific 
chromosome painting probes interrogating eight loci (1p36, 2p24, 5q21, 7q32, 
17p13, 17q21, 19q13 and Yq21)29. Stamouli et al. presented a 24-color multi-
color FISH assay on primary specimens obtained from two male gastric cancer 
patients30. These results showed remarkable rearrangements that were 
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previously not revealed using classical cytogenetics. A more recent study by 
Yamashita et al. analyzed a significantly larger number of samples. However, 
none was from primary GC tissue; the metaphases being derived instead from 
ascitic fluids of seven patients with carcinomatous peritonitis and from ten 
established gastric cancer cell lines33
 
. From this study, Yamashita et al. 
reported recurrent genomic rearrangements at 8q24 and 11q13. Thus all 
cytogenetic studies to date show that GC karyotypes are characterized by 
numerous complex structural and whole chromosomal gains and losses. Many 
of these rearrangements remain incompletely characterized. Although multi-
color FISH was an important technical advancement, the scarcity of 
metaphase spreads of decent quality from primary GC tissues limited its 
utilization for uncovering clinically relevant rearrangements.  
4.2 Classical and array CGH 
The advent of comparative genomic hybridization (CGH) revolutionized the 
way cancer cytogenetics was investigated, not least by obviating the 
requirement for tumor metaphase spreads.  CGH is essentially based on the 
principles of FISH probe hybridization. In classical CGH, genomic DNA 
extracted from a tumor sample is fluorescently labeled and co-hybridized with 
an equimolar of reference normal DNA (labeled with a different fluorophore) 
to chromosomes from normal diploid cells. Ratios of fluorescence intensity 
values reflect tumor genome copy number relative to the reference DNA 
across the entire tumor genome. This powerful technique, which was 
optimized by Kallioniemi et al.42, set the stage for what is now known as 
whole genome copy number analysis. The greatest advantage of this technique 
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is that high mitotic index tumor cells are no longer required as tumor 
metaphase spreads are not analyzed – only genomic DNA extracted from 
tumor samples. Furthermore, the relatively low resolution of classical 
chromosomal CGH (~ 10 Mb) has seen tremendous improvements in array 
CGH methods in which the hybridization platforms have migrated from whole 
chromosomes to BAC clone, oligo-mers and SNP arrays having resolving 
powers of 50-100Kb or better. Regardless of resolution, genome-wide copy 
number analyses in GCs consistently reveal regions of gains and losses 
affecting almost every chromosome. Meta-analysis of CGH data in GC 
(Figure 4-2) has shown frequent copy number gains at 20p, 20q, 8p, 8q, 7p, 













Figure 4-2 Genome-wide DNA copy number alterations summarized from 
879 GC cases analyzed using chromosomal CGH and/or arrayCGH. Green 
bars indicate the percentage of cases with copy number gains and red bars, 
losses.  Data was obtained from Progenetix 
(http://www.progenetix.net/progenetix/LC16/, June 2009).   
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Several studies have shown a correlation between metastatic lymph node 
status and DNA copy number alterations. Kang et al. showed that copy 
number loss at 9p23 was correlated with lymph node invasion while losses at 
4q23 and 4q28 were associated with metastasis and poor differentiation in a 
study of 28 GC tumors43. Morohara et al. reported that loss of 22q11 and gains 
of 5p14, 7q21 7q31 and 7q36 closely correlated with peritoneal dissemination 
and/or positive peritoneal cytology44. Weiss et al. performed hierarchical 
cluster analysis of BAC-based array CGH data to show that DNA copy 
number alterations predicted nodal status and patient survival45. The same 
authors validated their observation in a later study of 35 primary GCs using 
array CGH where copy number gains at 1q32.3 were significantly correlated 
with metastatic lymph node status (p = 0.007), and loss of 18q22.1 and gain of 
1q32.3 were associated with a worse prognosis46
Genome copy number abnormalities correlate inconsistently with other 
clinico-pathological features such as the Laurén histotypes. Wu et al. reported 
that gains of 8q and 17q, and losses of 3p and 5q were more frequent in 
intestinal type GC. Gains in 13q were more common in the diffuse type
.  
47.  In 
agreement with Wu et al., Kokola et al.48 and Amadori et al.49 also reported 
gains in the same regions in intestinal GC types. Separately, Koizumi et al. 
showed 13q gains to be more frequent in the diffuse type50. Koo et al. found 
copy number gains of 18q and 20q to correlate more significantly with 
intestinal GC while gains in 8q, 13q and 17q were, in contrast, more frequent 
in the diffuse type51. Separately, van Grieken et al. using chromosomal CGH52 
and Carvalho et al. using array CGH53 failed to detect any significant 
differences between the two histotypes.  
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Loss of heterozygosity (LOH) genotyping was proposed to be a useful 
independent prognostic indicator. Jiao et al. reported strong evidence that 
cardia tumors had significantly higher LOH at 1p36, 9p21, 18q21 and 
22q13.31 compared to non-cardia tumors54. The authors also concluded that 
intestinal GCs had LOH at 3p14, 4p15, 5q21-22, 9p21, 13q22 and 18q21 that 
had probable associations with tumor initiation. LOH on 1p36, 8p11-12, 
17p31.1 and 22q13.31 correlated significantly with aggressive tumor behavior. 
This supports earlier evidence by Koo et al. that LOH at 22q was related to 
tumor progression55. Suzuki et al. performed quantitative microsatellite 
analysis on patient samples and showed that 6q and 16q LOH were associated 
with poorer survival56
 
. In summary, these analyses highlight the remarkable 
genomic complexities and alterations in GCs.  
4.3 Altered gene expressions 
Central to genetic mutations are altered expressions of critical genes such as 
oncogenes (MYC, KRAS and CTNNB1) and tumor suppressors (TP53, APC, 
RUNX3). Hanahan and Weinberg57
 
 have reviewed progressive acquisition of 
the ‘hallmarks’ of cancer through genetic alterations that transform normal 
human cells to malignant. We examine these ‘hallmarks’ in the context of 
gastric oncogenesis under three functional categories of dysregulated gene 
expression: 1) cell growth and proliferation; 2) averting growth inhibition and 
apoptosis; and 3) tumor invasion and metastases. 
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It is imperative that intimate cell-cell interactions exist to regulate the 
production of growth factors and signal transduction, thereby achieving 
homeostasis as normal cells alternate between quiescent and active states. Cell 
surface receptors, responding to these growth stimulatory signals in turn, are 
targets of altered expressions that drive the oncogenic process. Several 
oncogenic growth factors and receptors have been implicated in gastric 
oncogenesis.  
4.3.1 Cell growth and proliferation 
 
MET oncogene is the receptor of hepatocyte growth factor (HGF). HGF is 
frequently over-expressed in diffuse and intestinal types of GCs58
 
.  
MYC was over-expressed in more than 40% of GC59 and this correlated 
significantly with copy number amplification at 8q24.12-q24.13, where MYC 
is physically mapped60. The MYC oncogene encodes a ubiquitous transcription 
factor involved in modulating cell proliferation and differentiation61. An allelic 
gain generated through aneusomy of chromosome 8 is one of the mechanisms 
of MYC amplification. Not all cases, however, showed concordance of MYC 
locus amplification with up-regulated expression. Other mechanisms of MYC 
gene activation include chromosome duplication, translocation, integration of 
retroviral enhancers and activating point mutations. Multiple copies of the 
MYC gene may also appear as homogeneously staining chromosomal regions 
and double minutes62,63. MYC over-expressing GC, especially of the intestinal 
type, are more aggressive and likely to metastasize. MYC over-expression also 
promotes genomic instability and sensitizes cells to apoptotic stimuli64.  
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FGFR2 belongs to the family of fibroblast growth factor receptors and is 
selectively amplified and frequently over-expressed in 50% of diffuse type 
GCs65-67.  FGFR2 over-expression was associated with increased tumor 
aggression and metastases in diffuse GC68
 
.  
KRAS belongs to the family of RAS oncogenes that regulate signal 
transduction through GTPase activity. It is mutated in up to 28% of GC. 
Although point mutations of KRAS were much higher in colon cancer (7-
80%), lung cancer (10-50%) and pancreatic cancer (70-100%)69, KRAS 
mutations in GC appear to be limited to patients with chronic atrophic 
gastritis. Whether KRAS plays a role in the development of pre-neoplastic 
lesions is still controversial. H. pylori infected patients with KRAS mutations 
were initially reported to progress to intestinal metaplasia within three years. 
However follow-ups after six years revealed that metaplasia had not 
progressed to intestinal GC70
 
.  
A well-studied signaling pathway in colorectal cancer is the Wnt-Frizzled-β-
catenin pathway. However, understanding of the role of this pathway in GC is 
still fragmentary. WNT2 was reported to be over-expressed in association with 
DNA copy number gains at 7q31-q32. Transcriptome analysis also showed 
up-regulation of WNT5A and other WNT ligand receptors such as frizzled-
related protein 4 and frizzled homologue 1. In the canonical WNT signaling 
pathway, enhanced beta-catenin expression at either the cell membrane or the 
cytoplasm was reported in 45% of seventy-five primary GCs and was more 
significant in intestinal-GCs (p = 0.0049)71. This finding also confirmed an 
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earlier study by the same group involving 20 patients where increased 
CTNNB1 mRNA expressions levels were found to be more frequent in 
intestinal-type GCs as compared to diffuse-type (P < 0.01)72. It is interesting to 
note that inhibition of beta-catenin by over-expressing E-cadherin could result 
in suppressed beta-catenin dependent pro-proliferation gene transcription73
 
.   
The adenomatous polyposis coli (APC) tumor suppressor protein is also 
known to be a key component of the WNT canonical signaling pathway. 
Although the roles of APC are better defined in colorectal cancer, the 
significance of APC mutations in GCs is less clear. The frequency of APC 
mutations range from 0-5% in diffuse type GC and 4-20% in intestinal type 
GCs73. APC mutations were reported in 20-76% of gastric adenomas or flat 
dysplasias, in contrast to only 1-4% in adenocarcinomas. This led to the 
suggestion that APC mutations participate in adenoma formation and dysplasia 
but not in tumor progression74
 
.  
PTGS2 gene encodes cyclo-oxygenase 2, an inducible enzyme involved in the 
regulation of prostaglandin biosynthesis. PTGS2 is not normally expressed in 
gastric mucosa. Yamac et al. showed PTGS2 over-expression in 49% of sixty-
five primary GCs75. PTGS2 over-expression correlated significantly with early 
gastric cancers suggesting its role in initiating gastric oncogenesis. On the 
other hand, other studies showed down-regulated PTGS2 expression from 
hypermethylation of PTGS2 CpG islands76,77
 
.  
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ERBB2 maps to 17q21.1 and codes for a plasma membrane receptor tyrosine 
kinase. The structure of the receptor tyrosine-protein kinase erbB-2 (p185) is 
similar to human epidermal growth factor receptor (EGFR). Although only 5% 
of GC tumors were found to harbor mutations in the erbB-2 kinase domain78, 
15% of GCs were reported to over-express erbB-2 and this correlated with 
increased venous invasion and poor prognosis79. Trastuzumab, a monoclonal 
antibody that binds to the extracellular domain of erbB-2, is currently used as 
adjuvant therapy in breast cancer. This agent could therefore be helpful to the 
subset of GC patients over-expressing erbB-2. Similarly, EGFR was reported 
to be up-regulated in 44% (36 of 82) of GC patients80. High expression of 




Vascular endothelial growth factor (VEGFA) was also over-expressed in 48% 
of GC tumors81 and this was associated with lymph node metastases and poor 
prognosis82,83
Many critical cell cycle regulators are implicated in gastric carcinogenesis, 
such as CDKN2A (p16) and CDKN1B (p27). p16-INK4a exhibits various 
alternative spliced variants encoding at least three distinct proteins of which 
two have structurally related isoforms that function as inhibitors of Cyclin-
dependent kinase 4. The third variant contains an alternate open reading frame 
whose product functions to stabilize tumor suppressor p53 by sequestering 
MDM1. p16-INK4a is also believed to regulate CDK4 and p53 in G1 phase of 
the cell cycle. This gene is frequently mutated or deleted in a wide variety of 
tumors. Expression of CDKN2A was reported to be down-regulated in almost 
.   
Literature Review- Chapter 4 
 
                                                                                                                                     
             80 
half of GCs84,85 and this was significantly associated with hypermethylation (p 
< 0.0001,  chi-square test) 84
p27Kip1 binds to and inhibits the activity of cyclin-CDK2 or -CDK4 
complexes, and blocks cell cycle progression at G1. CDKN1B expression is 
known to be down-regulated in GC. A study from Italy concluded that loss of 
p27Kip1 protein expression was significantly associated with poorly 
differentiated advanced tumors and poorer survival. Multivariate analysis of 
this cohort of 84 patients showed that low p27Kip1 protein expression 
correlated with shorter survival (p = 0.004)
.    
86
 
. However, the mechanism 
leading to reduction or loss of p27Kip1 expression is unclear.  
 CCNE1 (Cyclin E1) regulates cyclin-dependent kinases. The G1/S-specific 
cyclin-E1 accumulates at the boundary of G1-S phase and is then degraded as 
the cell progresses through S phase. CCNE1 is over-expressed in many tumors 
including GCs. Although immunohistochemical staining detected G1/S-
specific cyclin-E1 protein expression in 41-46 % of GC tumors, its association 
with clinico-pathological features is controversial87,88. Kouraklis et al. noted 
that positive G1/S-specific cyclin-E1 immunostaining was associated with 
intestinal GC (p = 0.003), nodal infiltration (p = 0.0025), tumor size >5 cm (p 
= 0.032), and lymphatic (p = 0.042) and vascular invasion (p = 0.0029). 
However, cyclin-E1 expression did not correlate with patient survival in this 
study87. Choi et al. on the other hand, found that cyclin-E1 protein expression 




Literature Review- Chapter 4 
 
                                                                                                                                     
             81 
To proliferate and propagate, cancer cells inhibit antigrowth signals and 
inactivate tumor suppressor genes. Many of such genes have been implicated 
in GC including TP53, TGF-β, SMAD4, RUNX3 and BCL2. Some of these key 
genes are discussed below.  
4.3.2 Averting growth inhibition and apoptosis  
 
TP53 is located at 17p13.1 and encodes a key nuclear protein that is involved 
in the regulation of target genes involved in cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism. Cellular tumor antigen 
p53 functions as DNA-binding protein containing transcription activation, 
DNA-binding, and oligomerization domains. It is suggested that in normal 
cells, p53 act as a tumor suppressor through interactions at p53 binding sites. 
Activation of downstream genes could exhibit tumor suppressive functions 
such as growth inhibition and/or invasion. The function of TP53 is abrogated 
through point mutations or LOH in GCs73. Most single base mutations of TP53 
are transitions (G-C to A-T substitutions) arising from cytosine methylation at 
CpG islands. However, the frequency of TP53 mutations in GCs varies widely 
from 0% to 77%89. In their review, Hamilton & Meltzer noted TP53 mutations 
in 38% of intestinal metaplasias, 58% dysplasias and 71% GCs67. Inactivation 
by LOH occurred in 60-70% of intestinal type GCs. There was a suggestive 
association of TP53 mutations with H. pylori seropositivity, although a clear 
molecular mechanism has not been described67
 
.   
The TGF-β signaling pathway is frequently altered in GCs. TGFB1 function is 
mediated through the formation of a heteromeric complex after binding with 
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TGF-beta-1 receptors, TGF-beta receptor type-2 and TGF-beta receptor type-1 
















Figure 4-3 The TGF-β signaling pathway. (Figure is from 
http://www.biocarta.com/pathfiles/h_TGFBPATHWAY.asp)  
 
Ligand-activated TGF-beta-1 receptors transduce signals to downstream 
targets by phosphorylating SMAD 2 and SMAD 3. SMAD 2/3 subsequently 
interacts with SMAD 4 as a complex and translocates into the nucleus where 
target genes are activated either by direct binding to promoter elements or by 
recruiting other transcription factors90. The role of TGFB1 in cancer is 
biphasic91. TGF-beta-1 suppresses cell proliferation in the early stages of 
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carcinogenesis but reverses its role at a later stage to support tumor 
progression92,93. Mutations or repression of TGFBR2 94 and/or TGFBR195 can 
abolish or attenuate binding of TGF-beta-1 and lead to unrestrained cell 
proliferation and reduced apoptosis in GC. Downstream molecules in the 
TGF-β signaling pathway are frequently affected in GCs. For example, LOH 




The RUNX3 gene encodes a member of the runt domain-containing family of 
transcription factors. It forms a heterodimer that either activates or suppresses 
transcription. In GCs, RUNX3 is frequently transcriptionally silenced by 
hypermethylation in its promoter’s CpG island96 or deleted leading to loss of 
expression97.  Silencing of RUNX3 was implicated in down-regulation of 
genes involved in cell adhesion, proliferation and apoptosis, thereby 
promoting peritoneal metastasis of GC98
 
. 
BCL2 encodes an apoptotic inhibitor that regulates cell death by controlling 
the mitochondrial inner membrane permeability. Caspase activity is inhibited 
by either blocking Cytochrome c release from the mitochondria or binding to 
the apoptosis-activating factor APAF-1. LOH at the BCL2 locus is frequently 
reported in GCs99. Two independent studies showed that BCL2 expression 
inversely correlated with lymph node metastasis, depth of invasion and tumor 
grade100,101. Inada et al. concluded in a multivariate analysis that patients with 
BCL2 positive GC had longer survival102
 
.  
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One of the hallmarks of cancer is the ability to invade adjacent tissues and 
migrate to regional and/or distant sites to establish new tumor foci 
(metastases). In fact, metastases cause 90% of cancer deaths
4.3.3 Tissue invasion and metastasis 
57
 
. To be capable 
of metastasizing, a tumor must modify its adhesion properties, manifested as 
altered cell-cell interactions with adjacent cells while concurrently acquiring 
cell motility.  
Loss of CDH1 (E-cadherin) expression is by far the best studied example of 
this phenotype in GCs. CDH1 encodes a calcium-dependent glycoprotein 
composed of five extracellular cadherin repeats, a transmembrane domain and 
a highly conserved cytoplasmic tail. Loss of function has been shown to play a 
role in epithelial-derived cancer progression by increasing cell proliferation, 
invasion, and/or metastasis. In GCs, loss of CDH1 function is caused by LOH, 
mutation as well as promoter hypermethylation. Expression of CDH1 is 
reduced in 20-90% of GCs, with a higher proportion in the diffuse type. CDH1 
is frequently down-regulated due to hypermethylation. Graziano et al. reported 
that 54% of GCs showed hypermethylation at CDH1 promoter, predominantly 
in diffuse GCs103. Patients with low CDH1 expressing GC were reported to 
have significantly shorter survival104. HDGC (hereditary diffuse gastric 
cancer) kindreds transmit germline CDH1 mutations105-107. In a recent study of 
36 new HDGC families More et al. reported 9 different mutations, 7 of which 
were novel108
 
. Including this study, there are known to be at least 27 
truncating and 3 missense mutations of CDH1 in HDGC.   
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4.5 microRNA expression 
MicroRNAs (miRNAs) are non-protein-coding, small RNAs that are 
expressed endogenously from the human genome. miRNAs modulate gene 
expression by several mechanisms, namely translational repression, mRNA 
cleavage and mRNA decay initiated by miRNA-guided rapid deadenylation. 
Expression of specific miRNAs is known to be critical in oncogenesis of the 
breast, brain, liver, colorectum, lung, and in leukemia. Over-expressed 
miRNAs may, for example, abrogate or repress genes involved in cell 
differentiation or apoptosis. On the other hand, under-expressed miRNAs can 
function as tumor suppressors leading to up-regulation of oncogenes, cell 
growth and proliferation. Within the last 3 years, several studies have reported 
dysregulation of miRNA expression in GCs109-111. In particular, miR-21 was 
shown to be over-expressed in 92% of GCs112. Zhang et al. reported that 
induced high expression of miR-21 promoted cell proliferation and invasion in 
AGS, a human GC cell line113. In a recent study, Takagi et al. showed by real-
time RT-PCR that miR-143 and -145 were under-expressed in > 50 % of the 
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The attributes we have discussed thus far portray GC to be genomically 
unstable and possibly possessed most, if not all, of the hallmarks of cancer. 
Cancer in general is a genomic disease that accumulates mutations and other 
aberrations as it progresses. As of June 2009, a total of 56,428 chromosomal 
rearrangements (balanced and unbalanced translocations, insertions, 
duplications and inversions) had been reported in 11,206 publications1. Many 
are intimately associated with aspects of clinical oncology or cancer biology, 
especially in hematological malignancies. Although development of new 
methodologies in the last few decades has greatly advanced cancer 
cytogenetics, the study of cancer chromosomes in fact dates back to the 19th 
century. In the late 1800’s, German pathologists had already begun to use 
techniques to observe gross alterations in mitotic cells in tissue sections from 
different neoplasms2. The insights of Theodor Boveri (1862-1915) were 
especially prescient. He was the first to propose that tumors resulted from 
acquired aberrations of the somatic cell genome3 
 
(Figure 5-1). Regardless, the 
prevalent view until the 1960s was that chromosome abnormalities were 


















Figure 5-1 A chronology of discoveries of fusion genes in epithelial tumors 
beginning with Boveri’s hypothesis in 1914 to the discovery of some well-
documented gene fusions during the late 20th
 
 century. Reports of fusion genes 
intensified with the advent of better developed tools in the new millennium 
(Figure is adapted from ref. 2). 
5.1 Cancer cytogenetics in hematological malignancies 
The Philadelphia chromosome in chronic myeloid leukemia (CML), 
discovered in 1960 by Nowell and Hungerford4, re-focused attention on cancer 
cytogenetics not as the arcane study of epiphenomena but as a means to 
uncover fundamental oncogenic processes. Decoding the Philadelphia 
chromosome took about three decades of research beginning with its 
cytogenetic definition as a reciprocal translocation involving chromosome 9 
and chromosome 22, t(9;22)(q34;q11)5. Molecular identification of the fusion 
gene by Groffen6 and others provided substantial evidence that the BCR/ABL 
fusion gene alone was leukemogenic7. (This longstanding view may be 
modified by a recent study that showed that induction of CML required 











































that most translocations to date have been discovered in leukemias and 
lymphomas, molecular characterization of pathogenic chromosome 
rearrangements has had a particularly tangible impact on clinical management 
of hematologic malignancies. Signature translocations are clinically useful in 
distinguishing benign from malignant proliferative states, for accurate 
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diagnosis, in patient stratification (e.g. selecting patients for targeted therapy) 
and for prognostication9. A few examples will suffice to illustrate the breadth 
of current clinical applications. Chromosomal alterations that lead to 
dysregulated expression of BCL2 had been widely used to distinguish benign 
reactive lymph nodes from lymphomas and leukemias10. The Philadelphia 
chromosome is the gold standard diagnostic biomarker of CML, including 
residual disease and relapse after treatment11. Successful development of 
imatinib, a tyrosine kinase inhibitor targeted at the BCR/ABL protein is a 
recent triumph, albeit coming more than three decades after the Philadelphia 
chromosome was first observed12. More recently, imatinib-resistant kinase 
domain mutations were reported to be the main cause of CML relapse. This 
spurred the development of 2nd generation kinase inhibitors such as dasatinib 
and nilotinib13. A different signature translocation, t(15;17), in acute 
promyelocytic leukemia explains the remission-inducing effect of 
pharmacologic doses of all-trans retinoic acid and is also a predictor of 
therapeutic response. The product of t(15;17) is the PMR/RARα fusion 
protein, an aberrant retinoid receptor with reduced ligand affinity, whose 
expression inhibits the differentiation of malignant promyelocytes14. All-trans 
retinoic acid overcomes this maturation arrest and induces remission in at least 
90% of newly diagnosed patients15. Crucially, cytogenetic and/or 
transcriptional evidence of t(15;17) is highly predictive for response to all-
trans retinoic acid16 . This convergence of developmental cell biology with 
molecular cytogenetics has made acute promyelocytic leukemia the most 
curable form of acute myeloid leukemia17. The association of many specific 
translocations with prognosis is now known. For example, Philadelphia 
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chromosome-negativity is a poor prognostic biomarker in CML18
 
 but portends 
a more favorable survival in adult and pediatric acute lymphoblastic leukemia. 
5.2 Translocations in epithelial cancers 
The considerable technical challenges encountered in solid tumor cytogenetics 
led to the once-pervasive view that chromosomal translocations of oncogenic 
relevance were restricted largely to hematologic malignancies and solid 
tumors of mesenchymal origin (sarcomas)19. A global census of recurrent 
chromosome translocations20 in nine major neoplastic entities revealed that 
78% were recorded in hematologic malignancies, 13% in carcinomas and 12% 
in sarcomas. Thus, 90% of known recurrent chromosome translocations were 
identified in hematologic malignancies and mesenchymal tumors that, in 
reality, comprise less than 10% of all malignant disorders20. The fact that 
recurrent translocations appear to be relatively rare in carcinomas has 
generated two competing explanations. The first posits that hematologic 
malignancies and sarcomas arise from oncogenic processes that are 
fundamentally different from those that generate carcinomas. In support of this 
view, 70% of somatic mutations in ‘cancer genes’ are associated with 
hematologic malignancies and sarcomas suggesting that a larger and more 
complex repertoire of genetic aberrations is needed to generate these disorders 
than carcinomas21.  An alternate view maintains that, as the frequency of 
recurrent balanced translocations is simply a function of the prevalence of 
abnormal karyotypes, structurally rearranged chromosomes are likely to be 
more common in carcinomas than is currently known20. Difficulties in 
karyotyping solid tumors with classical cytogenetic techniques are well 
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known. Carcinoma cells do not grow readily from primary tumor explants in 
vitro – such cultures are usually overgrown by karyotypically normal stromal 
fibroblasts. Chromosome morphology of solid tumors is usually so poor that 
karyotyping is either not possible or only partial. When metaphase quality 
permits complete karyotyping, the karyotypes and abnormal chromosome 
structures are generally so complex that it is often difficult to discern recurrent 
rearranged chromosomes of biological significance against the high 
background of non-recurrent genomic aberrations.  Despite all the odds, some 
translocations were nonetheless identified by karyotyping epithelial tumors. 
For example, the RET-PTC gene fusion in papillary thyroid cancer was 
described by Grieco et al. in 199022 (Figure 5-1). Less than a decade later, 
PRCC-TFE3 was reported in renal cell carcinomas23. In chronological order, 
several fusion genes were discovered, primarily from G-banded karyotypes i.e. 
CTNNB1-PLAG and HMGA2-FHIT fusions were reported in pleomorphic 
adenomas of salivary glands24,25, PAX8-PPARγ  in follicular thyroid tumors26 
and BRD4-NUT in NUT midline carcinomas (NMC)27
Nonetheless, the limited availability of decent G-banded karyotypes from most 
other epithelial tumors meant that the vast majority of fusion events, if present, 
remained hidden. Recent molecular cytogenetic techniques, such as FISH and 
SKY, have revealed the extreme karyotypic complexity of many common 
epithelial cancers such as those of the pancreas
. NMC is a uniformly 
lethal malignancy defined by a chromosomal translocation of the nuclear 
protein in testis (NUT) gene.  
28, cervix29 and breast30. Using 
FISH analysis in 13 cases of the rare secretory subtype of breast carcinoma, 
Tognon et al. showed that 92% had a signature t(12;15) translocation and 
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expressed an ETV6-NTRK3 fusion gene, first discovered in pediatric 
mesenchymal tumors31. The recent discovery of androgen-sensitive 
TMPRSS2-ETS gene fusion in prostate cancer32 and tyrosine-kinase EML-ALK 
fusion in non-small-cell lung cancer33
 
 established precedents for mining 
transcriptome data and screening transcripts in the search for fusion genes. 
These advances have rekindled considerable interest in solid cancer 
cytogenetics from which many novel and pathogenic chromosomal 
translocations may be discovered and their functional sequelae investigated.  
5.3 Consequences of structural alterations  
Structural alterations of chromosomes can arise from translocations, 
insertions, deletions or inversions. A thorough molecular characterization and 
understanding of the functional consequences are pre-requisites in the design 
of small molecules or biologic agents against druggable targets (e.g. imatinib). 
Here our discussion focuses on the potential outcomes of chromosomal 
translocations, simply defined as two non-homologous genomic segments 
fused or juxtaposed to each other. These fusion events may have three possible 
effects (Figure 5-2): a) enforced expression of a fusion transcript and/or 
functional protein; b) misexpression of oncogenes or tumor suppressor genes 
from promoter/regulatory element swapping; c) loss of binding sites for trans-
acting regulatory molecules e.g. deletion of miRNA-specific binding seed 





























Figure 5-2 Schematic representation of possible functional outcomes of 
chromosomal translocation. Examples of fusion events from a variety of 
cancers are shown. Type a) Enforced expression of a fusion transcript by 
which an abnormal chimeric protein is produced; b) Misexpression of 
oncogenes or tumor suppressor genes from promoter/regulatory element 
swapping; c) Rearrangements leading to the loss of regulatory sequences. Loss 
of 3’UTRs may compromise the repressive functions of regulatory molecules 
such as miRNAs (Adapted from ref. 34). 
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Tyrosine kinases and transcription factors are often implicated in type a) 
fusion events. The best studied BCR-ABL fusion product results in constitutive 
activation of the ABL tyrosine kinase. Other fusions involving tyrosine 
kinases were subsequently discovered including RET-PTC rearrangements in 
papillary thyroid cancers.  
5.3.1 Type a) Enforced expression of fusion transcripts 
The RET oncogene maps to 10q11.2 which encodes a membrane bound 
receptor tyrosine kinase (TK) that autophosphorylates on activation and 
signals through the MAPK pathway. Fusions of RET often involves multiple 
partners. At least nine rearrangements are known, collectively termed RET-
PTC rearrangement. RET-PTCH1 and RET-NCOA4 represents the majority of 
rearrangements in papillary thyroid cancers. Molecular characterization 
showed most RET fusions had a breakpoint at intron 11. Regardless of the 
multiple partners, the fusions retain an intact TK domain in the RET-PTC 
oncoprotein that result in the binding to SHC (Src homology 2 domain-
containing) transforming protein and subsequently activate the RAS-RAF-
MAPK cascade35. Interestingly, RET-PTC rearrangements were reported to be 
more prevalent among individuals who developed thyroid cancer after 
exposure to ionizing radiation namely, the Nagasaki and Hiroshima atomic 
bombings37 and the Chernobyl nuclear power plant disaster36,37. Children with 
papillary carcinomas were found to have RET-PTC rearrangements in up to 
80% of tumors removed 5–8 years and 50–60% of those removed 7–11 years 
after exposure to the nuclear accident35
The EML4-ALK fusion on the other hand, first discovered in a surgically 
resected lung adenocarcinoma, was the product of an inversion in 
.  
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chromosome 2p33. ALK is a tyrosine kinase having a putative transmembrane 
domain and an extracellular domain, while EML4 belongs to the EMAP 
(echinoderm microtubule-associated protein) family of proteins involved in 
microtubule assembly. Following its discovery, other investigators using PCR 
and FISH analysis concluded that the EML4-ALK fusion was found in only a 
minority (3.4–7.5%) of lung cancer patients39-41
Another membrane-bound tyrosine kinase recently described in epithelial 
cancers is ROS1. ROS1 oncogene is highly expressed in a variety of tumor cell 
lines and belongs to the sevenless subfamily of tyrosine kinase insulin receptor 
genes. Two rearrangements were reported in lung cancers. Both SLC42A-
ROS1 and CD74-ROS1 fusions resulted in a tandem transmembrane structure 
that constitutively activates the ROS1 tyrosine kinase
.  
42
One of the most notable gene fusions discovered in recent times is the 
TMPRSS2-ERG gene fusion in prostate cancer whose expression is up-
regulated by androgens
.  
32 via a non-canonical androgen response element 
linked to TMPRSS2 (an androgen-dependent transmembrane serine 
protease)43. There is evidence that ERG over-expression could initiate 
prostatic neoplasia and promote cell invasion. In vivo targeted elevation of 
ERG expression resulted in transformation of luminal prostate epithelial cells 
to focal prostatic intraepithelial neoplasia in transgenic mice44. Consistent with 
the latter observation, ERG gene rearrangements were identified by break-
apart FISH signals in foci of high- and low-grade intraepithelial neoplasia in 
human prostate tissues45
The promiscuous pattern of chromosomal rearrangements involving multiple 
translocation partners is also increasingly being observed. Interestingly, 
. 
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fusions involving multiple partners are not restricted to a particular cancer 
type (Figure 5-2). For example in sarcomas, multiple partners are known to 
fuse to the 3’- ends of EWS and FUS genes. Likewise in papillary thyroid 
carcinomas, at least nine known partners are fused to the 3’ end of RET.  
In prostate cancer, the ETS family of transcription factor genes (ETV1, 4 and 
6) may fuse to TMPRSS2 (androgen sensitive) or to constitutively active 
promoters (SLC45A3, HERV-K). In the latter, the promoter swapping fusion 
closely resembled that of type b). The juxtaposition to constitutively active 
promoters results in the forced expression of -ETV fusion genes (Figure 5-2). 
Another notable example of type b) fusions is the signature translocation, 
t(8;14) in Burkitt’s lymphoma. The fusion results in the juxtaposition of an 
enhancer, immunoglobulin gene (IGHG1) at 14q32.33 to 8q24.21, thus 
constitutively driving expression of the MYC oncogene
5.3.2 Type b) Misexpression of fusion genes from promoter/regulatory 
element swapping 
46,47. Similarly, MYC 
translocations are frequently fused to other non-IG partners known to be 
involved in lymphomagenesis, namely BCL6, BCL11A, PAX5 and IKAROS48. 
In acute myelogenous leukemia (AML), the MLL gene is known to have at 
least 70 different fusion partners49
 
. The increasingly observed phenomenon of 
multiple fusion partners is possibly a harbinger of a bounty of such fusions 
awaiting discovery. 
miRNAs play a critical regulatory role on gene expression by specifically 
binding to seed sequences located at the 3’ UTRs of target genes
5.3.3 Type c) Loss of binding sites for trans-acting regulatory molecules  
50. Fusions 
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that displace these critical binding sites may impair the repressive function of 
miRNAs, thereby resulting in enforced over-expression of target genes. This is 
shown vividly in translocations involving HMGA2-FHIT and HMGA-NFIB, 
first discovered in pleomorphic adenoma. HMGA2 (high mobility group AT-
hook 2) is a small nuclear protein belonging to the non-histone chromosomal 
high mobility group protein family. Although the HMGA protein family does 
not participate in transcriptional activity directly, regulation of gene 
expression is modulated by altering the conformation of AT-rich DNA 
regions, thereby altering the interaction of transcription factors. In this way, 
HMGA proteins are associated with a wide array of biological functions such 
as differentiation, growth, proliferation, and apoptosis51. In the aforementioned 
translocations, the 5’ end of HMGA2 is fused to FHIT or NFIB. Using a 
3’UTR luciferase conjugated reporter, Mayr showed that let-7 directly 
represses HMGA2 expression52
 
.  The HMGA2-FHIT/NFIB fusion(s) are thus 
examples of a type c) translocation (Figure 5-2) in which replacement of the 
3’ UTR by a fusion partner results in the loss of a key regulatory element (in 
this case, let-7-specific seed binding sites) and hence, an abnormal increase in 
HMGA2 gene expression. Such discoveries shed light on the complex 
functional mechanisms of structurally rearranged genes.  
A recent review by Felsher reignited the concept of oncogene addiction53.  It 
was suggested that “oncogene activation initiates tumorigenesis precisely 
because it directly overrides physiologic programs inducing a state of cellular 
amnesia, not only inducing relentless cellular proliferation, but also bypassing 
checkpoint mechanisms that are essential for cellular mortality, self-renewal, 
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and genomic integrity.” It is proposed that targeted ‘oncogenic inactivation’ is 
a plausible treatment option for achieving tumor regression. Conceptually, 
enforced oncogenic expression through a type a) or b) fusion could underpin 
oncogenic addiction. By mechanisms which are still not fully understood, 
oncogenes such as MYC, whose sequence integrity remain unaltered, is 
irrevocably activated in a t(8;14) fusion involving the immunoglobulin gene 
family. Tyrosine kinase fusions such as the BCR-ABL and EML4-ALK may 
also fit in with the concept of oncogene addiction. In essence, imatinib acts as 
an inhibitor that suppresses the ‘addicted’ tyrosine kinase and its downstream 
players54
 
. Furthermore, it is almost impossible for a cancer cell with complex 
rearrangements to ‘revert’ to its pre-neoplastic diploid state. In other words, a 
chromosomally rearranged genome had already inked the ‘path of no return’.  
A fusion event that confers a selective advantage, such as enhanced cell 
proliferation or apoptosis evasion, will likely be retained. As with the theory 
of Darwinian evolution, the fittest cancer genome in a given tumor 
microenvironment is likely to prevail. This acquired survival advantage will 
be reflected in its progeny cells in whose genomes with the selected 
advantageous mutation(s) are likely to predominate. Identification and 
characterization of these signature alteration(s) could thus provide a valuable 
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Materials and Methods 
Materials 
Gastric cancer cell lines: 
Seventeen gastric cancer cell lines were used in this study (Table 6-1). Seven 
of these (AGS, SNU-1, SNU-5, SNU-16, KATO III, Hs 746T, NCI-N87) were 
purchased from American Type Culture Collection (Manassas, VA, USA) and 
three (IM95, FU97, MKN7) from Japanese Collection of Research 
Bioresources (Osaka, Japan).  YCC1, YCC2, YCC3, YCC6, YCC9, YCC11, 
YCC16 were derived from gastric cancer patients at the Yonsei Cancer Center, 
Korea. All cell lines were cultured in conditions recommended by their 
respective sources.  
Table 6-1 A total of 17 gastric cell lines were acquired for this study. YCC cell 
lines were generously provided by Dr Sun Young Rha, Yonsei Cancer Center, 
Seoul, South Korea. 
 
No Cell line Sex Age 
Primary 
site Specimen site Source 
1 AGS F 54 stomach Primary tumor ATCC 
2 SNU-1 M         44 stomach Ascites ATCC 
3 NCI-N87 M     - stomach Liver ATCC 
4 SNU-5 F 33 stomach Ascites ATCC 
5 SNU-16 F 33 stomach Ascites ATCC 
6 KATO III M 55 stomach Pleural effusion ATCC 
7 Hs 746T M 74 stomach Leg ATCC 
8 IM95 M 63 stomach Primary tumor JCRB 
9 MKN7 M 39 stomach Primary tumor JCRB 
10 FU97  F 66 stomach Primary tumor JCRB 
11 YCC1 M 65 stomach Ascites YCC 
12 YCC2 M 73 stomach Ascites YCC 
13 YCC3 M 58 stomach Ascites YCC 
14 YCC6 F 46 stomach   Ascites YCC 
15 YCC9 M 64 stomach        Ascites YCC 
16 YCC11 M 69 stomach       Ascites YCC 
17 YCC16 F 40 stomach        Blood YCC 
 
ATCC: American Type Culture Collection (Rockville,MD) 
JCRB: Japanese Collection of Research Bioresources (Osaka, Japan) 
YCC: Dr Sun Young Rha, Yonsei Cancer Center (Seoul, South Korea) 
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Primary carcinomas (TMA FISH): 
Archived formalin-fixed paraffin-embedded (FFPE) primary carcinomas and 
biopsies were obtained from the Pathology Department, Singapore General 
Hospital. The primary adenocarcinomas used in this study were from patients 
treated during the period 2005–2008 (number of specimens of each tumor type 
within parentheses): gastric (99), prostate (20), lung (15), pancreas (6), liver 
(8), colorectal (19) and breast (15). Optimization and validation of the FISH 
break-apart assay was performed on 3 cases of follicular lymphoma and 5 
cases of benign gastric ulcer disease from the same period. Access to archived 
tissues was approved by the Singapore General Hospital Institutional Review 
Board (IRB). 
 
Fresh frozen primary adenocarcinomas  
Forty fresh frozen primary gastric adenocarcinomas (1998–2001) were 
obtained from the National Cancer Centre tissue repository. All tissues were 
collected with prior informed consent and the project had IRB approval. 
Tumor content of each tissue specimen was assessed by a pathologist to be 
>70% prior to total RNA extraction. 
 
Normal stomach reference  
Normal stomach total RNA was purchased from Ambion (Applied 
Biosystems/Ambion Inc, TX, USA) (extracted from a cancer-free individual) 
and Stratagene (Stratagene/ Agilent Inc, TX, USA) (pooled from two 
stomachs). Both commercial sources specified that small RNAs were retained 
during extraction.  
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BAC clone list for FISH analysis: 
A total of 75 BAC clones were acquired to map the translocation breakpoints 
in SNU-1, (Table 6-2). For the 18q2 TMA FISH assays, 6 BAC clones 
spanning 18q12q22 were obtained from Children's Hospital Oakland Research 
Center, CA, USA (CHORI) and 21 from Invitrogen (Invitrogen/Life 
Technologies Corp., CA, USA).  
Table 6-2 BAC clones acquired for SNU-1 FISH walking analysis and 18q 



















 No. Band BAC clone Start End Clone size source No. Band BAC clone Start End Clone sizsource 1 1q24.2 RP11-52A20 163915806 164085432 169626 CHORI 76 18q12.1 RP11-79G13 26532501 26698513 166012 CHORI
2 1q24.2 RP11-79C7 167063949 167230779 166830 CHORI 77 18q12.1 RP11-19F14 28038323 28227027 188704 CHORI
3 1q24.3 RP11-81H19 167964786 168155220 190434 CHORI 78 18q12.1 RP11-81J17 30046710 30219414 172704 CHORI
4 1q24.3 RP11-125J13 169486552 169655007 168455 CHORI 79 18q21.1 RP11-115P6 43575491 43734371 158880 Invitrogen
5 1q25.1 RP11-177M16 170943385 171123923 180538 CHORI 80 18q21.1 RP11-813F20 45385722 45610087 224365 Invitrogen
6 1q25.2 RP11-91K17 174230596 174414293 183697 CHORI 81 18q21.2 RP11-348N10 46796668 46969852 173184 Invitrogen
7 1q25.2 RP11-57D16 176357204 176513966 156762 CHORI 82 18q21.2 RP11-440L16 47431168 47602010 170842 Invitrogen
8 1q25.3 RP11-46A10 178351052 178490056 139004 CHORI 83 18q21.2 RP11-52C21 49639625 49795840 156215 Invitrogen
9 1q25.3 RP11-118P13 182680727 182841254 160527 CHORI 84 18q21.2 RP11-850A17 49945242 50148726 203484 Invitrogen
10 1q25.2 RP5-1180C10 176694900 176827398 132498 CHORI 85 18q21.2 RP11-61D1 50155529 50313134 157605 Invitrogen
11 1q25.3 RP11-375F5 177048215 177235197 186982 CHORI 86 18q21.2 RP11-289E15 50360135 50526341 166206 Invitrogen
12 1q25.3 RP11-33M22 178250845 178417943 167098 CHORI 87 18q21.2 RP11-727C1 51406584 51499595 93011 Invitrogen
13 1q25.3 RP11-538D16 178539698 178614212 74514 CHORI 88 18q21.2 RP11-214L13 51615427 51759434 144007 Invitrogen
14 1q25.3 RP1-223H12 178832752 178984808 152056 CHORI 89 18q21.2 RP11-160B24 51861143 51993728 132585 Invitrogen
15 1q25.3 RP11-317P15 179083258 179230304 147046 CHORI 90 18q21.2 RP11-99A1 50538204 50702087 163883 Invitrogen
16 1q25.3 RP1-127C7 179988850 180174681 185831 CHORI 91 18q21.31 RP11-79L15 53192567 53367243 174676 Invitrogen
17 1q25.3 RP11-90B21 180545849 180731155 185306 CHORI 92 18q21.31 RP11-787K12 54427690 54606119 178429 Invitrogen
18 1q25.3 RP1-53A19 181163321 181299508 136187 CHORI 93 18q21.32 RP11-4G8 56232485 56373041 140556 Invitrogen
19 1q25.3 RP11-831N4 179246980 179425164 178185 CHORI 94 18q21.33 RP11-866E20 57325319 57518023 192704 Invitrogen
20 1q25.3 RP11-316H13 179366938 179544623 177686 CHORI 95 18q21.33 RP11-91H13 58739319 58915632 176313 Invitrogen
21 1q25.3 RP11-1096P6 179462328 179651281 188954 CHORI 96 18q21.33 RP11-299P2 58927479 59074166 146687 Invitrogen
22 4q31.1 RP11-89I24 140323590 140463966 140376 CHORI 97 18q21.33 RP11-28F1 59058635 59215681 157046 Invitrogen
23 4q31.21 RP11-5K16 141942600 142079466 136866 CHORI 98 18q21.33 RP11-933E2 59191513 59377029 185516 Invitrogen
24 4q31.21 RP11-82L8 145264280 145516085 251805 CHORI 99 18q21.33 RP11-75O12 59638194 59781804 143610 Invitrogen
25 4q31.22 RP11-91O3 148499060 148670510 171450 CHORI 100 18q22.2 - 18q22.3 RP11-57F7 66823682 66981732 158050 CHORI
26 4q31.23 RP11-24I21 150590832 150763388 172556 CHORI 101 18q22.3 RP11-90L15 68667334 68809432 142098 CHORI
27 4q31.3 RP11-73G16 153679767 153863511 183744 CHORI 102 18q22.3 RP11-504H5 70049589 70219028 169439 CHORI
28 4q31.3 RP11-84M15 156097485 156187656 90171 CHORI 103 6p24.3 RP11-90O12 9634150 9733184 99034 CHORI
29 4q32.1 RP11-79J7 157518282 157657978 139696 CHORI 104 18q12.2 RP11-318J15 34864201 35049945 185744 CHORI
30 4q32.1 RP11-89I8 162184639 162334712 150073 CHORI
31 4q32.2 RP11-41G4 163154072 163154350 278 CHORI
32 4q32.3 RP11-177L7 165293687 165449651 155964 CHORI
33 4q34.1 RP11-110O14 174840918 175029155 188237 CHORI
34 4q34.3 RP11-79G20 181029006 181175336 146330 CHORI
35 4q35.1 RP11-451F20 184713296 184909339 196043 CHORI
36 4q35.2 RP11-237D3 188876850 189042067 165217 CHORI
37 4q32.3 RP11-808H17 165696353 165899199 202846 CHORI
38 4q32.3 RP11-153D1 166298327 166461427 163101 CHORI
39 4q32.3 RP11-1030I6 166722157 166927349 205193 CHORI
40 4q32.3 RP11-79E19 166881634 167041593 159959 CHORI
41 4q35.1 RP11-90E7 185505460 185665534 160074 CHORI
42 4q35.1 RP11-13O14 185750574 185921254 170680 CHORI
43 4q35.1 RP11-274E20 186104288 186274229 169941 CHORI
44 4q35.1 RP11-228F3 186349030 186499507 150477 CHORI
45 4q35.1 RP11-50L21 186766565 186951828 185263 CHORI
46 4q35.1 RP11-159A22 187141604 187313927 172323 CHORI
47 4q35.1 - 4q35.2 RP11-173M11 187750213 187917644 167431 CHORI
48 4q35.2 RP11-33M11 188159511 188360234 200723 CHORI
49 4q26 RP11-362M19 115465940 115632027 166087 CHORI
50 4q26 RP11-778G8 118881577 119045551 163974 CHORI
51 4q26 RP11-6K22 120384125 120557978 173853 CHORI
52 4q26 RP11-101N17 120664392 120822142 157750 CHORI
53 4q27 Rp11-96A1 121309042 121484670 175628 CHORI
54 4q27 RP11-647P12 122410063 122586902 176839 CHORI
55 4q27 RP11-63B13 123120138 123269261 149123 CHORI
56 4q27 RP11-100E15 124057935 124225855 167920 CHORI
57 4q27 - 4q28.1 RP11-636M7 124366978 124477860 110882 CHORI
58 4q28.1 RP11-27C19 124747822 124881080 133258 CHORI
59 4q28.1 RP11-728C8 125303102 125470892 167790 CHORI
60 4q32.3 RP11-138D4 166804797 166968329 163532 CHORI
61 4q26 RP11-362M19 115465940 115632027 166087 CHORI
62 4q26 RP11-655C19 115764425 115929094 164670 CHORI
63 4q26 RP11-91O14 116020867 116170892 150025 CHORI
64 4q26 RP11-145H19 116239593 116410065 170473 CHORI
65 4q26 RP11-475O17 116463648 116644239 180592 CHORI
66 4q26 RP11-230G7 116723060 116909529 186470 CHORI
67 4q26 RP11-236J10 116880013 117028224 148212 CHORI
68 4q26 RP11-21L12 117158852 117327130 168279 CHORI
69 4q26 RP11-265B4 117280145 117461051 180907 CHORI
70 4q26 RP11-358F14 117538990 117731202 192213 CHORI
71 4q26 RP11-180M11 117848642 117989898 141257 CHORI
72 4q26 RP11-36M4 117964165 118136792 172628 CHORI
73 4q26 RP11-60J9 118248825 118383371 134547 CHORI
74 4q26 RP11-79C14 118512245 118670744 158500 CHORI
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Methods 
1. Spectral karyotyping 
Metaphase spreads from each GC cell line were prepared using standard 
protocols. Spectral karyotype (SKY) paint assay was performed as instructed 
in the manufacturer’s protocol (ASI GmbH, Germany) based on the method of 
Schrock et al.1. Composite karyotypes of each cell line were recorded in 
accordance with ISCN 1995 nomencleature2
 
 with the following modification. 
Numerical and structural aberrations are described in the order of the 
chromosomes (from chromosome 1 to Y). This allows for easy referencing of 
aberrations shown in SKYgrams to the described composite karyotypes. For 
example in a GC cell line, AGS, the full karyotype description is as follows:  
47-50<2n>, XX[11], der(8)t(1;8)(q12;p22)[11], t(8;10)(?;p13)[5], 
i(13)(q10)[6], +13[3], +14[8], del(18)(q11.2)[8], -18[3], 
+der(19)t(6;19)(p22;q13.3)[11], +20[11], cp[11]. A composite karyotype 
“cp[n]” is generated where [n] represents the total number of metaphases 
analyzed (in this case, n =11). The number of chromosomes observed in each 
cell ranged from 47-50 in 11 analyzed metaphases of AGS. The ploidy status 
(in arrowed parentheses, <2n>) is derived from the modal chromosome 
number of these 11 metaphases. Cytogenetic description of each aberrant 
chromosome was detailed, followed by the number of times the alteration was 
observed (in square parentheses).  
For better visual representation of complex chromosomal rearrangements in 
each GC cell line (Table 7-1, page 143-144), SKYgrams at 400 band 
resolution were constructed from the composite karyotypes (shown in Figures 
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7-2 to 7-19, Page 145-161). Chromosomal rearrangements (i.e. translocations, 
deletions, etc), whole chromosomal gains and losses were represented by color 
codes assigned to each human chromosome. For example, a reciprocal 
translocation will be indicated by two fused colors and the involved partner(s) 
being listed at the top of the rearranged chromosome. Overall, structural 
rearrangements and numerical aberrations were considered recurrent if (a) the 
abnormality occurred in at least 3 of 10 (30%) of metaphases in a single cell 
line; and (b) was observed in at least 2 of 17 cell lines. 
 
2. Affymetrix GeneChip® Human Mapping 100K Set arrays  
High quality genomic DNA was extracted from all 17 GC cell lines and 
purified using the Blood and Cell Culture Midi Kit (Qiagen GmbH., Hilden, 
Germany). Labeling and hybridization experiments with Affymetrix 
GeneChip®
 
 Human Mapping 100K Set arrays (hereafter termed 100K SNP 
mapping arrays) were performed as instructed in the supplier’s protocols 
(Affymetrix Inc., CA, USA). 
Raw data from 100K SNP mapping arrays were processed using Affymetrix 
GeneChip
2.1 Copy Number Analysis 
® Genotyping Analysis Software (GTYPE Ver.4.1) and analyzed 
using Copy Number Analysis Tools (CNAT Ver. 4.0). We used 35 individuals 
from the Mapping 100K HapMap Trio Dataset (Affymetrix) as the normal 
reference. Log2 ratios > + 0.33 and < -0.33 were defined as copy number gains 
and losses, respectively. An altered copy number locus in each cell line was 
defined as a cluster of  ≥ 3 consecutive SNPs showing the same copy number 
Materials and Methods – Chapter 6 
 126 
change (i.e. gain or loss).  Common regions of copy number abnormalities 
were defined as occurring in  ≥ 50% of cell lines. 
 
The cell lines used in this part of the study are shown in Table 6-3 and the 
complete raw SNP array data for the NCI-60 panel of non-GC lines are 
available at 
2.2 Identification of unique GC copy number clusters in comparison to NCI-
60 panel  
http://dtp.nci.nih.gov/mtargets/mt_index.html and at 
http://www.ncbi.nlm.nih.gov/geo (accession number GSE2520)3. Copy 
number data of the NCI-60 panel were generated on an early release 100K 
SNP mapping array format which had slight differences compared to a later 
array format used in this study. Owing to these differences, separate reference 
normals were used. The GC cell lines were referenced to the Mapping 100K 
HapMap Trio Dataset (Affymetrix) while the NCI-60 panel was referenced to 
copy number profiles of six individuals as reported by Garraway et al. Both 
sets of copy number analyses were performed using dChip 
(biosun1.harvard.edu/complab/dchip/). 
To identify unique GC copy number SNPs, we used Significance Analysis of 
Microarrays (SAM)4
 
 algorithm on normalized copy number data generated by 
dChip. GC cell lines were defined as class I while the other non-GC 
neoplasms were separated into different class II groups by their individual 
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Table 6-3 Seventeen GC cell lines and the panel of NCI-60 non-GC cell lines 











SAM analysis was performed in pairwise fashion using unpaired t-statistics 
(i.e. Class I versus Class II) over 1000 permutations and a false discovery rate 
set at 0%. Each round of SAM analysis compared GC (Class I) with one type 
of non-GC neoplasm (Class II). The process was then repeated with the next 
non-GC cancer type. Each pair-wise analysis generated an output list of 
significantly amplified and deleted copy number SNP clusters. A complete list 
of all altered copy number SNPs in all 74 cell lines was next consolidated 
using Microsoft Excel 2003.  
 
To determined GC copy number signatures, a filter was applied to the 
consolidated data. Only SNPs clusters that registered a gain or loss of ≥ 2 
copies in more than 50% (9/17) of the GC lines were retained. An 
unsupervised hierarchical clustering was performed using average linkage 
analysis (Cluster ver. 3.0, http://bonsai.ims.u-
tokyo.ac.jp/~mdehoon/software/cluster/software.htm#ctv).  The segregation 
786-0, A498, ACHN, CAKI-1, SN12C, TK-10, UO-317Renal
BT-549, Hs578t, MCF7, MDA-MB-231, T47D5Breast
AGS, SNU-1, SNU-5, SNU-16, Hs746T, KatoIII, 
NCI-N87, MKN7, FU97, IM95, YCC1, YCC2, YCC3, 
YCC6, YCC9, YCC11, YCC1617Gastric
IGR-OV1, OVCAR-3, OVCAR-4, OVCAR-5, 
OVCAR-8, SK-OV-3, NCI/ADR-RES 7Ovarian
LOX IMVI, MALME-3M, M14, SK-MEL-2, SK-MEL-28, 
SK-MEL-5, UACC-257, UACC-62, MDA-MB-4359Melanoma
SF-268, SF-295, SNB-19, SNB-75, U251, SF-5396CNS
COLO 205, HCC-2998, HCT-116, HCT-15, 
KM12, SW620, HT297Colon
A549, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, 
NCI-H322M, NCIH460, NCIH5229Non-Small Cell Lung
CCRF-CEM, K562, MOLT4, RPMI8226, SR, HL606Leukemia
Cell linesNumberMalignancy
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pattern from cluster analysis was visualized with Treeview Ver. 1.60 
(http://rana.lbl.gov/EisenSoftware.htm). 
3. Messenger RNA profiling: Affymetrix Human Genome U133A and U133 
Plus 2.0 Arrays 
 
Total RNA (Trizol, Invitrogen) extracted from the same series of GC cell lines 
was converted to cRNA, labeled and hybridized according to the 
manufacturer’s recommendations without modification (Affymetrix). 
Expression profiles of AGS, SNU-1, SNU-5, SNU-16, KATO III, NCI-N87 
and Hs 746T were generated on Affymetrix U133A expression arrays. These 
data were kindly provided by Dr. Patrick Tan (Duke-NUS Graduate Medical 
School, Singapore). The remaining ten cell lines and two normal gastric 
reference specimens were hybridized onto Affymetrix U133 Plus 2.0 
expression arrays. Three technical replicates were performed on each of the 
normal gastric reference for quality assessment and assurance. Datasets from 
both U133A and U133 Plus 2.0 arrays were merged and globally normalized 
to the median intensity values of normal stomach reference RNA.  
 
U133A expression data of the NCI-60 panel of non-GC lines (Table 6-4) was 
downloaded from Symatlas, a publicly available database of the Genome 
Institute of Norvatis Foundation (
3.1 Identification of GC mRNA expression patterns compared to NCI-60 
panel  
http://www.gnf.org/resources/). Using a 
matched set of 22,277 probesets present in both array formats (U133A and 
U133 Plus 2.0), expression values from all 86 arrays of GC and non-GC cell 
lines, including technical replicates, were globally normalized to the 
abovementioned normal stomach reference RNA. After excluding probesets 
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that showed absent calls in > 90% of all arrays, 14,203 probesets were retained 
for further analysis. Breast cancer cell lines were also excluded as data was 
available for only three lines. Similar to the analysis of copy number 
signatures using SAM, GCs were designated Class I and other neoplasms, 
Class II. SAM was then performed (vide supra) to determine statistically 
significant altered mRNA expressions between each pair of GC and non-GC 
samples.  
To identify a unique GC transcription signature, probesets generated by SAM 
were filtered to retain those greater than 2-fold difference (compared with 
normal stomach) in more than 50% of all GC cell lines but in fewer than 50% 
of all non-GC cell lines (considered as a whole group). Redundant or expired 
probesets were then removed prior to clustering (Cluster Ver. 3.0) using 
information provided by an online resource program for updated Affymetrix 
probeset annotations (http://bioinfo2.weizmann.ac.il/geneannot/). The 
segregation pattern was viewed using Treeview Ver. 1.60. 
 
Table 6-4 Seventeen GC lines and NCI-60 non-GC cell lines used to 










AGS, SNU-1, SNU-5, SNU-16, Hs746T, KatoIII, 
NCI-N87, MKN7, FU97, IM95, YCC1, YCC2, YCC3, 
YCC6, YCC9, YCC11, YCC1617Gastric
786-0, A498, ACHN, CAKI-1, RXF 393, 
SN12C, TK-10, UO-318Renal
IGR-OV1, OVCAR-3, OVCAR-4, OVCAR-5, 
OVCAR-8, SK-OV-3, NCI/ADR-RES 7Ovarian
LOX IMVI, MALME-3M, M14, SK-MEL-2, SK-MEL-
28, SK-MEL-5, UACC-257, UACC-62, MDA-MB-4359Melanoma
SF-268, SF-295, SNB-19, SNB-75, U251, SF-5396CNS
COLO 205, HCC-2998, HCT-116, HCT-15, 
KM12, SW6206Colon
A549, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, 
NCI-H322M, NCIH4608Non-Small Cell Lung
CCRF-CEM, K562, MOLT4, RPMI8226, SR5Leukemia
Cell linesNumberMalignancy
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4. MicroRNA expression profiling 
4.1 Small RNA extraction
Total RNA from 17 GC cell lines and 40 fresh frozen primary tumors were 
extracted using the mirVana kit (Ambion) according to the manufacturer’s 
instructions. Quality and quantity were assessed by spectrophotometry 
(NanoDrop ND-1000, Nanodrop Technologies LLC./Thermo Fisher Scientific 
Inc., DE, USA). Samples were advanced to the next step only when ratios of 
absorbance readings for 260 nm/230 nm > 1.8 and 260 nm/280 nm > 2.0. 
Normal pooled stomach total RNA was purchased from Stratagene. Small 
RNA, in which the miRNA fraction resides, was isolated using the flashPAGE 
fractionator (Ambion). Exactly 20 µg of total RNA from each sample was 
loaded onto a column filled with a denaturing polyacrylamide gel matrix and 
the mixture was fractionated by applying an electrical current. A loading dye 
included with the RNA sample served to track RNAs that were < 40 
nucleotides in size. The small RNA eluate (< 40 nucleotides) was collected 
and precipitated overnight in l00% ethanol to which was added 1/10 volume 
3M sodium acetate, pH5.2 and 0.01% linear polyacrylamide. The precipitated 
small RNA pellet was reconstituted in 6ul of nuclease-free water.  
  
 
The recommended protocols from Ambion gave poor signal to noise ratios, 
prompting the use of a different protocol to improve signal intensities. To the 
reconstituted small RNAs, 1x labeling solution and 1 uL of Cy-ULS (Cyanine-
Universal Linkage System) dyes were added and mixed as recommended by 
the manufacturer (Kreatech Biotechnology, Amsterdam, Netherlands). Test 
4.2 miRNA labeling and hybridization  
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and reference samples were incubated at 85oC for 15 minutes. After removing 
excess unconjugated dyes using the proprietary spin column, fluorescently 
labeled cell line miRNAs (Cy3-labeled) was co-hybridized with the normal 
reference sample (Cy5-labeled) on a mirVana miRNA Bioarray Ver. 1 
(Ambion) for 12–16 hours at 42o
 
C in a humidified sealed chamber placed in a 
water bath. Post-hybridization processing comprised one low stringency and 
two high stringency washes, all performed at room temperature. The slides 
were spun dried and scanned in a GenePix 4000B Array Scanner (MDS Inc, 
Ontario, Canada).  
All data spot intensities were filtered using 2 criteria prior to normalization: 1) 
mean intensity ≥ 50% above negative control spots; 2) signal to noise ratio > 5 
on both duplicate miRNA spots within each array. Global mean normalization 
was applied to the filtered signal intensity ratios and the average log




scaled to zero. miRNAs whose expression levels were ≥ 2-fold different 
compared to the reference (pooled normal human stomach) were extracted. 
Separately, normalized miRNAs expression values were also processed by 
SAM (SAM algorithm draws out significantly altered expression values 
although they may be < 2-fold different). The resulting merged list from both 
analyses that showed altered expressions in at least 75% of all GC cell lines 
and primary tumors were clustered by average linkage using un-centered 
correlation (Cluster Ver. 3.0) and visualized with Treeview Ver. 1.60.  
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Validation of miRNA expression profiles was performed on a selected number 
of miRNAs. At least 10 µg of total RNA from each sample was pre-mixed 
with 5’ end radio-labeled antisense oligos (complementary to target 
miRNAs).The mixture was denatured at 95–100
4.4 Solution hybridization 
oC for 3 minutes before 
hybridizing overnight at 42o
 
C. Following this, double-stranded RNA was 
detected by autoradiography in an RNase protection assay (15% PAGE gel; 
film exposure 1-3 hours). 
5. FISH-walking analysis 
Translocation breakpoints were best deduced from SKY and SNP copy 
number analysis. BACs clones (Table 6-2) mapping to presumptive 
breakpoints were selected through the UCSC genome browser, Build hg18 
(http://genome.ucsc.edu/). Before use, all unmapped BAC clones were FISH-
validated on normal human metaphases.  
 
Isolation of BAC DNA was performed using the Qiagen Plasmid Midi kit 
(Qiagen) according to the manufacturer’s instructions with slight 
modifications that increased the yield of DNA. 1) Bacterial cells were pelleted 
from 1.2 liters of LB broth culture centrifuged at 15200 g, 15 minutes, 4°C. 2) 
12 mL of solutions P1, P2 and P3 were used. 3) After incubation on ice, 
centrifugation was at 22000 g, 60 minutes, 4°C. 4) 15 mL of QF buffer was 
used to elute the DNA. 5) DNA was precipitated by adding 10.5 mL of 
propan-2-ol (0.7 volume) to the QF eluate and stood overnight at 4
5.1 BAC DNA isolation  
oC. Excess 
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salts were removed from the DNA pellet with 5 mL 70% ethanol before 
dissolving in 100 μL of nuclease-free water. DNA concentration and purity 
were determined by spectrophotometry (NanoDrop ND-1000).  
 
Direct labeling with fluorophores was performed using the BioPrime labeling 
kit (Invitrogen), according to the manufacturer’s instructions. BAC probes 
were labeled with fluorescein isothiocyanate (FITC) or Texas Red
5.2 Probe labeling and cytogenetic validation of probes 
 (Perkin 
Elmer Inc., WA, USA). Free fluorophores were removed using Microcon YM-
30 Centrifugal Filter Unit (Millipore Inc., MA, USA). Freshly purified probes 
were ethanol precipitated and dissolved in 10 µL hybridization buffer (50% 
formamide and 10% dextran sulfate in 2 x SSC) before hybridization. All 
labeled BAC probes were combined in equimolar concentrations to form the 
probe hybridization mixture and stored at -20o
Premixed dual-labeled FISH probes and metaphase spreads were heat-
denatured at 72
C until use.  
o
6. TMA construction 
C for 4 and 2 minutes, respectively, before hybridizing for at 
least 48 hours. FISH images were digitally captured and analyzed with 
CytoVysion Ver. 2.7 (Applied Imaging, Genetix, U.K.) and FISHview 
imaging software (ASI). 
FFPE tissue sections, stained with hematoxylin and eosin (H&E), were 
marked for the presence of neoplastic cells. High tumor content samples that 
had weak or no immunostaining for Ki-67 were judged unsuitable for FISH 
because nuclear material was likely to be severely degraded. Tissue 
microarrays (TMAs) were constructed by coring each FFPE tissue block with 
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a hollow 1 mm diameter metal capillary to obtain a representative cancer-rich 
tissue core. Each tissue block was cored in duplicate. Cores were remounted in 
a new recipient block aligned to a predetermined array configuration using a 
manual tissue arrayer (Beecher Instruments Inc., WI, USA). Edges of adjacent 
cores were 1 mm apart. Each TMA section was no larger than 24 mm2
 
. A 












Figure 6-1 A H&E stained section of a gastric cancer tissue microarray. Two 
tonsil cores in the lower right corner serve as orientation markers. 
 
7. Break-apart FISH assay 
Probes for the break-apart FISH assay (Table 6-2) were assembled using 
chromosome 18q1q2-mapped BAC clones. The rationale for the probe design 
is detailed in Chapter 11. BAC DNA was prepared using standard methods 
(vide supra). Probes were labeled with different fluorophores that gave 
stronger signal intensities on FFPE sections. Probes mapping to 18q12 and 
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18q21 were labeled with SpectrumGreen and 18q22 probes with 
SpectrumOrange (both from Vysis/Abbott Molecular Inc. IL, USA). Free 
fluorochromes were removed using ChargeSwitch PCR Clean-up kit 
(Invitrogen). All freshly labeled BAC clones were FISH-validated on normal 
human metaphases to confirm their cytoband positions before hybridizing to 
interphase nuclei in FFPE samples. Probe intensity and specificity were also 
assessed on both metaphase spreads and interphase nuclei obtained from 
peripheral blood lymphocytes and primary epithelial cells derived from human 
umbilical cord-lining membrane.  
 
FFPE sections were deparaffinized and rehydrated using the Histology FISH 
Accessory Kit (Dako, Denmark A/S). Supplied solutions were: pre-treatment 
(vial 1), pepsin (vial 2), wash buffer (vial 3) and stringency buffer (vial 4). 
Working concentrations of vials 1, 3 and 4 were diluted 1:20 in distilled water 
as recommended.  
7.1 Optimization of FISH assay on FFPE sections 
Modifications to the protocol from our optimizations (vide infra) markedly 
improved hybridized FISH signals. Four variables were optimized: i) FFPE 
section thickness; ii) heat pre-treatment; iii) pepsin digestion; iv) hybridization 
duration.  
 
Commercial FISH probes, (split-apart MYC FISH DNA probe, Dako), were 
used. FISH signals developed on 1, 2 and 4 µM sections mounted onto 
positively charged poly-L-lysine coated slides were compared.  Two-micron 
i) FFPE section thickness 
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sections were judged to be optimal as these produced non-overlapping and 
uniformly distinct signal intensities. Four-micron sections were too thick for 
accurate signal interpretation and enumeration, while 1 µM sections generated 
large numbers of truncation artifacts.  We confirmed the optimal section 
thickness to be 2 µM by hybridizing a commercial BCL2 break-apart probe 
(Vysis/Abbott Molecular) to a follicular lymphoma positive for t(14;18) 
(Figure 11-6, page 250).  
 
To allow better FISH probe penetration into nuclei during hybridization, FFPE 
sections were placed in diluted pre-treatment solution and boiled continuously 
in a domestic microwave oven (Whirlpool with ‘Sixth Sense function’) for at 
least 20 minutes.  
ii) Heat pre-treatment  
 
Five to eight drops of cold pepsin (vial 2, ready-to-use) were placed over the 
entire FFPE tissue section and incubated for 3–6 minutes at 37°C in a Dako 
Hybridizer (Dako) as recommended by the supplier. Digested slides were 
rinsed twice in wash buffer for 3 minutes at room temperature and dehydrated 
in a graded series of 70%, 95% and 100% ethanol (2 minutes each).  
iii) Pepsin digestion 
 
Ten µL of probe hybridization mixture was placed over each FFPE tissue 
section and overlaid with a glass coverslip to ensure that the hybridization 
mixture was evenly spread over each TMA core. The coverslip was sealed 
iv) Hybridization duration 
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with rubber cement to prevent evaporation and placed in the Dako Hybridizer. 
The labeled probes and nuclear DNA were co-denatured at 82°C for 5 
minutes, followed by hybridization at 37°C for 24 or 72 hours. Upon removal 
of the sealed cover-slips, post-hybridization washings were performed as 
follows: 1) washed once at room temperature using the stringency buffer; 2) 
the same wash was repeated at 65°C for 10 minutes; and 3) two washes in 
wash buffer for 3 minutes each at room temperature.  The washed sections 
were counterstained with 4,6-diamino-2-phenylindole (DAPI), cover-slipped 
and stored at 4°C in the dark before viewing. Comparing both hybridization 
durations, 72 hours gave signal intensities that were considerably stronger 
without increase in background fluorescence. 
 
FISH signals were enumerated under a 100X oil immersion objective lens 
attached to an Olympus BX-61 fluorescence microscope (Olympus 
Corporation, Japan) equipped with appropriate filters for probe visualization. 
Digitized FISH images were captured and analyzed using FISHview imaging 
software with Z-stacking function (ASI). FISH signals were scored manually 
on morphologically intact and non-overlapping nuclei. Signals from a 
minimum of 50–100 cancer cells from usable tumor cores were enumerated. 
7.2 FISH signal enumeration and analysis 
 
FISH signals of probes to 18q12q21 (SpectrumGreen) and 18q22 
(SpectrumOrange) were considered to be split in the break-apart assay if the 
distance between the dual colors was greater than twice the diameter of the 
7.3 Threshold determination 
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larger signal. Recognizing that break-apart FISH signals could also be 
detected in normal cells due to the physical structure of uncondensed 
chromatin, the percentage of false positive break-apart signals in normal 
nuclei was determined in 5 cases of benign gastric ulcer disease and gastritis. 
Two independent observers enumerated FISH signals of > 200 nuclei from 
each sample. From these pooled data, we established our diagnostic criterion 
for 18q21q22 break-apart positivity in cancer tissues. This threshold 
percentage was the mean percentage plus 3 standard deviations of false 
positive signals in normal gastric tissues5
 
 (Table 11-1, page 251).  Thus, given 
the mean percentage (6.4%) and standard deviation (4.6%) of false positive 
split signals in normal gastric nuclei, the diagnostic criterion for break-apart 
positive cancers was [6.4 + (3 x 4.6)] i.e. > 20.2%. Separately, the threshold 
value to exclude truncation artifacts due to tissue sectioning was determined 
by assessing 1000 nuclei each from sections of two benign gastritis tissues 
(Table 11-1, Page 251). 
8. Immunostaining and immunofluorescence of prostate tissue 
To distinguish malignant from benign prostatic epithelium, double-staining for 
cytokeratin 5/6 (CK5/6) and alpha-methylacyl-CoA racemase (AMACR) was 
performed on 4 µM prostate cancer tissue sections. All sections were placed 
on poly-L-lysine treated slides and incubated for 16 hours in a 50
8.1 Immunostaining  
oC oven. All 
antigen retrieval, immunostaining and detection steps were performed as 
recommended using the automated Bond™ system (Leica Microsystems 
GmbH., Wetzlar, Germany). Sections were de-waxed and heat induced 
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epitope retrieval (HIER) was performed using Bond Epitope Solution 2 (Leica 
Microsystems). Incubation with the primary monoclonal antibody against 
human CK5/6 (1:25 dilution; M7237 clone: D5/16 B4, Dako) was for 20 
minutes and binding was detected with Bond Polymer Refine Detection 
reagent (Leica Microsystems). Immunostaining for AMACR used a polyclonal 
antibody (1:50 dilution; P504S, Biocare Medical LLC, CA, USA) incubated 
for 30 minutes, followed by an alkaline phosphatase blocking reaction. 
Detection was performed with Bond Polymer AP Red Detection reagent 
(Leica Microsystems). 
 
Immunofluorescence was performed as detailed by Mattsson et al.
8.2 Immunofluorescence  
6. Tissue-
bound primary anti-AMACR antibody (above) was detected with a secondary 
anti-rabbit antibody conjugated to Alexa Fluor 488 (Molecular 
Probes/Invitrogen). Primary anti-CK5/6 antibody was detected with a 
secondary anti-mouse IgG1
 
 conjugated to Alexa Fluor 568 (Molecular 
Probes/Invitrogen). Digital imaging was performed using FISHview imaging 
software (ASI). 
9. Immunnohistochemistry  
Immunohistochemistry (IHC) was performed on 4 µM gastric adenocarcinoma 
tissue sections on poly-L-lysine treated slides incubated at 50oC for 16 hours. 
Standard deparaffinization and rehydration steps were performed followed by 
boiling in a microwaveable pressure cooker (Nordic ware, Cat No. 62104) for 
3 minutes in 0.05M Tris-EDTA (pH9.0) for antigen retrieval. After rinsing the 
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cooled slides in water, tissue sections were pretreated with 3% hydrogen 
peroxide for 10 minutes, rinsed in distilled water for 5 minutes and then 
soaked with 0.05M Tris-buffered saline pH7.6 for 5 minutes. Sections were 
immunostained for 30 minutes at room temperature with anti-human Serpin 
B8 monoclonal antibody (ab49634 clone: PI-8, Abcam Ltd., Cambridge, UK) 
and anti-CD226 antigen polyclonal antibody (HPA015715, Sigma-Aldrich 
Inc. MO, USA), both diluted 1:100. Immunostaining with anti-Serpin B2 
(Lifespan Biosciences Inc. WA, USA) and anti-SOCS-6 (ab53211; rabbit 
polyclonal, Abcam) antibodies were performed at 1:100 and 1:5 dilution, 
respectively, for 30 minutes at room temperature. Slides were washed with 
0.05M Tris-buffered saline for 5 minutes, followed by incubation with the 
polymer link (DAKO ChemMateTM Envision, Dako) for a further 30 minutes.  
Following a second wash in 0.05M Tris-buffered saline for 5 minutes, 
antibody binding was detected using DAB (Dako) for 10 minutes and lightly 
counterstained with hematoxylin. 
 
Expression of Serpin B8 expression was scored on i) staining intensity in the 
nucleus; and ii) extent of expression in the tissue section. Three grades of 
nuclear staining intensity in gastric adenocarcinoma cells were scored (Figure 
6-2): 2+ for intense staining (monocyte nuclei served as internal 2+ controls); 
1+ for weak staining and 0 for negative staining. The extent of 
immunoreactivity in each gastric cancer core was also assessed as a 
percentage of all positively-stained carcinoma cells in 10 random fields. The 
binary scoring criteria for Serpin B8 expression was defined: 1) Grade 2+ in 
9.1 Scoring Serpin B8 immunostaining  
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≥50% or Grade 1+ in >70% of neoplastic cells as “High expression” and 2) 
Grade 2+ in <50% or Grade 1+ in ≤70% or Grade 0 as “Low expression” 
(Figure 6-2). Scores were tabulated and two-tailed Fisher’s exact test was 













Figure 6-2 Representative images of the binary scoring criteria for Serpin B8 
immunostaining. 
 
To identify tissues that had sustained cytoplasmic antigenic loss sufficient to 
cause false negative immunostaining for our antigens of interest, GC TMAs 
were evaluated by immunostaining with anti-human pan-cytokeratin 
antibodies (dilution 1:200; DAKO M3515; Clone: AE1/AE3; Dako). Most 
TMA cores showed positive cytoplasmic staining in gastric adenocarcinoma 
cells (Figure 13-5, Page 279).  However, a few weakly stained cores identified 
9.2 Cytokeratin clone AE1/ AE3 immunostaining 
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were excluded from immunostaining analysis of CD226 antigen, Serpin B2 
and SOCS-6 expression.  
 
Staining for CD226 antigen, Serpin B2, and SOCS-6 were predominantly 
cytoplasmic and staining intensities were uniform within the neoplastic cells 
of each sample core (different from that of Serpin B8 immunostaining). A 
binary score (Figure 6-3) was developed based on: 1) intense cytoplasmic 
staining as “High expression”; 2) weak or no staining as “Low expression”. 
Scores were tabulated and two-tailed Fisher’s exact test was performed based 
on break-apart status. 














Figure 6-3 Scoring criteria for CD226 antigen, Serpin B2 and SOCS-6 
immunostaining. Representative images of CD226 antigen immunostaining 
are shown. 
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10. Precise breakpoint determination of flow-sorted GC cell line chromosomes 
10.1 Flow-sorting 
Chromosome suspension was prepared based on the method of Yang et al.
10.1.1 Chromosome preparation 
7. 
Eight to ten flasks (150 cm2) of cell line cultures (70% confluent at 
exponential growth phase) were arrested in metaphase by adding 10 µg/mL 
demecolcine (Sigma-Aldrich) to a final concentration of 0.01 µg/mL for 6-24 
hours. Arrested cells appeared as ‘rounded-up’ cells scattered against adherent 
cells and were harvested by manual shaking. Conditioned medium after 
“mitotic shake-off” was rendered hypotonic for 18 minutes at room 
temperature, during which the degree of cell swelling was monitored by 
staining an aliquot with Truck’s stain (Sigma-Aldrich). Lightly stained 
“swollen” cells were visible at 20X magnification in a light microscope. 
Swelling time was increased by 5–10 minutes if necessary. The suspension 
was centrifuged for 5 minutes at 289 g to remove the supernatant. The pellet 
was triturated in 3 mL of ice-cold polyamine isolation buffer (PAB) and stood 
on ice for 10min after which it was vortexed for 10–20 seconds to lyse cells 
and released chromosomes in suspension. The density of suspended 
chromosomes was assessed by staining an aliquot with propidium iodide 
(Sigma-Aldrich) and viewing in a fluorescence microscope. If necessary, 
apply additional vortexing for 10–15 seconds to fully dispersed chromosomes.  
Cell debris was removed by brief centrifugation and the supernatant 
(containing suspended chromosomes) was filtered through a 20 µM mesh 
filter (Celltrics, Partec, Germany). Isolated chromosomes were stained 
overnight with 5 µg/mL of Hoechst 33258 (Ho) and 40 µg/mL of 
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chromomycin A3 (CA3) (both from Sigma-Aldrich) in 10 mM MgSO4
 
. To the 
stained chromosome suspension, 10 mM sodium citrate and 25 mM sodium 
sulfite (working concentrations) was added for at least an hour before flow 
cytometry analysis and sorting.  
Analysis and sorting of a suspension of stained chromosomes requires a flow 
cytometer equipped with two lasers
10.1.2 Analysis and sorting of chromosomes on a MoFlo® flow cytometer   
7
Data for forward scatter, pulse width, Ho and CA3 fluorescence were 
collected using Ho fluorescence as the trigger signal. Flow karyotypes for all 
cell lines were displayed as bivariate flow karyograms of Ho versus CA3 
fluorescence after gating on forward scatter (FSC) versus pulse width to 
. One is a UV (330–360 nm) laser for Ho 
excitation and the second is a laser tuned to have an emission spectrum of 
457.9 nm for excitation of CA3. In the flow cytometer used, both lasers were 
fixed at a power rating of 300 mW. Ho emission was collected via a 400 nm 
long-pass and a 480 nm short-pass filter. CA3 emission was collected with a 
single long-pass filter at 490 nm. The instrument’s optical light path was 
calibrated and aligned using 3 µM Sphero Rainbow Fluorescent particles (BD 
Biosciences, Ontario, Canada). The MoFlo® flow cytometer was adjusted for 
a high-purity sort option using a single mode per single drop envelope, and set 
at a data rate of 2000–12000 events per second. The sheath pressure was set at 
60 psi using sheath buffer (1 mM EDTA, 0.05% sodium azide (w/v), 100 mM 
NaCl, 10 mM Tris-HCl). Drop drive frequency was adjusted to 95 KHz with a 
70 µM nozzle tip. Sorted chromosomes were collected in gamma-irradiated 
microfuge tubes containing 33 µl of UV-treated water. 
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exclude doublets, clumps and debris. A total of 100,000 events were acquired 
for each cell line at a rate of 1,000 events per second.    
 
10.2 Reverse FISH analysis of sorted chromosomes 
Pure fractions of at least 1000 copies of flow-sorted chromosomes were 
collected from each spot. The genomic material was first amplified by DOP-
PCR using standard Telenius universal degenerate primers
10.2.1 DOP-PCR labeling and FISH hybridization 
8. To verify the 
identity of the sorted chromosome spot, an aliquot of the initial amplified 
DOP-material was used as the template for a second labeling reaction using 
one of three fluorophores: FITC (Perkin Elmer), TexasRed®
 
 (Perkin Elmer) or 
Cy3 (Amersham/GE Healthcare, UK). The fluorescently-tagged sorted 
chromosomal DNA was hybridized onto normal human metaphases using 
standard chromosome FISH paint protocols. Images were digitally captured 
using FISHview imaging software (ASI). 
10.3 Array painting 
Sorted chromosomes were amplified by one of three methods: 1) DOP-PCR; 
2) GenomePlex (Sigma-Aldrich); or 3) GenomiPhi (GE Healthcare, UK) 
before labeling and hybridization to DNA microarrays. Labeling and 
hybridization protocols to Agilent 244K oligoarrays (Agilent Inc, CA, USA) 
and Affymetrix GeneChip
10.3.1 Copy number transition point analysis 
® Human Mapping 500K Set arrays were performed 
as recommended by the respective manufacturers. To determine the copy 
number transition points, copy number data from Agilent arrays were analyzed 
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using DNA Analytics software 4.0 (Agilent Inc.) and Affymetrix 500K 
mapping arrays, CNAT 4.0. 
 
To validate the fusion points determined from array painting data, BAC clones 
mapping to the breakpoint were acquired (RP11-159C8, 6p22.3 and RP11-
318J15, 18q12.2). BAC DNA from each clone was labeled with 
SpectrumGreen or SpectrumOrange using standard protocols (vide supra). The 
dual-labeled fusion probe assay was performed on metaphase spreads prepared 
from YCC2 cell line.  
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Results and Discussion 
 
7. Spectral karyotyping of  GC cell lines  
Recurrent chromosomal translocations are closely or uniquely associated with 
specific cancer types and have proven relevance in many hematological 
malignancies1 and more recently, in epithelial tumors such as prostate 
carcinomas2-4. However, relatively little is known about the cytogenetic 
aberrations in gastric cancer, largely due to the technical challenges of 
preparing decent quality metaphases for karyotypic analysis5
SKY is a powerful molecular cytogenetic technique
. To circumvent 
this longstanding problem, we exploited the ease of metaphase preparation 
from rapidly dividing gastric cancer cell lines. We reasoned that the karyotype 
data of cell lines could be a useful point of departure for discovering 
chromosomal aberrations in clinical samples of primary gastric cancer tissues, 
provided GC cell lines are a reasonable biological surrogate for primary GC 
tumors (this concern is addressed in Chapter 8, page 174). Multi-color spectral 
karyotyping (SKY) was performed to dissect the architecture of complex 
rearranged chromosomes. 
6. It uses a “paint” mixture 
produced by fluorescence labeling of each human chromosome. By using 5 or 
6 fluorochromes in different combinations, a palette of different spectral 
“colors” (one for each of the 24 chromosomes) is produced7
 
 (Figure 7-1). The 
probe mixture is co-hybridized onto tumor metaphase spreads. 
 
 












Figure 7-1 Schematic diagram of spectral karyotyping performed on 
metaphase spreads (Adapted from ref.7). 
 
Juxtaposed colored regions were noted as probable translocations. Other 
aberrant features, such as whole chromosomal gains and losses, were also 
recorded using standard nomenclature as described in ISCN 19958.  By 
focusing on recurrent breakpoint cytobands and structural rearrangements 
across the panel of 17 cell lines, it may be possible to identify genomic regions 
and/or genes that are clonally selected as drivers of oncogenesis. These 
putative drivers may be necessary for tumor initiation, progression or 
metastasis. However, a caveat to SKY analysis is that although the rearranged 
patterns are informative, the technique is compromised by its relatively low 
resolution (5-10 Mb). To overcome this limitation and ascertain the breakpoint 
regions at higher resolution, we integrated spectral karyotypes with whole 
genome copy number data from 100K SNP mapping arrays (an approach also 
discussed in subsequent Chapters). Details on the methods for whole genome 
copy number analysis are presented in Chapter 6, page 118. 
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7.1 Spectral karyotypes reveal 45 recurrent breakpoint cytobands  
To fully characterize the gross chromosomal aberrations (translocations, 
whole chromosome duplications and deletions) in 17 GC cell lines, spectral 
karyotypes were generated from an average of 14 metaphases per cell line. All 
karyotyping were complied with standard nomenclature of ISCN 19958 with 
the following modification. Numerical and structural aberrations are described 
in the order of the chromosomes (from chromosome 1 to Y). This allows for 
easy referencing of aberrations shown in SKYgrams to the described 
composite karyotypes. It is a well established fact that karyotypic 
heterogeneity exists in primary cultures as well as cell lines9
 
. We were more 
stringent than ISCN 1995 in defining clonality of chromosome abnormalities 
and restricted this designation only to alterations that were observed in ≥ 30% 
of the total metaphases analyzed in each cell line. The overall clonal patterns 
are represented by the composite karyotypes in Table 7.1. The ploidy states 
and chromosome numbers varied widely. Five cell lines were near-diploid, 
seven near-triploid and the remaining five, near-tetraploid (Table 7.1). FU97 is 
a polyploid cell line, having chromosome numbers ranging from 103 to 160. 
Composite karyotypes showed simple rearrangements in 2 lines, SNU-1 and 
IM95. It is worth noting that the near-diploid lines were as likely to harbor 
complex rearrangements as the triploid and tetraploid lines, as exemplified by 
NCI-N87 and YCC9. For ease of visualization of these complex 
rearrangements, the composite karyotype of each cell has been converted to 
SKYgrams shown in Figures 7-2 to 7-18. Classified SKY images of the 17 
GC cell lines are shown in Appendix Figures 1 to 17. 

























































































































































































































































Note: Chromosome numbers was reported as a range followed by the ploidy of the cell line as 
indicated in arrowed brackets: <2n> = near-diploid. Description of cytogenetic aberrations 
was detailed in accordance to ISCN 1995 guidelines. Square parentheses indicated the 
number of metaphases with the described aberration(s). cp[n] showed the total number of 




Karyotype: 47-50<2n>, XX[11], der(8)t(1;8)(q12;p22)[11], t(8;10)(?;p13)[5], 
i(13)(q10)[6], +13[3], +14[8], del(18)(q11.2)[8], -18[3], 
+der(19)t(6;19)(p22;q13.3)[11], +20[11], cp[11] 
 






















































Karyotype: 47<2n>, XY[10], der(4)t(1;4)(q25;q32)[11], +20[11], cp[11] 
 






















































Karyotype: 42-44<2n>, XYY [8], t(1;5)(p36.1;?)[6], 
der(3)del(3)(p24)ins(3;8)(p12;?)[10], -4, t(5;19)(p13;?q)[4], 


























































Karyotype: 68~92<3n>, XX[9], +t(X;15)(p11.2;q10)[9], der(1)(1;5)(p36.1;?)[9], 
+der(1)(1;5)(p36.1;?)[7], der(1)t(1;8)(p36.1;q23)[10], 
+der(1)t(1;8)(p36.1;q22)[9], +der(2)t(2;3)(p22;q22)x3[10], +3[7], 
+t(4;13)(q32;q22)x2[9], +der(4)del(4)(q25)ins(4;13)(q12;?)[5], +del(5)(p)[10], 
+5x2[8], del(6)(q24)x2[10], +der(7)t(3;7)(q22;q31)x2[10], 
+der(7)t(4;7)(q28;q31)x2[10], +7x2[9], +der(8)ins(8;1)(q23;?)[5], 
der(9)t(2;15;9)(?;q10;p12)[9], +10[9], +11x2~3[10], +12x1~2[7], 
+t(13;18)(q22;q21)[8], +14[8], +t(9;15)(p12;q10)[10], +16x2[10], 
+i(17)(q10)x2[10], +19x2[10], +20x2[10], +21x1~2[8], +22[9], cp[10] 
 






















































Karyotype: 57~92<4n>, XXX[6], XXXX[3], +1x2[7], +2x2[8], +3[8], 
+der(4)t(4;21)(p12;q11.2)[10], +der(5)t(5;11;10)(q12;?p;?)[6], 
+i(5)(p10)x1~3[10], +5[3], +der(6)del(p21.1p21.3)del(6)(q22)[3], +6[6], 
+7x2~4[9], +8[8], +9[9], +del(10)(q21)[10], +del(10)(p10)[2], +10[2], 
+der(11)t(1;11)(p33;p14)[8], +11[8], +del(12)(p11.2)x1~3[10], 
+der(13)t(8;13)(q11.2;q12)[4], +13[9], +14x1~4[9], +15x1~2[9], +16x1~2[9], 
+del(17)(p11.2)x2[9], +18[10], +19x1~2[10], +20x2[9], +22[9], cp[10] 
 






















































Karyotype: 74~84<4n>, XXX[12], +1[8], +del(2)(?)[10], +del(3)(p21)[12], 
+3x2[12], +4[12], +5[8], +6x2[10], +7x1~3[12], +der(7)t(7;11)(q21;q13)[11], 
+8x2[11], +9x2[11], +10[11], +i(11)(q10)[12], +der(11)hsr(11;10)(q13;q?)[11], 
+der(12)t(2;12)(q23;q14)[9], +12[8], +13x2[12], +14[10], +i(15)(q10)[12], 
+16x2[12], +dup(17)(q12)[10], +17x2~3[12], +18[8], +19[7], 
+dup(20)(q13.1qter)[11], +20x1~2[12], +22x1~3[12], cp[12]  
 









































































Karyotype: 68~73<3n>t(X;10)(p10;p10), t(X;18;2)(q22;q21;?), Y, 
t(1;2;7)(q10;q10;q32;q31), t(1;5;4;X)(q10;p10;?;?), +t(2;7)(q32;q31), 
t(2;16)(q10;p10), +t(2;17)(p10;p10), +3, t(3;19)(p10;p10), t(3;8)(q10;q10), 
dic(4;9)(4p15.2;p23)x2, +t(1;4)(q21;q32), +5, t(5;22)(p10;q10), t(5;9)(q10;p10), 
+6, t(6;11)(p21.1;q13)dup(11)(q13), t(7;16)(p10;p10)x2, 
+t(1;7)(p10;q10)dup(7)(q31), +t(10;7;22)(?;p22;q31;?), 
+t(2;7;11;8)(q31;q32;?;p22), +t(16;20;8)(q22;?;q12), +9, 
t(3;10)(?;q25)hsr(10)(q24), t(12;11)(p10;q10), t(10;12)(q11.2;p13), 
t(12;16)(p10;q10), t(11;13)(p10;q10), t(14;22)(q10;q10), t(10;22;14)(?;q10;q10), 
+t(14;22;3)(q10;q10;q13;?), t(6;14)(q10;q10), +t(1;15)(p10;q10), 
+t(5;1;15)(?;p10;q10),-16, +17, -18, t(16;21)(q10;q10), 
+t(11;20;19)(q13;q13.2;q10;p10), +mar(t(17;18;20;8;21;4;3;20)(?), cp[6] 






















































Karyotype: 43~47<2n>, X[24],-Y[24], t(1;2)(q23;p23)[24], +7[24], +8[22], 
del(13q14)[23], -14[2], cp[24] 
 






















































Karyotype: 61~70<3n>, XXY[10], inv(1q12)[11], +3[11], t(3;4)(?;p15.1)[9], 
t(4;7)(p15.1;?)[10], +5[10], , del(6)(q24)[4], t(1;6)(q25;q25)[11], 
+t(7;15)(q21;q15)[10], t(8;17)(p10;p10)[10], t(8;17)(q10;p10)x3[11], 
der(9)t(2;9;12)(q21;q21;?)[11], t(20;9;8)(?;q31;?)[10], 
der(11)t(13;11)(q12;p13)ins(11;19)(q13;q13.1qter)[8], +11[11], +11[10], 
del(12p)x2[11], +i(12p)[11], +t(12;17)(p10;p10)[10], t(20;1;13)(?;?;q10)[11], 
+t(19;14)(q10;q10)x2[11], +14[10], i(15q)[10], -15[3], t(1;16)(?;q12)[9], 
t(7;16)(?p;q22)[10], t(17;20)(q10;p10)[10], +t(9;18)(?;q21)x2[10], 
t(19;11)(?;?)[10], +t(19;6)(?;?)[8], +20[11], +20[11], +21[8], 
+t(11;22)(q13;q12)[11], cp[10] 






















































Karyotrype:103~160<5n>, XXx2~4[19], t(X;3)(p10;?)x2[19], 
t(X;17)(p10;q12)dup(17)(q12)x2[18], t(X;22)(p10;q12)[16], 
+der(3)t(3;12)(q10;p10)x3[19], +der(3)t(3;20)(p10;q10)x3[19], 
+der(3)t(3;6)(p14;?)ins(3;20)(p12;q11.2)[19], +3[17], +mar(4)x2[17], +4[17], 
+4[17], +4[15], +mar(5)x2[19], +5[19], +5[17], +5[16], +5[8], +6[19], +6[19], 
+6[18], +6[16], +7[19], +7[19], +7[19], +7[18], +7[16], del(8)(q24.1)x4[18], 
+8[19], +8[9],+9[18], +9[18], +9[13], +mar(10)[18], +10[18], +10[17], +10[17], 
+10[12], +der(11)t(11;15)(p12;q24)x2[16], +der(11)t(11;19)(q10;p10)x2[18], 
+11[18], +11[17], +der(12)t(12;22)(p10;q10)[17], +12[19], +12[19], +12[17], 
+12[15], +12[13], +13[19], +13[17], +13[17], +13[12], +13[8], +14[17], +14[12], 
+15[18], +15[18], +15[15], +15[10], +der(16)t(11;16)(?;?p13.3)x3[13], +16[19], 
+16[17], +16[8], +16[6], i(17q10)t(17;3)(q25;?)x2[10], 
+der(18)t(8;18)(q22;q21)x2[19], +18[18], +18[17], +19[17], +19[17], +19[14], 
+20[19], +20[19], +20[19], +20[19], +20[17], +20[13], +21[19], +21[17], 
+21[15], +21[6], +22[16], +22[10], cp[19] 
 






















































Karyotype: 59~66<3n>, X[10], mar(X)[10], +del(1p)(36.1)[10], 
+der(1)t(1;5)(q10;?)[5], +del(2)(p22)[10], +der(3)t(3;5)(q10;p10)[7], 
+der(3)t(3;12)(p21;?p)[10], der(6)t(6;10)(q24;p13)[9], +dup(7)(q31)[10], 
+t(6;8)(p10;q10)x2[10], +8[10], del(9)(q21)[10],+mar(9)[9], +mar(10)[5], 
t(8;11)(q22;q23)[10], +t(11;17)(p13;q21)[10], t(10;12)(q10;q10)[10], 
t(9;13)(q31;q10)[9], +i(13)(q10)t(X;13)(?;q32)[10], +t(9;14)(q31;q10)[10], 
+t(6;15)(?p;q10)[10], +15[5], t(19;16)(?;q10)[5], 
+t(1;17)(p10;q10)dup(17q21)[10], +t(7;18)(?;?)[9], +19[6], 


























































Karyotype: 81~86<4n>, XX[7], X[3], i(X)(p)[3], i(16p)t(Y;16)(q11.2;q13)[10], 
+1[9], t(1;2)(q12;p24)[8], +t(2;5)(q12;p12)x2[10], 
+der(2)t(2;19)(q10;p10)x2[10], del(3)(?p)x2[10], +der(3)t(2;3)(?;q10)[10], 
+der(3)t(21;13;3)(q10;q22;q13.2)[10], +der(3)t(3;10)(q10;p10)[9], 
der(4)t(4;2;8)(q10;q36;?)[10], inv(5)(pterq12)[10], +der(5)t(3;5)(?;p15.1)[10], 
der(6)t(6;12)(p10;?)x2[9], +der(6)t(6;18)(p22;q21)[10], +del(6)(p11.2pter)[5], 
der(6)t(6;4;5)(q10;q10;?)[10], +der(7)t(7;8)(q36;q22)[10], 
+der(8)t(4;8)(q25;q24.1)[10], der(8)t(8;13)(q24.1;?)[10], del(8)(q24.1)[9], +9[6], 
+der(10)t(10;14)(q10;?)[8], +del(11)(q23qter)x3[10], 
der(12)t(22;8;12)(?;?;p13)[9], inv(12)(q14)ins(8;12)(?;q14)[7], +13[10], 
der(13)t(18;19;13)(q10;q10;q31)[8], +14[10], +der(14)t(14;19)(q10;q10)x2[7], 
der(15)t(7;15)(q10;q10)[10], der(15)t(11;15)(q10;q10)x2[10], 
+der(15)t(12;15)(?p;q10)x3[10], der(16)t(2;16)(?;q21)[10], 
der(16)t(16;20)(q10;p10)[8], der(17)t(17;19;6)(p10;q10;?)[10], +17[10], +17[9], -


























































Karyotype: 61~67<3n>, der(X)t(X;15)(p21;q22)x2[20], 
+der(1)t(1;6)(p21;?)del(1)(q25)[20], +2[16], +3[20], +3[20], +5[19], 
t(6;18)(p22;q21)[20], t(7;17)(p10;p10)x3[20], t(7;17)(q10;q10)x2[20], +8[18], 
+del(8)(p21)[19], der(10)t(10;13)(q10;q21)[19], +der(10)t(10;19)(p10;q10)[18], 
+der(11)t(7;11)(?;q23)dup(11)(p14pter)[20], +t(12;13)(q10;q21)[20], 
i(13)(q10)dup(13)(q21)[20], t(13;22)(q10;q10)[20], +14[20], +14[20], 
der(15)t(13;15)(?;q24)[19], der(16)t(4;16)(q10;q10)del(4)(q32), 
+der(16)t(16;4;6)(?q10;q10q34;p22)[19], der(17)t(1;17)(q25;p13)[20], -17[20], 
+der(19)t(19;20)(q10;q10)[18], +20[19], +20[17], +i(22)(q10)x2[19], cp[20] 
 
 






















































Karyotype: 57~71<3n>, XX[10], XXX[3], +t(1;11)(p21.1;q10)x1~2[17], 
+t(1;13)(q10;q10)x1~2[17], +2[16], +del(3)(p11)[17], +del(3)(p11)[14], 
+del(4)(q28.3)[14], +5[17], +del(5q)(31)[2], +6[15], +der(6)t(1;6)(p10;?q25)[17], 
+dup(7q)(q21q22)[16], +t(7;11)(q10;q10)[16], +9[10], +i(10q)[16], 
+der(12)t(12;18)(q24.2;?q)[14], +13[10], +der(14)t(21;14;12)(q10;q32;?p)[17], 
+15[12], +16[11], +17[15], -18[17], -18[17], +19[15], +20[16], +20[13], +20[11], 
+der(22)t(7;22)(?;q12)[15], cp[17] 






















































Karyotype: 38~41<2n>, X[24], del(3)(p12p24)[22], 
der(4)t(9;6;4)(p12;?;p15.1)[24], t(4;6)(p15.1;q24)[23], del(7)(q21)[24], 
t(3;7)(?p24;q31)[23], i(8)(q)[22], del(9)(?p12)[23], t(9;Y)(q10;q10)[24], 
der(14)i(14)(q10)t(3;14)(q13.2;q21)[23], t(17;22)(q24;q12)[24], -18[24], 
t(3;19)(?;p13.1)[24], -21[24], -22[24], cp[24] 
 






















































Kayotype: 78~91<4n>, XX[11], +del(1)(q25)[9], +der(1)t(1;20)(p13;q12)x2[11], 
der(1)t(1;20)(p13;q12)dup(1q)[9], +der(1)t(1;15)(q44;q12)ins(1)(q12q31)[11], 
t(2;6)(p22;p12)x2[11], +mar(2)[9], +mar(2)[9], +t(3;7)(q10;q10)[11], 
+dup(4)(q25)[11], +5[11], +5[11], +5[10], t(7;8)(p22;q24.1)[8], 
t(7;8)(p22;q24.1)x2[11], +der(7)t(7;8;15)(p22;q24.1;q12)[10], +8[10], +8[9], 
+der(9)t(9;20)(q10;q10)[8], +9[11], +9[7], +10[11], +10[11], +11[11], 
+t(10;12)(p10;q10)del(12)(q22)[9], t(12;21)(q10;q10)[9], 
der(13)t(2;13)(p10;q10)x2[11], +der(13)t(2;13)(p10;q10)inv(13;2)(q22;p13)[9], 
+14[9], der(15)t(15;7)(pterq12;q33)x2~3[11],+16[11], +16[9], +17[10], +17[6], 
der(18)t(6;18)(p22;q22)[8], der(19)t(15;19)(p10;q13.4)[11], +20[7], 
der(21)t(21;12;3)(q10;q10;q21)x2[10], t(3;22)(?;q10)[7], +22[4], cp[11] 
 























































Karyotype: 52-58<3n>, XXYY[24], +der(1)t(1;7)(q12;q31)[26], 
+dic(1;9)(p21;p21)[21], +del(1p)[22], +2[23], +5[5], der(7)(t(7;8)(p12;?q24)[25], 
der(9)t(7;9)(p14;p24)[24], inv(11)(q13)[26], +del(12)(p12pter)[26], 
+der(14)t(10;14)(q10;q10)[24], +15[25], der(16)t(7;16)(q11.2;q11.2)[23], 
+17[24], +20[20], cp[26] 
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Most studies of GC cytogenetics to date have relied on classical banding 
techniques. Consequently, reports of partial karyotypes (especially of 
structural rearrangements) are common owing to the considerable technical 
limitations of conventional cytogenetics. SKY facilitates the characterization 
of complex rearrangements, especially those involving two or more donor 
chromosomes. There are several pre-conditions for obtaining good quality 
SKY analysis: 1) The overall quality of metaphase spreads should be optimal. 
As much as possible, chromosomes should not be overlaid on each other; 
neither would an “over-spread” metaphase be desirable, as scattered 
chromosomes would be out of the field at the desired magnification. 
Metaphase spreads whose chromosomes are too compact are also unsuitable. 
2) The analyst must be sufficiently trained in classical cytogenetics to 
accurately describe rearranged chromosomes. As such, knowledge and 
familiarity with standard cytogenetic nomenclature is essential, especially for 
description of highly complex chromosomal rearrangements. 3) We took 
cognizance that the phenomenon of fluorochrome ‘flaring’, caused by 
overlapping spectra, can result in misinterpretation of regions where material 
from different chromosomes are juxtaposed10,11. For example, when a red 
probe assigned to chromosome 13 is adjacent to a green probe (chromosome 
10), the overlapping region will be yellow. If yellow is assigned to 
chromosome 1, then the rearrangement could be easily misinterpreted to 
involve three donor chromosomes, instead of two. Tools available in the 
acquisition and imaging processing software (ASI SKYview), such as the 
“pixel-confidence” function, allows one to differentiate between genuine 
juxtaposed segments and flaring. In the spectral-based system, the pixel 
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confidence tool toggles the intensity of each captured pixel. Overlapping 
“flared” regions have weak pixel intensities in comparison to the genuine 
donor or acceptor chromosomes. To determine the authenticity of each 
translocation, each fusion point had to be carefully examined. Inter-
chromosomal rearrangements, such as micro-deletions and inversions, cannot 
be detected using SKY because the reagents are whole chromosome paint 




Our results of the spectral karyotypes of cell lines obtained from the American 
Type Culture Collection (ATCC) in Table 7.1 are in agreement with the 
classical cytogenetic karyotypes provided by ATCC (http://www.atcc.org). 
This supports the reliability of our spectral karyotype data. In this regard, 
Yamashita et al. had claimed recurrent GC chromosomal translocations at 
breakpoint cytobands 8q24 and 11q12 from SKY analysis of ten GC cell lines 
and seven samples of metastatic GC ascitic fluid12. However, their spectral 
karyotypes of three ATCC registered GC cell lines (SNU-1, SNU-5 and SNU-
16) differ noticeably from our SKY data and also from ATCC karyotypes.  
Reasons for the discrepancies are unclear. It may be relevant that Yamashita et 
al. did not obtain their cultures from ATCC directly. In our data, two cell lines 
in our collection had translocations at 8q24 (YCC2 and YCC11) and three had 
breakpoint junctions at 11q13 (YCC3, MKN7 and KATO III). These two loci 
were not in our ranking of the top ten lists of recurrent translocations (Table 
7.2). But we noted that many of our recurrent breakpoints were also observed 
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by the Japanese group such as 18q21, 7q31q32 and 17q11.2q12, although our 
ranking orders differed. 
 
7.2 Recurrent patterns of translocation  
An analytical approach integrating SKY karyotypes and copy number data 
revealed 45 identifiable recurrent breakpoints (Table 7.2). Whole genome 
copy number profiles (Table 7.1) were derived from SNP genotype data 
performed on 100K SNP mapping arrays. Regions of copy number alteration 
frequently co-localized with breakpoint cytobands (Table 10-1, Page 229). 
The SNP mapping arrays offered high resolution that allowed a finer mapping 
of translocation breakpoints as well as detection of subtle deletions and 
amplifications. It had also been suggested that copy number deleted start sites 
and Loss of Heterozygosity (LOH) loci may indicate the breakpoint boundary 
regions13,14. Our combined analysis using spectral karyotypes and copy 
number data of the 17 GC cell lines revealed at least two broad patterns of 
rearrangements: simple and complex translocations. In the former, 
translocations were reciprocal or involved a single pair of acceptor and donor 
chromosomes. The latter was observed in 90% of the cell lines where 
rearrangements were often unbalanced and involved multiple chromosomal 
partners. To determine if an underlying pattern existed amidst these 
complexities, we focused on recurrent translocation breakpoints. We defined 
recurrent translocations to be rearrangements that were observed in at least 
30% of metaphases of each cell line and in at least twice in the 17 cell lines 
(Table 7.2). A rearranged chromosome was frequently the fusion of partners 
from several different chromosomes. For example, 35% (6/17) of the cell lines  
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had recurrent rearrangements of chromosome 18 in which a breakpoint locus 
at 18q21 was fused to 6p22, 8q22, 9q22 or 13q22.  
























Breakpoints Cell line Translocations Breakpoints Cell line Translocations
SNU-5 +t(13;18)(q22;q21) KATO III +der(7)t(7;11)(q21;q13)
FU97 +der(18)t(8;18)(q22;q21) KATO III +der(11)hsr(11;10)(q13;q?)
MKN7 +t(9;18)(q22;q21) MKN7 der(11)t(13;11)(q12;p13)ins(11;19)(q13q13.1qter)
YCC2 +der(6)t(6;18)(p22;q21) YCC16 inv(11)(q13)
YCC3 t(6;18)(p22;q21) KATO III +dup(17)(q12)
YCC11 der(18)t(6;18)(p22;q22) FU97 t(X;17)(p10;q12)dup(17)(q12)
AGS der(8)t(1;8)(q12;p21) YCC9 t(17;22)(q24;q12)
MKN7 inv(1q12) AGS +der(19)t(6;19)(p22;q13.3)
YCC2 t(1;2)(q12;p22) MKN7 der(11)t(13;11)(q12;p13)ins(11;19)(q13q13.1qter)
YCC11 +der(1)t(1;15)(q44;q12)ins(1)(q12q31) MKN7 t(19;11)(13.4;?)
YCC16 +der(1)t(1;7)(q12;q31) MKN7 +t(19;6)(13.4;?)
SNU-5 der(2)t(2;3)(p22;p13) YCC11 der(19)t(15;19)(q10;q13.4)
YCC1 del(2)(p22) SNU-5 +der(12)t(2;12)(p13;q14)
YCC2 t(1;2)(q12;p22) YCC11 +der(13)t(2;13)(p10;q10)inv(13;2)(q22;p13)
YCC11 t(2;6)(p22;p12); Hs 746T der(3)t(3;8)(p21;q?)ins(3;21)(p14;q?)ins(2;3)(?;q13.1)
IM95 t(1;2)(q23;p23) FU97 +der(3)t(3;12)(p14;p10)
SNU-5 +der(7)t(3;7)(q13.2;q31) SNU-16 +der(4)t(4;21)(p12;q11.2)
SNU-5 +der(7)t(4;7)(q25;q31) YCC9 der(4)t(9;6;4)(p12;?;p15.1)
YCC1 +dup(7)(q31) YCC9 t(4;6)(p15.1;q24)
YCC2 +der(7)t(7;8)(q31;q22) MKN7 t(3;4)(?;p15.1)
YCC6 +dup(7q)(q31q11.2) MKN7 t(4;7)(p15.1;?)
YCC16 +der(1)t(1;7)(q12;q31) SNU-5 +der(4)del(4)(q25)ins(4;13)(q12;?)
SNU-5 der(1)t(1;8)(p36.1;q22) NCI-N87 der(11)t(4;11)(q12;p14)
SNU-5 +der(8)ins(8;1)(q22;?) NCI-N87 t(5;19)(p12;?)
FU97 +der(18)t(8;18)(q22;q21) YCC2 +t(2;5)(q12;p12)
YCC1 t(8;11)(q22;q23) SNU-16 +der(5)t(5;11;10)(q12;?;?)
YCC2 +der(7)t(7;8)(q31;q22) YCC2 inv(5)(pterq12)
Hs 746T der(8)t(8;14)(q21.3;q12) NCI-N87 der(6)t(18;14;6)(?;q11.2;p12)
SNU-5 der(1)(1;5)(p36.1;?) YCC11 t(2;6)(p22;p12)
SNU-5 der(1)t(1;8)(p36.1;q22) YCC1 der(6)t(6;10)(q24;p13)
NCI-N87 t(1;5)(p36.1;?) YCC9 t(4;6)(p15.1;q24)
YCC1 del(1p)(36.1) KATO III +der(7)t(7;11)(q21;q13)
SNU-5 +der(7)t(3;7)(q13.2;q31) MKN7 +t(7;15)(q21;q15)
Hs 746T der(3)t(3;8)(p21;q?)ins(3;21)(p14;q?)ins(2;3)(?;q13.1) YCC2 +der(8)t(4;8)(q25;q24.1)
YCC2 +der(3)t(21;13;3)(q10;q22;q13.2) YCC2 der(8)t(8;13)(q24.1;?)
YCC9 der(14)i(14)(q10)t(3;14)(q13.2;q24) YCC11 t(7;8)(q33;q24.1)
SNU-5 +der(7)t(4;7)(q25;q31) YCC11 i(7q)t(7;8)(q33;q24.1)
YCC2 +der(8)t(4;8)(q25;q24.1) YCC11 +der(7)t(7;8;15)(q33;q24.1;q12)
YCC3 der(16)t(4;16)(q25;p12) SNU-5 der(9)t(2;15;9)(?;q10;p12)
YCC11 +dup(4)(q25) SNU-5 +t(9;15)(p12;q10)
SNU-5 t(4;13)(q32;q22) YCC9 der(4)t(9;6;4)(p12;?;p15.1)
SNU-5 +t(13;18)(q22;q21) MKN7 t(20;9;8)(?;q31;?)
YCC2 +der(3)t(21;13;3)(q10;q22;q13.2) YCC1 t(9;13)(q31;q10)
YCC2 der(13)t(18;19;13)(q10;q10;q21) YCC1 +t(9;14)(q31;q10)
YCC3 i(13)(q10)dup(13)(q22) AGS t(8;10)(?;p13)
YCC11 +der(13)t(2;13)(p10;q10)inv(13;2)(q22;p13) YCC1 der(6)t(6;10)(q24;p13)
NCI-N87 der(17)del(17)(p12)t(17;22)(q21;q12) MKN7 der(11)t(13;11)(q12;p13)ins(11;19)(q13q13.1qter)
Hs 746T +dup(22)(q12) YCC1 t(11;17)(p13;q21)
FU97 t(X;22)(p10;q12) SNU-16 +der(11)t(1;11)(?;p14)
MKN7 +t(11;22)(q13;q12) YCC3 +der(11)t(7;11)(?;q23)dup(11)(p14pter)
FU97 t(1;14)(p21;q10) YCC1 t(8;11)(q22;q23)
YCC3 +der(1)t(1;6)(p21;?)del(1)(q25) YCC3 +der(11)t(7;11)(?;q23)dup(11)(p14pter)
YCC16 +dic(1;9)(p21;p21) KATO III +der(12)t(2;12)(p13;q14)
SNU-1 der(4)t(1;4)(q25;q32) YCC2 inv(12)(q14)ins(8;12)(?;q14)
MKN7 t(1;6)(q25;q25) YCC6 +der(14)t(21;14;12)(q10;q24;?p)
YCC3 +der(1)t(1;6)(p21;?)del(1)(q25) YCC9 der(14)i(14)(q10)t(3;14)(q13.2;q24)
YCC3 der(17)t(1;17)(q25;p13) YCC1 t(11;17)(p13;q21)
NCI-N87 der(3)del(3)(p24)ins(3;8)(p12;?); YCC3 der(17)t(1;17)(q25;p13)
Hs 746T +der(1)t(1;3)(p31;p12) NCI-N87 der(17)del(17)(p12)t(17;22)(q21;q12)
FU97 +der(3)t(3;6)(p14;?)ins(3;20)(p12;q11.2) YCC1 t(11;17)(p13;q21)
YCC1 +der(3)t(3;12)(p21;?p) YCC1 +t(1;17)(p10;q10)dup(17q21)
Hs 746T der(3)t(3;8)(p21;q?)ins(3;21)(p14;q?)ins(2;3)(?;q13.1) KATO III +dup(20)(q13.1qter)
YCC9 t(3;7)(p21;p22) YCC1 dup(20q13.1)
SNU-1 der(4)t(1;4)(q25;q32) YCC11 +der(1)t(1;20)(p13;q12)
SNU-5 t(4;13)(q32;q22) YCC11 der(1)t(1;20)(p13;q12)dup(1q)
YCC3 +der(16)t(16;4;6)(p12;q32;p22) YCC3 t(6;18)(p22;q21)
Hs 746T +der(7)t(6;7)(?;q11.2) YCC3 +der(16)t(16;4;6)(p12;q32;p22)
YCC6 +dup(7q)(q31q11.2) MKN7 der(9)t(2;9;12)(q21;q21;?)
YCC16 der(16)t(7;16)(q11.2;p11.2) YCC1 del(9)(q21)
YCC3 der(16)t(4;16)(q25;p12)
YCC3 +der(16)t(16;4;6)(p12;q32;p22)
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A point to note is that translocations involving fusions to multiple partner 
chromosomes are increasingly being documented. The MLL gene has at least 
70 fusion partners, of which 50 have been cloned1,15. Prostate cancers were 
first reported to have signature translocations involving TMPRSS2 and the 
ETS family members. Subsequently, ETV1 was also found to fuse to other 5’ 
partners SLC45A3, HERV-K_22q11.23, C15orf21 and HNRPA2B116,17,18,19. 
These discoveries were supported by evidence from at least two recent studies. 
FISH analysis in 429 prostate cancer patients20 showed at least 23 fusion 
variants involving the ETS family members. The second FISH study21
 
 showed 
at least 44% of prostate cancers had additional fusions (not of the TMPRSS 
subtype) juxtaposed to the ETS family members. Among these were: 1) 
SLC45A3 at the 5’ fused with ERG at 3’, 2). FLJ35294 fused with ETV1, 3) 
CANT1 with ETV4 and lastly 4) a ubiquitously expressed, androgen-
insensitive gene, DDX5, fused in frame with ETV4.  
The complexity of these rearrangements is intriguing and substantiates the 
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8. Multimodality whole genome characterization of gastric 
cancer 
 
The rationale and motivation for work described in this chapter was derived 
from two considerations: a) we recognized that integrating parallel datasets 
from high resolution 100K SNP mapping copy number analysis of the same 
GC cell lines with their spectral karyotypes could define translocation 
breakpoints at a higher resolution. b) Global genomic and transcriptomic 
characterizations of GC could provide datasets to mine for the likely 
consequences of specific recurrent translocation(s). 
 
To this end, we embarked on the following whole genome characterizations of 
17 GC cell lines by profiling: 1) high-resolution genome copy number 
analysis; 2) mRNA expression; and 3) microRNA (miRNA) expression. 
Recognizing the hazard of assigning biological relevance to cell line artifacts1, 
patterns of genome copy number abnormalities in cell lines and primary 
tumors were noted to be substantially similar (vide infra),  indicating that cell 
lines were biologically legitimate surrogates for primary GCs. The next aim 
was to identify candidate GC-signature(s) in comparison to the NCI-60 panel 
of non-GC cell lines. The NCI-60 panel of human tumor cell lines was 
established, in the early 1980’s at the US National Cancer Institute, from 
leukemia, melanoma, cancers of the brain, breast, colon, lung, kidney, ovary 
and prostate2. These cell lines have been widely used as a resource for high 
throughput anti-cancer drug screening3. Ross et al. undertook global gene 
expression profiling on cDNA arrays of this panel and observed that gene 
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expression patterns in the cell lines resembled patterns of their cognate tumor 
tissues4. Beyond drug screening, the NCI-60 cell panel has demonstrated 
potential for cancer gene discovery. Thus, by integrating whole genome copy 
number and mRNA expression datasets, Garraway et al. identified MITF as 
the target of a novel melanoma amplification. Their data showed that MITF 
amplification correlated with metastatic disease, chemoresistance and shorter 
survival – features consistent with a role for MITF in oncogenesis of 
melanomas5
To ascertain if GCs might have distinctive copy number and/or mRNA 
expression signature(s), we analyzed data obtained from similar microarray 
platforms in two stages: 1) The regions of altered copy number for the same 
panel of GC cell lines against the NCI-60 panel of non-GC cell lines. 2) 
Global mRNA expression analysis from GC cell lines versus that of the NCI-
60 panel. Finally, we also showed a common set of dysregulated miRNAs 
generated from profiling miRNA expression in our series of 17 GC cell lines 
and 40 fresh frozen primary GC tumors.  
.  
 
8.1 Whole genome copy number analysis 
Whole genome copy number analysis was performed on 17 GC cell lines (as 
detailed in Chapter 6, page 118). Raw copy number data were analyzed by 
CNAT 4.0 using the Mapping 100K HapMap Trio Dataset (Affymetrix) as the 
normal reference panel. This normal reference, available from the 
International HapMap project (
8.1.1 High resolution copy number analysis revealed 363 abnormal copy 
number clusters  
www.hapmap.org), consists of 35 CEPH 
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individuals (Utah residents with ancestry from northern and western Europe). 
CNAT 4.0 computed the copy number differences by generating a log2 ratio 
between sample and reference. We defined a copy number gain or loss as log2 
ratios of ≥ 0.3 or ≤ -0.3, respectively. To resolve copy number profiles into 
regions of authentic gains and losses, two or less consecutive SNPs having the 
preceding log2
 
 ratio thresholds were disregarded. A copy number change 
cluster was defined as a region in which 3 or more consecutive SNPs showed 
the same altered copy number, as a conservative measure of a true gain or loss. 
We then compiled a total of 363 characteristic copy number change clusters in 
GCs (Appendix Table 2, page 306), defined by occurrence in > 50% (9/17) of 
GC cell lines (Figure 8-1). Copy number gains outnumbered loss clusters. 
Two hundred and five amplicon clusters mapped to loci in 1q21qter, 3q25qter, 
7pterq31, 8q22qter and 20q, while 158 regions of copy number loss mapped to 









Figure 8-1 Whole genome copy number profiles of 17 GC cell lines aligned to 
their cytoband positions (chromosome 1 to X, left to right). Each green 
vertical line represents a copy number gain expressed as a percentage of all 
cell lines and, red, copy number loss. 
Results and Discussion: Chapter 8 
 181 
Copy number aberrations were detected in all chromosomes and altered 
regions tended to be more frequent in near-triploid and near-tetraploid cell 
lines (Table 7-1, page 143-144). To ascertain if the algorithms used in copy 
number analysis of high resolution SNP mapping data may have generated 
false profiles, we compared copy number profiles derived from SNP data with 
our previous copy number analysis of the same cell lines using low resolution 
classical chromosomal CGH (Figure 8-2). Both profiles were highly 
concordant i.e. 81% of copy number abnormalities were present in both 
datasets, notwithstanding the fact that the lower resolution inherent in classical 














Figure 8-2 Classical chromosomal CGH profiles showing DNA copy number 
gains and losses in 17 GC cell lines. Gains are shown as green bars to the right 
of chromosomes and losses as red bars to the left. Highly amplified regions are 
represented by thick solid bars.  
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Comparison of the copy number profiles of GC cell lines from this study with 
our earlier report of 60 primary GCs by classical CGH
8.1.2 GC cell lines as biological surrogates of primary GC tumors 
6
 
 showed concordant 
copy number altered cytobands (Figure 8-3). For example, 5p, 7p, 8q, 11q, 



















Figure 8-3 Summary of CGH profiles showing DNA copy number gains and 
losses in 17 GC cell lines, on the left panel and 44/60 primary GC tumors that 
showed copy number alterations, on the right. Gains are shown as green bars 
to the right of chromosomes and losses are shown as red bars to the left. 
Highly amplified regions are represented by thick solid bars. 
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We extended our comparison to a larger dataset of 203 GCs manually curated 
from the Progenetix CGH database7 (www.progenetix.net) by reference to the 
primary literature to exclude gastric tumors that were not adenocarcinomas 
and tumors of uncertain histologic type. To further validate GC cell lines as 
biologically meaningful surrogates of primary GC tumors, we applied SOTA 
(Self-Organizing Tree Algorithm) analysis8 to Progenetix and our own 
datasets. Using Progenetix GC data as the training set, SOTA analysis 
identified two subtypes distinguished by different patterns of copy number 
abnormalities (Figure 8-4). Sub-classification of tumors by copy number 
abnormalities has been shown also for human glioblastoma9, breast11, lung13, 
renal14 and cervical15
When test datasets, comprised of the 17 GC cell lines and 44 primary GC 
tumors (our NCC data) were analyzed by SOTA, a clustergram of cell lines 
admixed with tumors, very similar to the training set, was generated (Figure 8-
4). Ten genomic classifiers from 17q and 20q cytobands, derived from 
analysis of the training set, achieved an accuracy of 72.6% in classifying 
tumors in the test dataset (Figure 8-4). 17q and 20q were chosen because they 
were among the most frequently amplified regions.  
 cancers.   
The consistency of observed features that emerged from these comparisons 
across datasets generated by us and other investigators (Progenetix), imparted 
a degree of confidence that the GC cell lines in this study were reasonably 

































Figure 8-4 SOTA analysis of 203 primary GCs (training set) from Progenetix 
CGH database showing 2 distinct subtypes of copy number profiles (left 
panel). A similar supervised clustering was next performed on a test set of 44 
primary GCs (previous study6
 
) and 17 gastric cancer cell lines (present study).  
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Our view that GC cell lines are biologically representative of primary GCs is 
supported by work of other investigators. Greshock et al. meta-analyzed array 
CGH data of seven different malignant solid tumors and found that trends of 
copy number aberrations were highly correlated between cell lines and their 
histologically matched tumors16. In another study, Neve et al. found that 
recurrent genomic and transcriptional features of 51 breast cancer cell lines 
were mirrored in 145 primary breast cancer tumors17
 
. They also observed 
similar genomic and transcriptional heterogeneity in cell lines as in tumors, 
and showed that biomarkers identified in cell lines were predictive of clinical 
response to targeted therapies.  
Overall, the results of our copy number analyses of GC lines confirmed other 
published studies as well as those from the public database 
(www.progenetix.net)18-20
 
. Similar copy number gains such as 7p22q32, 
8q22q24, 11q, 20p and 20q were reported. Common deleted regions include 
1p36, 4p, 4q, 9p21, 10q23q24 and 18q.  
Having established reasonable confidence in copy number analysis using high 
resolution 100K SNP mapping arrays, we compared our data with that of the 
NCI-60 cell line panel comprised of leukemia (6), non-small cell lung cancer 
(9), colon cancer (7), central nervous system (6), melanoma (9), ovarian 
cancer (7), renal cancer (7) and breast (5), (numbers of different cell lines for 
each tumor/leukemia type are within parentheses). Availability of NCI-60 
copy number data was of particular interest as the absence of GC cell lines in 
8.1.3 GC cell lines revealed signature copy number altered regions  
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this panel allowed us to compare our GC cell line data with other common 
non-gastric cancers. We took cognizance that at least 4 of the NCI-60 cell 
lines had ‘mistaken identities’ and attention was taken to reassign them to their 
correct tissue types (http://dtp.nci.nih.gov/docs/misc/common_files/cell 
list.html).   
 
In this part of the work, we aimed to: 1) devise an approach that could 
segregate cell line data by their respective tumor origins or lineages; and 2) 
identify a signature of copy number clusters that was distinctive only of GC 
lines. We performed comparative analysis of data from 100K SNP mapping 
arrays using dChip (biosun1.harvard.edu/complab/dchip/). Data of the NCI-60 
panel were generated on an early release array format by Garraway et al.5. 
Owing to slight differences between the early release and the later array 
format used by us, we used two separate sets of normal references in the 
analysis of NCI-60 data and our GC data. The GC cell lines were referenced to 
the Mapping 100K HapMap Trio Dataset (Affymetrix) while for the NCI-60 
panel, the normal reference was copy number profiles of six healthy 
individuals as reported by Garraway et al.5
 
.  
We developed a novel approach in attempting to identify a GC copy number 
signature. We first performed Significance Analysis of Microarrays22 (or 
SAM; detailed in Chapter 6, page 119) to identify SNP probesets whose log2 
copy number ratios were significantly different between GC cell lines and 
each group of non-GC cell lines of the NCI-60 panel. The SAM algorithm has 
been widely used to process microarray expression datasets to draw out 
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statistically significant differences in expression between pairs of datasets e.g. 
treated versus untreated samples or tumor versus normal samples. For our 
purpose, we grouped all cell lines derived from the same histologic tumor type 
as a single class. For example, all GC cell lines were group as class 1 versus 
colon cancer lines of the NCI-60 panel as class 2. SAM was then performed 
using an unpaired t-statistics with a default setting of at least 1000 
permutations. To be highly stringent, we fixed the false discovery rate at 0%. 
This process was repeated in the same pair-wise fashion with all cell line 
groups of the NCI-60 panel. To ascertain if there might be a GC copy number 
signature, we applied a filter to the outputs from SAM such that only SNPs 
that registered a gain or loss of ≥ 2 copies in at least 50% of the GC lines were 
retained for further analysis. These stringent criteria ensured that only high 
frequency abnormalities were advanced to the next stage. This filter whittled 
the data to a relatively small list of 1120 SNPs that was processed to 156 SNP 
clusters with copy number gains and 188 clusters showing losses. An 
unsupervised hierachical clustering using average linkage analysis of GC cell 
lines against all NCI-60 cell lines (Figure 8-5) showed tight clustering of GC 
lines as a single block – “uncontaminated” by non-GC cell lines. In contrast, 
non-GC cells were considerably more dispersed in the dendrogram and none 
clustered in a single block. Thus, we appear to have identified a copy number 
signature of GC cell lines that was distinctive compared to the non-GC cell 
lines of the NCI-60 panel. Among these 344 unique GC clusters were 
amplicons mapping to 8p21.2p23.2, 11q31.1q33.2 and 14q21.3q24.3; and 
deletions at 2q21.3q33.1, 5p13.2p15.32, 5q21.1q35.1, 7q31.1q35 and 
8q23.1q24.2 (Appendix Table 3, page 314).  
























Figure 8-5 Hierarchical clustering of copy number abnormalities showed clear 
segregation of GC cell lines away from all other non-GC cell lines of the NCI-
60 panel. Red denotes copy number gains and blue, copy number losses. Rows 
show the copy number status of 1120 SNPs and columns show 17 GC cell 
lines of this study and the NCI-60 cell lines. Cell lines are color coded by their 
histologic tumors of origins. 
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  8.2 Global mRNA expression profiling  
We combined two datasets to identify differentially expressed protein-coding 
genes. Data of 7 cell lines (SNU-1, SNU-5, SNU-16, AGS, NCI-N87, Hs 
746T and KATO III) generated from Affymetrix U133A expression arrays 
were merged with data of 10 cell lines (YCC1, YCC2, YCC3, YCC6, YCC9, 
YCC11, YCC16, MKN7, FU97 and IM95)  generated on Affymetrix 
U133Plus 2.0 arrays. All expression values were referenced to normal stomach 
mRNA obtained from two commercial sources: a pooled normal from 2 
individuals (Stratagene) and from a single individual (Ambion). The intended 
purpose was to generate a database for investigating the possible effects or 
consequences in relation to chromosomal rearrangements (to be discussed in 
Chapter 13 with reference to 18q). In the same manner as described above for 
high resolution copy number analysis, we also attempted to ascertain if there 
could be unique expression signatures that would segregate GC from non-GC 
cell lines.   
8.2.1 mRNA transcriptomes of GC cell lines 
 
To determine if GCs have a distinctive mRNA expression profile, we 
performed a meta-analysis on the transcriptomes of GC lines (of this study) 
with selected NCI-60 cell lines i.e. leukemia (5), non-small cell lung cancer 
(8), colon cancer (6), central nervous system (6), melanoma (9), ovarian 
cancer (7) and renal cancer (8). All data were downloaded from Symatlas, a 
publicly available database from Genome Institute of Novartis Foundation 
(
8.2.2 mRNA transcriptomes of GC cell lines compared with the NCI-60 panel 
http://www.gnf.org/resources/). We removed breast cancer cell lines from the 
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analysis as only three cell lines had reliable expression data (a minimum of 
five or more lines are needed for greater statistical power). All mRNA 
expression analyses were performed using data derived from Affymetrix 
expression arrays (U133A or U133Plus 2.0). To identify the unique GC 
expression patterns: 1) All expression values were referenced to the mean of 
six replicates of normal stomach mRNA rather than a universal mRNA 
comprised of a mixture of mRNAs from different tissue sources. We reasoned 
that GC expression profiles were most appropriately analyzed with reference 
to its normal cognate tissue of origin i.e. stomach. 2) Genes whose expression 
was significantly different in GC compared to non-GC cell lines were derived 
by processing datasets using SAM in the same manner as described for 
comparative copy number analysis (vide supra). Our analysis revealed a list of 
1651 significantly dysregulated probesets that clearly distinguished GCs from 
other non-gastric neoplasias. Unsupervised hierarchical clustering showed a 
distinct segregation of GC cell lines as a single block (Cyan). Similarly, 
leukemias, melanomas, renal and CNS cancers, each clustered as 
homogeneous single blocks (Figure 8-6). Thus, our analysis succeeded in 
classifying 4 large homogeneous blocks of cell lines by their histologic tumors 
of origin. In contrast, Ross et al.4
 
 transcriptonally profiled NCI-60 cell lines on 
spotted cDNA microarrays and at best, clustered 2 homogeneous blocks of cell 








































Figure 8-6 Hierarchical clustering of differentially expressed mRNAs showed 
a distinct segregation of GC cell lines from all other non-GC lines of the NCI-
60 panel. Rows are probesets. Columns are color coded GC and NCI-60 cell 
lines. Red denotes over-expression and blue, under-expression.  
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However, the dendrogram also showed three other non-GC tumor types 
(colon, ovarian and non-small cell lung cancer) within the GC branch of the 
dendrogram (Figure 8-6). To affirm if there is a more distinctive GC 
transcriptional signature, we therefore proceeded to refine these initially 
selected probesets to derive a more restricted dataset that would cluster only 
GC lines as a single homogeneous block. This was done by retaining only 
probesets whose expressions were dysregulated ≥ 2-fold  in > 50% of 17 GC 
cell lines compared with normal stomach mRNA, and did not show these 
features in the NCI-60 cell lines.  This yielded a 65 probeset or 63-gene 
signature which segregated 15 of 17 GC lines as a single block while leaving 
all tumor types, except melanoma and CNS tumors, thoroughly admixed 
(Figure 8-7). This sub-analysis did, however, cluster a single colon cancer cell 
line, HCC2998, with GC lines and showed two other colon cancer cell lines, 
HCT15 and HCT116, to be closely related to GC lines on the dendrogram. 
There are plausible reasons for why two GC lines (SNU-1 and Hs746T) 
clustered separately (Figure 8-7, arrows). Unlike the other GC lines, SNU-1 
was not derived from an adenocarcinoma but rather from a rare gastric 
neuroendocrine tumor23. Hs 746T was derived from a tumor of the leg, that 
was presumed to have metastasized from a poorly differentiated gastric 
adenocarcinoma24. It is worth noting that the leg is an unusual metastatic site 
for gastric cancer. The atypical nature of both primary tumors of origin of 
SNU-1 and Hs 746T may account for their segregation away from the other 
GC cell lines. A list of the 63-gene set is shown to the right axis of the 
clustergram (Figure 8-7). The percentage of GCs showing the misexpressed 
63-gene set is detailed in Appendix Table-4, page 321).   












































Figure 8-7 63-gene expression signature distinguishes GC from non-GC cell 
lines. Red denotes over-expression and blue, under-expression. The list of 
genes in this signature is shown in rows to the right of the clustergram. Note 
that cell lines Hs 746T and SNU-1 (arrows) did not cluster with other GC cell 
lines.  
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Likewise, a distinctive GC signature pattern can be shown using principal 
component analysis (PCA) of the 63-gene set. PCA is a powerful 
mathematical procedure that reduces the multi-dimensionality of large data 
sets, such as those from microarray analysis, into a smaller number of 
variables called principal components. In our data, the PCA algorithm 



















Figure 8-8 A 3-dimensional plot from principal component analysis of the 63-
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8.3 Global miRNA expression profiling  
 
miRNAs are small non-protein-coding RNAs that function, at least in part, as 
gene regulators. There is already a substantial body of evidence for miRNAs’ 
pivotal role in cancer. Mutations and misexpression of miRNA have been 
shown to correlate with various human cancers
8.3.1 miRNA expression profiling of GC cell lines and primary tumors 
25-30. Moreover, miRNAs can 
function as tumor suppressors or oncogenes31, the latter termed as “oncomirs”. 
miRNAs have been shown to repress the expression of important cancer-
related genes such as RAS, BCL2 and E2F1. More than 50% of miRNA genes 
reside in cancer-associated genomic regions such as fragile sites, regions of 
frequent loss of heterozygosity and copy number altered loci32,33.  Several 
studies have demonstrated that chromosomal translocations in chronic 
lymphocytic and acute myeloid leukemias are associated characteristically 
with dysregulated expression of specific subsets of miRNAs 34-38. 
Chromosomal translocations can perturb miRNA expression and functions 
through several mechanisms39. These include 1) abnormal fusion sequences 
that prevent normal processing of primary miRNA transcripts to mature 
miRNAs; 2) ectopic expression from promoter or regulatory element 
swapping, and epigenetic effects; 3) miRNA gene deletion; 4) deletion or 
disruption of miRNA target sequences e.g. in the 3’ UTR of target mRNAs; 
and 5) miRNA gene fusions that generate novel oncogenic transcripts. To the 
best of our knowledge, there has been no report of signature GC chromosomal 
translocations associated with perturbed expression of specific miRNAs. 
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We undertook miRNA expression profiling of 17 GC cell lines and 40 primary 
adenocarcinomas using spotted oligonucleotide microarrays. Here we took 
pains to ensure that the sensitivity of detection of miRNA hybridization to 
microarrays was not compromised due to low abundance of small RNAs in 
extracted total RNA. We therefore enriched total RNA samples for the small 
RNA fraction using a proprietary flashPAGE (Ambion) technique, as detailed 
in Chapter 6, page 122. By altering the labeling protocol (ULS labeling, 
Kreatech), signal intensities were significantly improved and the results were 
highly reproducible. Figure 8-9 is an example of a miRNA microarray co-
hybridization. The background was negligible and the technique produced 
very good signal to noise ratios. miRNA microarray data were processed as 













Figure 8-9 Representative image of miRNA microarray hybridization of GC 
cell line, NCI-N87. Red spots indicate over-expression and green, under-
expression.   
Results and Discussion: Chapter 8 
 197 
Co-hybridization was performed with Cy-3 labeled test sample and Cy-5 
labeled enriched pooled of normal stomach small RNAs. Dye-swap 
experiments confirmed that the data were highly reproducible. Processed log2
In order to identify the most dysregulated miRNAs, we filtered the data to 
select those whose expression intensities were ≥ 2-fold different compared 
with the reference control. Separately, normalized miRNAs expression values 
were also processed by SAM. The resulting merged list from both analyses 
that showed altered expressions in at least 75% of all samples (i.e. cell lines 
and tumors) was clustered. These criteria revealed 31 dysregulated miRNAs 
(14 up- and 17 down-regulated) shown as a clustergram in Figure 8-10. As 
seen in the dendrogram, GC cell lines were intermingled with primary cancers, 
hence we were able to derive a common subset of dysregulated miRNAs that 
characterized both GC cell lines and primary tumors. 
 
intensity ratios were computed and filtered for frequently aberrant miRNAs 
across all 17 GC lines and 40 primary gastric adenocarcinomas.  
To check on the robustness of our miRNA array data, we validated the 
expression of a selected number of miRNAs using solution hybridization as 
detailed in Chapter 6, page 124. This technique showed that miR-23b and 
miR-26a were under-expressed in 6/6 and 4/6 cell lines, respectively, while 
miR-122 was over-expressed in 4/6 cell lines (Figure 8-11), validating the 
data obtained from miRNA microarray experiments. miR-122 was reported to 





















Figure 8-10 Unsupervised hierarchical clustering of 31 dysregulated miRNAs 
identified from analysis of 17 GC cell lines and 40 primary gastric 
adenocarcinomas. Expression levels of the miRNAs listed above were ≥2-fold 
different compared to a pooled normal stomach reference in at least 75% of 
the biospecimens (cell lines and primary tumors). Red denotes over-expression 







Figure 8-11 Three differentially expressed miRNAs were validated 
independently by solution hybridization. To the left are miRNAs that were 
under-expressed with reference to the normal pooled stomach and to the right, 
an over-expressed miRNA 
 
Several miRNAs dysregulated in GC are also misexpressed in other 
malignancies (Table 8-1). Some of these miRNAs have experimentally 
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validated targets that play important roles in tumorigenesis such as miR-122 
(BCL2L2), let-7b (CCND1, CCND3, CCNA1, CDK4) and miR-143 (KRAS).  
 
Table 8-1 List of dysregulated miRNAs in GC tumors and cell lines. 
Experimentally validated targets of the respective miRNAs are shown. 





















Experimentally proven targets 
(Official symbol) Implicated Cancers Reference(s) 
miR-196a/b HOXB8 40
miR-301 Hepatocellular carcinoma 41
miR-122a BCL2L2 42
miR-452 Urothelial carcinoma 43
miR-513 CD274 44
miR-147 Squamous cell carcinoma 
of tongue
45







miR-302c-AS-MM1 Maintain pluripotency of ES cells 48,49
miR-7 PAK1 50
miR-133a Squamous cell carcinoma 
of tongue
45
miR-145-MM2 Colorectal cancer 51
miR-1 Lung cancer 52
miR-143-MM2 KRAS Colorectal cancer 53
miR-26a EZH2 Rhabdomyosarcoma 54,55
miR-139 Squamous cell carcinoma 
of tongue; Lung cancer
45,56
miR-148a DNMT3B 57
miR-218 Cervical carcinoma 58
miR-195 Primary peritoneal carcinoma 59
let-7b CCND1, CCND3, CCNA1, CDK4 60
miR-375 PDPK1 61
miR-23b Prostate cancer 62
miR-497 Breast cancer; 
primary peritoneal carcinoma
63,59
miR-125b MDS, AML involving t(2;11)(p21;q23) 38
miR-143 KRAS Colorectal cancer 53
miR-125a Medulloblastoma 64
miR-145 Colorectal cancer 51
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It is worth noting the emerging evidence that implicates chromosome 
translocations with altered miRNA expression. The rare t(2;11)(p21;q23) 
translocation in mye 
lodysplastic syndrome and acute myeloid leukemia was mapped to a 
breakpoint on chromosome 11 close to three miRNAs (miR-125b-1, let-7a-2 
and mR-100). Of these, mir-125b was over-expressed up to 90-fold in patients 
who had the t(2;11)(p21;q23) translocation. In vitro experiments showed that 
miR125-b inhibited differentiation of hematopoetic and leukemic cells38. 
About 20% of Burkitt’s lymphomas have 8q24 translocation breakpoints 400 
kb downstream of MYC. In some of these variants, the translocation occurred 
within an exon of PVT1 that fused miR-1204 to the immunoglobulin light 
chain constant region gene and was highly amplified65. Another mechanism 
through which chromosomal translocations may have oncogenic effects is by 
disrupting the 3’UTR targets of miRNAs that physiologically repress the 
expression of oncogenes. Thus, a 12q15 translocation truncates the 3’UTR of 
HMGA2. As HMGA2 expression is regulated by the binding of let-7 miRNA, 




The datasets and analyses presented in this chapter highlighted the complex 
genomic and transcriptomic characteristics of GC. In undertaking these 
experiments, we intended to develop extensive and reliable databases that 
could be resources in studies of chromosomal translocations in GC.   
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9. Dissecting simple rearrangements in gastric cancer cell lines 
 
Parallel SKY and copy number analysis showed that our panel of GC cell lines 
could be broadly classified into two groups based on their ploidy status and 
structural rearrangements. Two cell lines, SNU-1 and IM95, showed relatively 
simple chromosomal rearrangements. In this chapter we examine and 
deconstruct the simple rearrangements in SNU-1. Using molecular cytogenetic 
techniques such as FISH-walking, we reconstruct the likely sequence of events 
and propose a translocation mechanism for SNU-1. We also discuss the 
implications and/or consequences of this rearrangement. Finally, this chapter 
highlights the advantages of integrating a suite of molecular cytogenetic 
methods to overcome inherent limitation(s) of each technique. The advantage 
is illustrated succinctly in IM95 where despite the high resolution obtained 
from SNP mapping arrays, balanced translocations remained obscure without 
SKY analysis.  
 
9.1 SNU-1: A simple rearranged gastric cancer cell line 
 
SNU-1 is a near-diploid GC cell line that was originally established from the 
primary site of a poorly differentiated carcinoma of neuroendocrine origin of a 
44-year-old Korean male. SNU-1 (sourced from ATCC) grows as a 
suspension culture and was reported to have a modal chromosome number of 
47. Our karyotype of this cell line (Figure 9-1) confirmed that of ATCC and 
the original Korean source
9.1.1 SNU-1: Cytogenetic findings 
1. The G-banded analysis also confirmed the 
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translocation between chromosomes 1 and 4, in addition to a whole 
chromosomal gain of chromosome 20. It was observed that between 5-10% of 
metaphases analyzed had undergone tetraploidization to 94 chromosomes. 
This was probably an artifact induced by culture conditions as structural 
rearrangements were identical in near-tetraploid as in near-diploid cells upon 



























Figure 9-1 G-banded metaphase spread of SNU-1. Translocations between 
chromosomes 1 and 4 are indicated by arrows. The complete G-band 
karyotype for SNU-1 is 47, XY, t(1;4)(q25;q32), +20. 
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We initially performed chromosomal CGH2
 
 on labeled SNU-1 genomic DNA 
against a normal reference to detect copy number alterations. In line with the 
reported gain of chromosome 20 from G-banded metaphases, copy number 
analysis further detected a copy number loss at 4q (Figure 9-2). However, the 
relatively low resolution of chromosomal CGH was insufficient to allow us to 
determine if the loss of 4q extended from 4q32 to 4qter. This became more 


























Figure 9-2 Copy number profile of SNU-1 by CGH detected a copy number 
loss at 4q (red bars) and a whole chromosomal gain at chromosome 20 (green 
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bars). Note that chromosome 1 did not show any detectable copy number 
aberrations.   
 
Spectral karyotyping (Figure 9-3) confirmed the findings from G-banded 
analysis. The color-coded SKY karyotype reaffirmed the translocation 
between chromosomes 1 and 4, while all other chromosomes were apparently 

















Figure 9-3 SKY analysis of SNU-1 confirmed the translocation between 
chromosomes 1 and 4, and trisomy 20. For each chromosome, the spectral 
image is shown on the left and its classified false color is shown on the right. 
The classified color assigned to each chromosome is based on its unique 
spectral profile.     
 
In visualizing and detecting possible rearrangements, the assigned false color 
greatly assists in precisely identifying donor and acceptor chromosome(s). For 
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example, both chromosomes 2 and 10 appear to have a similar ‘red’ spectrum 
as seen by the naked eye (Figure 9-3). To distinguish these chromosomes, the 
SKYview software (ASI) assigns a false or classified color based solely on the 
specific emission spectrum of each chromosome. Hence in t(1;4), the 
classified colors distinctly show the donor (yellow) and acceptor (cyan) 
chromosomes, respectively.  
 
The advantage of integrating different molecular cytogenetic techniques was 
readily apparent. For example, 4q32qter chromosomal loss was detected only 
in CGH but was not immediately apparent by G-banding and SKY (Figure 9-1 
to 9-3). Conversely, the translocation involving chromosomes 1 and 4, evident 
in SKY, was obscured in the copy number data. All three techniques detected 
chromosome 20 copy number gain, although ratio-based CGH analysis did not 
accurately reflect the total number of copy number increase. The simple 
genomic rearrangements in SNU-1 presented a good model for characterizing 
a possible translocation mechanism. 
 
9.2 SNU-1 FISH-walking 
 
To dissect how the translocation might have arisen and its possible 
consequences, we first mapped the breakpoint junctions in 1q and 4q. We 
began by examining data from high resolution SNP mapping copy number 
analysis. This technique has the advantage of finely mapping possible 
unbalanced translocation boundaries. Thus, when a rearrangement is 
accompanied by a copy number imbalance (as frequently occurs in solid 
tumors), the 100K SNP mapping array copy number data directs attention to 
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the likely translocation loci. We demonstrate the utility of this approach in 
SNU-1. When high resolution copy number data was processed using CNAT 
4.0 (Affymetrix), a sharp copy number transition was evident and mapped the 






















Figure 9-4 High resolution 100K SNP mapping array copy number analysis of 
chromosome 4q showed the deletion start site at 4q32.3 (arrow). 
 
To confirm and validate this breakpoint locus, we employed a different 
cytogenetic technique: fluorescence in situ hybridization (FISH)-walking. To 
be certain of the accuracy of the SNP mapping copy number data, we began 
our FISH-walking at 4q31.1, approximately 20 megabases (Mb) from the 
predicted deletion start site. Using custom-labeled, locus-specific BAC clones 
as probes, we FISH-walked systematically by performing co-hybridizations on 
SNU-1 metaphase spreads. A schema of the custom-labeled probes used in 
this exercise is shown in Figure 9-5. A dual-labeling strategy was utilized. 
With reference to the centromere, fluorophore-tagged BAC clones were 
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paired, beginning with the one at the most proximal end (4q31.1, green 
fluorophore) to the clone at the most distal end (4q32.3, red). Each paired set 
(green/red) was co-hybridized in a single experiment to SNU-1 metaphases. 
We then worked ‘inwards’ (indicated by facing arrows, Figure 9-5), one pair 
at a time, until we detected an absence of either the green or red probe. 
Absence of either FISH signal would indicate the start site of the breakpoint. 
Such a strategy can map breakpoints with reasonable accuracy. Our FISH 
analysis showed that signals from a fairly large number of labeled BAC clones 
proximal to 4q32.3 (in blue) were retained. However, labeled BAC clone 
RP11-79E19 (red) was clearly absent. We then systematically paired RP11-
808H17, RP11-153D1, RP11-1030I6 to RP11-79E19. Finally, our metaphase 
FISH analysis confirmed that the breakpoint was mapped to 4q32.3 (Figure 9-

















Figure 9-5 Customized probes were dual-labeled and systematically FISH-
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1030I6 (green) and RP11-79E19 (red) bar at 4q32.3. Blue bars indicate clones 
still present in der(4)t(1;4).  
 
On SNU-1 metaphases (Figure 9-6), normal chromosome 4 had signals from 
both RP11-1030I6 (green) and RP11-79E13 (red) labeled probes. However, 
only a single green probe was detected in the translocated chromosome 4, or 
der(4). In cytogenetic nomenclature, a derivative chromosome (der) is an 
acquired translocated chromosome that has undergone additional 
rearrangements. This confirmed the breakpoint start site to be located within 















Figure 9-6 A SNU-1 metaphase FISH image showed the presence of both 
RP11-1030I6 (green) and RP11-79E19 (red) in normal chromosome 4. In 
der(4)t(1;4)(q25;q32), only the green signal was present.  
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In retrospect, the accuracy in breakpoint determination using SNP mapping 
copy number data surpassed our expectations (Figure 9-4), having been 
confirmed by FISH, the gold standard technique for chromosomal 
translocations. Confident of the reliability of SNP mapping copy number data, 
we proceeded to characterize the fusion translocation at der(4). As shown in 
the SKY analysis (Figure 9-3), der(4) was a fusion between a portion of 1q 
and 4q32.3 (Figure 9-6). Unfortunately, it was not possible to directly perform 
FISH-walking on 1q as both low-resolution CGH (Figure 9-2) and high-
resolution 100K SNP mapping copy number analysis (Figure 9-7) showed no 
apparent copy number alterations at 1q. This implied that 1) the translocation 
event did not result in any loss of 1q material, strongly suggesting that it was a 
balanced translocation; and 2) without a copy number transition point, it was 
not possible to estimate a breakpoint start site at 1q, despite the superior 
resolution of SNP mapping copy number data. This posed fresh challenges in 










Figure 9-7 High resolution SNP mapping copy number analysis of 1q (SNU-
1). Unlike 4q, there are no detectable copy number transition points.  
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To map the balanced translocation breakpoint at 1q, we re-examined the G-
banded metaphases and SKY analysis. Guided by the banding patterns in 
highly stretched G-banded SNU-1 metaphase spreads as well as inverse DAPI 
banding images from SKY, the breakpoint was approximated to within 1q24 
and 1q25. A schema of the custom-labeled probes used in this analysis is 
shown in Figure 9-8. BAC clones at the estimated breakpoint region were 
labeled and hybridized using a similar strategy (vide supra). The total genomic 











Figure 9-8 BAC clones mapping to 1q24.2q25.3 were used for the FISH-
walking analysis. The breakpoint region was progressively refined to within 
1q25.3 (top panel).  
 
In this FISH-walking expedition, a split-apart FISH signal of RP11-316H13 at 
1q25.3 (Figure 9-9) was demonstrated, providing compelling evidence that the 
breakpoint start site was within this BAC clone. A portion of the red signal 
hybridized to der(1) and the remaining portion to der (4), contrasting starkly 
with the single distinct signal in the normal chromosome 1.  





















Figure 9-9 FISH analysis of RP11-316H13 hybridized to a SNU-1 metaphase. 
A spilt-apart red signal at der (1) and (4) indicated the translocation breakpoint 
was within 1q25.3.  
 
However, the fusion event is not a straight forward reciprocal translocation. 
Intriguingly, our SNP mapping copy number analysis showed a copy number 
loss within 4q32.3q35.1 (Figure 9-4), but also indicated that the telomeric end 
of 4q (4q35.1-q35.2) had reverted to a copy number neutral state. This 
apparent loss coupled with gain at the telomeric end of 4q could not be 
detected by lower resolution G-banded and SKY analyses. This fresh 
information had one of two possible implications: 1) The remnant 4q telomere 
was retained and had no association at all with t(1;4); or 2) The fusion event 
between 1q and 4q was a complex reciprocal translocation. The next stage of 
analysis confirmed the latter.  
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The discovery of this copy number neutral telomeric 4q region turned out to 
be essential in the framework of the proposed translocation mechanism. To 
localize the 4q telomeric region in SNU-1, we used six BAC clones that 







Figure 9-10 BAC clones mapped to 4q34.1q35.2 were custom-labeled and 
hybridized to SNU-1 metaphase spreads (vide supra).   
 
The hybridizations revealed some interesting results. The telomeric segment at 












Figure 9-11 FISH analysis revealed that 4q-specific telomeric BAC clones 
(4q35.2qter) hybridized to der(1).  
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Apart from this unexpected phenomenon, we stumbled upon an additional 
rearrangement in the midst of performing the FISH-walking analysis. We 
discovered that at least two 4q32.3 BAC clones were hybridizing at segments 
centromeric to their actual mapped positions. We initially attributed these two 
probes as ‘promiscuous’ clones that had regions of homology within 4q. But a 
re-examination using highly resolved G-banded chromosomes suggested 
another probable rearrangement between 4q26 and 4q32.3. We sourced for 











Figure 9-12 4q26-mapped BAC clones custom-labeled and hybridized to 
SNU-1 metaphase spreads  
 
This extended FISH-walking analysis revealed a paracentric inversion 
between 4q26 and 4q32.3 that was not observed in both high resolution SNP 
copy number analysis and SKY, and exemplifies the limitations of these 
techniques. High resolution FISH ultimately confirmed the discovery of this 
additional rearrangement (Figure 9-13). 
 
 
















Figure 9-13 FISH analysis showed that RP11-180M11(green) and RP11-
36M4 (red) hybridized in juxtaposition at 4q26 in normal chromosome 4. In 
der(4), Texas-Red labeled RP11-36M4 (red) was split into 2 parts, consistent 
with a paracentric inversion.   
 
Taken together, the discovery of additional rearrangements derived from the 
integrated analysis of several molecular cytogenetic platforms (G-band, SKY, 
classical CGH and SNP mapping copy number, and FISH) contributed to a 
fuller reconstruction of the sequence of events leading to the final 
rearrangement. This was crucial in working out chronological details of the 
translocation process. But more importantly, it highlighted an approach 
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9.3 Proposed translocation mechanism of SNU-1 
 
The important discovery of the paracentric inversion hinted at how the 
rearrangements in SNU-1 may have occurred. We have reconstructed the 
events that led to the final rearrangement in the following proposed order of 
events (Figure 9-14). An initiating reciprocal translocation between 1q25.3 
and 4q32.3 resulted in a balanced translocation. Hence there was neither copy 
number gain nor loss. Defects in DNA repair mechanisms or other forms of 
genomic instability next caused a deletion between 4q32.3 to 4q35.1 in der(1) 
while retaining 4qter. In this manner, a fusion was formed between 1q25.3 and 
4q35.2 in der(1). On der(4), a paracentric inversion at 4q26q32.3 resulted in 
juxtaposition of 4q26 to 4q32.3 and 4q26 to 1q25.3. Overall, as a result of the 
paracentric inversion at 4q, three fusion points were generated (Figure 9-14, 







































Figure 9-14 Proposed translocation mechanism of SNU-1. A primary balanced 
translocation (top right) was the initial event. Secondary rearrangements 
resulted in deletion of 4q32.3q35.1 at der(1) and a paracentric inversion at 
4q26q32.3 at der(4). In total, there were 3 fusion points involving 4 loci. 
Merged colors indicate fusions verified by FISH analysis.  
- RP11-316H13 (1q25.3) 
- RP11-138D4 (4q32.3) 
- RP11-36M4 (4q26) 
- RP11-173M11 (4q35.2) 
- Chromosome 1 
- Chromosome 4 
Deletion 
(4q32.3q35.1) 
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To date, this apparent translocation at t(1;4) had not been reported in GCs. 
However, two studies from other neoplasias reported translocations between 
chromosome 1 and 4. A hepatoblastoma study showed 4 hyperdiploid tumors 
having a recurrent translocation involving chromosomes 1 and 4, of which one 
case had t(1;4)(q25;q32) as the sole abnormality3. Another study showed a 
myelodysplastic patient with t(1;4)(q21;q35)4. Copy number loss at 4q in GCs 
was frequently observed (www.progenetix.net). Genomic deletion or loss of 
heterozygosity at 4q32q35 was also implicated in esophageal5, osteosarcomas6 
and sporadic basal cell carcinomas7
 
.  
9.4 Molecular consequences 
We next investigated genes that might be perturbed as a consequence of this 
rearrangement. A direct consequence was the deletion of 4q32.3q35.1 to 
which some forty-six known genes were physically mapped. These deleted 










Figure 9-15 Classification of 46 genes mapped to the deleted cytoband, 
4q32.3q35.1. Information on the classification of the biological functions was 
obtained from the Gene Ontology website (www.geneontology.org).  
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Transcriptome data of SNU-1 (Affymetrix U133A array) was used to correlate 
the expression of these 46 genes with the 4q deletion. Twenty-one of the forty-
six expressed genes mapping to 4q32.3q35.1 were down-regulated by 3- to 82-
fold compared to normal pooled stomach reference mRNA (Table 9-1). 
Among the highly down-regulated genes were ANXA10 (coagulation), CPE 
(metabolism), SORBS2 (transport), FLJ20035, KIAA0992 and DKFZ564J102 
(three hypothetical genes). Four of these (4/46) were up-regulated and twenty-
one remained unchanged.  
 
Table 9-1 Twenty-one genes whose expression levels in SNU-1 were at least 
2-fold down-regulated with reference to pooled normal stomach mRNAs 




. However, in the context of GCs, we were unable to find this translocation in 
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We speculated that the loss of a single allelic copy was enough to generate a 
sizable effect, with eight genes having > 20-fold down-regulation. However, a 
real time quantitative RT-PCR should be performed to validate these findings. 
Further work will also be needed to address if the deleted genes within these 
loci may be haploinsufficient, where a single allelic loss of the functional copy 
of critical gene(s) results in diseased phenotypes. Haploinsufficiency of tumor 
suppressors has been reported to have a role in carcinogenesis8,9
 
.  
Ji et al. profiled the mRNA gene expressions of 27 human cancer cell lines 
including 12 GC lines, and 15 cell lines of other tissue origins (T-cell, B-cell, 
monocyte, myelocyte, fibro-blast, endothelium, colon, breast and pancreas)10. 
These authors reported that SNU-1 (a GC cell line of neuroendocrine origin) 
had an expression profile that, on cluster analysis, segregated away from other 
epithelial tumors, did not stain on immunocytochemistry for pan-epithelial 
markers but was positive for neuronal specific markers (enolase and S100). 
Gastric cancer of neuroendocrine origin is extremely rare (1-2/million 
population) and poorly understood11,12
 
. Our reported translocation signature 
had not been documented in neuroendocrine tumors of the stomach, to date. 
The possibility of novel tumor suppressors or oncogenes within the deleted 
region of 4q and the potential oncogenicity of translocation fusions at 
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9.5 A balanced translocation in IM95  
Similar to SNU-1, IM95 is a near-diploid GC cell line with a modal 
chromosome number of 47. IM95 was derived from a moderately 
differentiated primary gastric adenocarcinoma resected from a 63-year-old 
Japanese male. Having gained substantial experience from the preceding study 
of SNU-1, an integrated analysis of both low and high resolution molecular 
cytogenetic techniques was performed. The spectral karyotype of IM95 
showed a reciprocal translocation between 1q23 and 2p23, trisomy 7, trisomy 













Figure 9-16 Spectral karyotyping of IM95 revealed a reciprocal translocation 
between chromosomes 1 and 2. The IM95 karyotype was: 47, X,-Y, 
t(1;2)(q23;p23), +7,+8, -13. 
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Low resolution classical CGH detected copy number alterations that reflected 
SKY analysis (+7, +8, -13 and –Y). However, CGH did not detect any copy 
number gains or losses in the reciprocal translocation between chromosomes 1 






















Figure 9-17 Classical CGH analysis showed copy number gains at 
chromosomes 7 and 8, and deletions at 13q and Y.  
 
Similar to the SNU-1 breakpoint at 1q25.3 (Figure 9-7), higher resolution 
copy number data from SNP mapping arrays also did not detect any copy 
number alterations at the breakpoints (Figure 9-18), thus confirming the t(1;2) 
was indeed a balanced translocation. 























Figure 9-18 Copy number analysis using SNP mapping arrays at high 
resolution. Loci indicated in dotted boxes are the translocation breakpoints in 
1q23 and 2p23 detected by spectral karyotyping. Abrupt copy number 
transitions were not observed.   
 
In summary, our work described in this chapter served to highlight that, in 
general, an integrated approach using low- and high-resolution molecular 
cytogenetic techniques was complementary to each other. More importantly, 
the approach overcame many of the inherent limitations in each method. 
Spectral karyotypes (albeit at low resolution) provided information on 
pathogenic structural rearrangements. SNP mapping analysis directed attention 
1q23 
2p23 
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to focal regions of copy number imbalances not adequately resolved by SKY 
analysis. Sharp copy number transition points were also useful in determining 
breakpoints associated with copy number imbalances. However, SKY was 
extremely useful in detecting translocations where copy number alterations 
were not apparent (as shown in 1q25.3 breakpoint of SNU-1 and t(1;2) of 
IM95). Finally, genomic rearrangements were validated using gold standard 
FISH analysis.  
 
In the case of SNU-1, extensive FISH-walking revealed the rearrangements 
were far more complex than originally anticipated. It will be interesting to 
bring this signature translocation of SNU-1 forward and screen for this 
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10. Dissecting complex rearrangements: integrating spectral 
karyotypes and whole genome copy number profiles  
 
We have shown that 15 of 17 (> 80%) GC cell lines in this study had complex 
structural and numerical chromosomal aberrations. For example, the near-
diploid GC cell line NCI-N87 had a modal chromosome number of 43 but was 
karyotypically complex with 10 translocations involving two or more partner 
chromosomes (Table 7-1, page 143-144). Despite the superiority in resolving 
power of SNP mapping copy number analysis, integrating other molecular 
cytogenetic techniques overcome many inherent limitations of each technique.  
 
In this chapter we move from simple to complex karyotypes which are 
characterized by multiple chromosomal translocations and often accompanied 
by various copy number abnormalities. It is not trivial to identify 
chromosomal aberrations of pathogenic significance in GC from incidental 
alterations i.e. to distinguish “driver” from “passenger” aberrations. To 
address this question, our approach is to identify loci that are rearranged, both 
structurally and numerically, with high frequency in the panel of 17 GC cell 
lines in this study. Hence, the specific aims in this chapter are: 1) to integrate 
genome-wide copy number profiles and SKY analyses to identify frequently 
rearranged loci; and 2) to determine translocation breakpoints at higher 
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10.1 Global integration of SNP mapping copy number analysis and recurrent 
translocation breakpoints 
 
The approach we adopted accentuates both the ‘depth’ and ‘breadth’ of this 
integrated analysis by means of a global inventory of recurrent genomic 
alterations in 17 GC lines in this study. As defined earlier (Chapter 7, page 
142), a rearrangement was considered recurrent if it was observed in at least 
30% of metaphases of one cell line and was also observed in at least two of 17 
GC lines. We aligned the 45 recurrent translocation breakpoints with whole 
genome copy number data from high resolution SNP mapping arrays of the 
same GC lines (Figure 10-1). This overview demonstrated that many recurrent 
translocation breakpoints were located near or within copy number altered 
regions. Regions of copy number gains, such as 7q12q31 and 8q22q24, had 3 
and 2 translocation breakpoints, respectively. Translocations also co-localized 
with prominent copy number loss regions at 3p14, 4q32, 17p and 18q. The 
association of breakpoints with copy number change regions is consistent with 
the fact that most solid tumor translocations are unbalanced.  




































Figure 10-1 Global summary of whole genome copy number alterations and 
recurrent translocations in 17 GC cell lines. Line plots to the right of each 
ideogram are copy number gains, shown in green, and to the left, are copy 
number losses in red. Each colored line indicates the percentage of cell lines 
having copy number gains or losses at the particular SNP locus. Copy number 
gain and loss were defined as log2
 
 ratios > 0.3 and <0.3, respectively. 
Recurrent translocation breakpoints from SKY analysis are denoted in 
asterisks.  




A detailed comparison of the 363 copy number clusters (205 copy number 
gains and 158 losses, Appendix Table 2, page 305) with reference to the 
recurrent translocation breakpoints was next performed. These copy number 
clusters were, by our definition, copy number aberrant regions common to at 
least 50% of all GC cell lines. Table 10-1 shows an integrated list of common 
copy number altered loci and their correlation with recurrent breakpoint 
cytobands. Almost 60% (26 of 45) of the recurrent breakpoints co-localized 
with 28 loci of copy number gains and losses. 
10.1.2 Translocation breakpoints are localized to abnormal copy number 
clusters 
 
Table 10-1 Copy number gain clusters (green) that co-localized with recurrent 
breakpoint cytobands are listed at the top panel and the copy number loss 
clusters at the bottom (red)    



















       breakpoints 
          (SKY)
3q13.12 3 0.03 3q13.1q13.2
7q11.21q11.23 55 13.7 7q11.2
7q21.11q22.1 24 17.6 7q21
8q21.3q22.3 43 13.1 8q22
8q24.11q24.3 400 22.0 8q24.1
9q22.2q31.3 7 19.4 9q31
11q13.1q13.5 43 11.6 11q13
11q22.3q23.3 19 12.4 11q23
14q24.3 14 3.2 14q24
16q22.1q23.1 8 10.5 16q21q22
17q12q21.1 9 0.8 17q12
19q13.32q13.43 20 11.2 19q13.4
20q12q13.2 343 16.5 20q13.1
1p36.22p35.3 30 18.6 1p36.1
2q21.1 6 9.6 2q21
3p21.2p22.1 7 12.0 3p21
3p14.2 109 7.8 3p14
3p12.3p13 8 6.3 3p12
4p15.2p13.3 42 14.1 4p15.3
4q12q13 4 0.2 4q12
4q25 5 0.2 4q25
4q32.1q33 67 11.0 4q32
6p22.1p21.33 9 0.3 6p22
17q21.31 3 0.1 17q21
18q12.1q12.3 103 15.9 18q21
18q21.1q21.33 104 17.2 18q21
18q22.1q22.3 205 11.7 18q21
22q11.23q13.31 20 22.0 22q12
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It was evident that almost the entire 18q showed copy number loss in close to 
50% of GC cell lines (Figure 10-1 and Table 10-1). Chromosome 18 is one of 
the smaller human chromosomes (76 million bases). By way of comparison, 
chromosome 1 is the largest (247 million nucleotides) and chromosome 21, 
the smallest (48 million bases). As the number of loss clusters in 18q among 
GC cell lines was disproportionately high relative to the size of this 
chromosome, we divided the loss clusters into 3 focal regions (Table 10-1).  
Of these regions, 18q22.1q22.3 harbored the highest number of copy number 
loss SNPs. Other focal regions of highly altered copy number regions that 
were also structurally rearranged included 20q12q13 (gains), and losses in 
8q21q24, 3p14.4 and 4q32q33.  
 
10.2 Determining translocation breakpoints by whole genome copy number 
analysis 
 
The analysis presented in Chapter 9 revealed an interesting insight into the 
chromosomal rearrangements in SNU-1. The translocation in SNU-1, 
t(1;4)(q25.3;q32.3), resulted in copy number loss at 4q32.3q35.1 (Figure 10-
2). The abrupt copy number transition at the centromeric boundary of 4q32.3 
coincided exactly with the translocation breakpoint site (Figure 10-2, red 
arrow) that was independently documented by our FISH analysis. 
10.2.1 Copy number loss regions are probable translocation breakpoint 
boundaries 
Kawamata et al. have recently exploited this phenomenon by molecularly 
characterizing unbalanced translocations occurring at a common 9p breakpoint 
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in pediatric acute lymphoblastic leukemia1
 
. In most cancer genomes where 
unbalanced translocations and aneuploidy abound, boundaries of copy number 
deleted regions, marked by sharp transition points, are helpful indicators of 













Figure 10-2 Chromosome 4 copy number data of SNU-1 from 100K SNP 
mapping array showed an abrupt copy number transition (red arrow) at 
4q32.3. The inset shows the translocation in der(4) analyzed using SKY.  
 
Integrated analysis showed chromosome 18 to be the most highly aberrant, 
both numerically and structurally (Figure 10-1). Nine of 17 (53%) GC cell 
lines showed an 18q copy number loss, while 6 (35%) showed a translocation 
at 18q21 (Figure 10-3).   
10.2.2 Chromosome 18 as a working model for investigating other recurrent 
translocation breakpoints   
 
 


















Figure 10-3 Chromosome 18 translocations were most frequent, occurring in 6 
of 17 (35%) cell lines. SKY clearly illustrates the fusion of 18q recurrent 
breakpoint to multiple partner chromosomes (3, 8q, 13q, 6p and 19).  
 
To determine and map translocation breakpoints at high resolution, we used 
our experience in the analysis of SNU-1 and Kawamata’s proof-of-concept 
study, to examine abrupt transition points of copy number deletions. We 
correlated our copy number data from 100K SNP mapping arrays with 
oligonucleotide array CGH data (Agilent 244K array) kindly provided by a 
collaborator (Dr. Patrick Tan) in six GC cell lines that had 18q translocations 
(Figure 10-3). Three distinctive patterns were discerned from this analysis 
(Figure 10-4). Two GC cell lines, FU97 and MKN7, showed copy number 
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transition at 18q21.2q22.2. Transition points in YCC2, YCC3 and YCC11 
were mapped to 18q12q21. However, SNU-5 had no obvious copy number 
transitions in its profile. Copy number analysis of SNU-5 suggested that most 


















Figure 10-4 High resolution copy number profiles identify probable 
breakpoint boundaries. Partial spectral karyotypes and copy number profiles 
for each of six GC cell lines with 18q translocation are shown in the left and 
right panels, respectively. Sharp copy number transitions are evident at three 
distinct cytobands: 18q22 (FU97, MKN7), 18q12 (YCC2, YCC3 and 
YCC11)) and 18q11 (SNU-5). 
 
GC cell lines with the 18q21 translocation were hyper-triploid or near-
tetraploid. There were four to six copies of normal chromosome 18 and two 
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copies of t(8;18)s in FU97 (Figure 10-4). MKN7 had one normal chromosome 
18, one chromosome with a deleted 18q and two t(9;18) chromosomes. In 
YCC2, chromosome 18 was also involved in other translocations with 
chromosome 13 and 19, apart from t(6;18).  These admixtures of normal 
chromosomes and rearranged chromosomes could be expected to complicate 
the analysis. As solid tumors are heterogeneous, most current techniques for 
copy number profiling aggregate a mixed population of cells. Hence, these 
data reflect the composite nature of multiple different karyotypes. Such a 
complex admixture diminishes the analytical precision of whole genome data 
in situations when one desires to characterize only a single chromosome 
species. Taken together, determination of translocation sites using copy 
number transitions may prove to be less straightforward in malignancies that 
are aneuploid. This was most apparent in SNU-5 in which t(13;18) was a 
minor species and would likely be obscured by other more dominant DNA 
species (Figure 10-4).  
 
It was immediately discernable from their spectral karyotypes that 
translocations at 18q in the six GC cell lines involved multiple fusion partner 
chromosomes. Increasing evidence has emerged to show that translocations 
involving multiple fusion partners are probably rampant in both hematologic 
and solid cancers. Arguably the best known example are the highly 
‘promiscuous’ rearrangements in translocations of common occurrence in 
acute leukemias of infancy and therapy-related leukemia involving the MLL 
gene at 11q232. A more recent example is the signature translocations in 
prostate cancers involving the ETV1/ERG family that have as many as 23 
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fusion variants uncovered in an extensive FISH analysis of 429 patient 
samples3
Intriguing as it is, the mechanism(s) underlying this ‘promiscuous’ behavior of 
certain signature breakpoints is unclear. To generate a fusion between two 
chromosomes, DNA double-strand breaks (DSB) must first occur in both 
partners, followed by re-ligation that seals the fusion
.  
4. It has been postulated 
that most translocations in the leukemias arise through error-prone non-
homologous end joining (NHEJ) of DSBs. DSBs may be generated by a 
variety of DNA-damaging agents such as ionizing radiation, ultraviolet 
radiation, reactive oxygen species, chemotherapeutic drugs (e.g. 
anthracyclines, etoposide, camptothecins) and tobacco use4
In the context of GC, it is possible that H. pylori-induced pH changes, 
oxidative stress or alterations to the stromal microenvironment initiate DNA 
DSBs
.  
5. A role for H. pylori in inducing genomic instability is strongly 
suggested by the association of gastric MALT (mucosa-associated lymphoid 
tissue) lymphomas with signature translocations6. At least 90% of this 
relatively uncommon gastric tumor are caused by H. pylori infection and 25-
30% bear the translocation, t(11;18)(q21;q21). Translocation-positive gastric 
MALT lymphomas are more likely to be metastatic and unresponsive to H. 
pylori eradication7.  Other signature translocations found in about 5% of 
gastric MALT lymphomas are t(1;14)(p22;q32) and t(1;2)(p22;q12).  All three 
translocations appear to exert oncogenic effects via NFκB activation6
Recurrent translocations that are clonal imply that these rearrangements may 
confer some survival advantage to neoplastic cells. Three-dimensional FISH 
studies have suggested that spatial organization of the genome and physical 
.  
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proximity of partner chromosomes in the nucleus facilitates DNA repair by 
NHEJ8
It is not certain why chromosomal regions such as 18q, are more prone to such 
inflictions. This may be partially attributed to the presence of structurally 
unstable chromosomal fragile sites within the genome
.  In this regard, it is noteworthy that three GC cell lines (YCC2, YCC3 
and YCC11) showed similar translocations between chromosomes 18 and 6.  
9
We take heed that translocation breakpoints in this study, defined by copy 
number transition points, were often located in known fragile sites. Fragile 
sites are gaps or breaks on chromosomes observed in metaphases of cells 
grown under conditions that compromise proper DNA replication, such as 
exposure to aphidicolin, bromodeoxyuridine, distamycin A or when grown in 
folic acid-deficient medium
. 
11. Fragile sites are well recognized as regions of 
chromosomal breaks and rearrangements in cancer. For example, the fragile 
site FRA3B is located within a large tumor suppressor gene, FHIT, whose 
expression is often lost because of deletions associated with breakpoints 
centered on exon 5. Fragile sites in chromosome 18 are FRA18A (18q12.2), 
FRA18B (18q21.3) and the recently discovered FRA18C (18q22.2)12
LOH in chromosome 18 has been reported in several cancers including 
gastric
. Not 
unexpectedly, the cytobands of these 18q fragile sites match regions of copy 
number loss (Table 10-1) and recurrent translocation breakpoint cytobands 
(Figure 10-4). The association between these fragile sites and the highly 
altered 18q (structural and numerical) in GCs has thus far not been 
documented. 
13,14, pancreatic15, ovarian16, and head and neck squamous cell 
carcinoma17. In a recent study of lung cancers, Ogiwara et al. found that all 
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LOHs could be ascribed to alterations of chromosome structure - unbalanced 
translocations being most common - or to whole chromosome losses18. LOH 
studies in Wilms’ tumors and neuroblastoma came to a similar conclusion19,20
 
.  
In summary, complex rearrangements in GCs frequently involved multiple 
chromosome partners. Our integrated approach, that draws parallels between 
structural and numerical chromosomal aberrations in a panel of 17 GC lines, 
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11. 18q2 translocation in primary gastric cancer 
  
Chromosome 18 was highly aberrant in our series of GC cell lines with 35% 
shown to have a translocation at 18q, albeit with multiple fusion partners. 
Copy number transitions as physical markers for determination of 
translocation breakpoint loci had been proven in our study of t(1;4) in SNU-1 
(Chapter 9) as well as other investigators1,2
 
 . We detected abrupt copy number 
transitions at 18q12q21 for YCC2, YCC3 and YCC11 and at 18q21q22 for 
MKN7 and FU97 (Chapter 10). Thus far, these data were derived solely from 
analyses of GC cell lines. We therefore proceeded to ascertain, by FISH 
analysis, whether 18q2 translocations also occurred in primary GCs and were 
not merely cell culture artifacts.  
In this chapter, we detail: 1) The design and use of a customized break-apart 
FISH probe assay; 2) FISH analysis of tissue microarrays (TMA-FISH) as a 
means of maximizing sample throughput and achieving significant cost 
reductions in labeled probe preparation and 3) Results of the break-apart FISH 
assay in primary GCs and non-GC tumor tissues.  
 
11.1  Break-apart FISH probe design and strategy 
FISH analysis is typically used when the target loci are known. These 
cytogenetically appropriate probes are then applied to bio-specimens (cells 
and tissues). Two approaches are commonly adopted for FISH analysis of 
chromosomal translocations: 1) The fusion approach requires that the donor 
11.1.1 An appropriate FISH approach: fusion or fission 
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and acceptor sites be known. FISH probes specific to each site are selected or 
designed, and tagged with a fluorescent label for visualization. Hybridized 
signals that are abnormally juxtaposed confirm the translocation in question; 
2) The fission approach, more frequently called split-apart or break-apart 
probe assays, interrogates a single locus within the chromosomal segment of 
interest. When this segment is disrupted by a translocation, probes that are 
juxtaposed in the normal chromosome should be clearly separated. The 
advantage of this strategy is that the identity of the fusion partner need not be 
known. In translocations involving multiple partners, this approach is 
especially useful. A fission approach was our preferred option at this stage of 
the study because our data showed that the 18q2 translocations involved 
multiple partner chromosomes. It can also be a direct means to determine the 
prevalence, if any, of 18q2 translocations in primary GC tumors. Our intention 
was to resolve this key point before investing more effort and resources in 
establishing fusion FISH assays. In designing a fission or break-apart probe 
strategy, we reasoned that a linear series of dual–labeled FISH probes aligned 
along the length of 18q (in the approximate vicinity of the translocation 
breakpoints) would serve our purpose of detecting a split signal pattern. Thus 
a pair of green and red probes would be closely juxtaposed when hybridized to 
an un-translocated 18q but would be physically separated i.e. split apart in a 
translocation. In six GC cell lines with 18q translocations, copy number 
transitions mapped the potential breakpoints to approximately 18q12.2 in three 
cell lines and to 18q22.2 in two lines (Figure 11-1).  
 
 














Figure 11-1 Copy number profiles of six GC cell lines (SNU-5, MKN7, FU97, 
YCC2, YCC3 and YCC11) analyzed using CNAT 4.0. Arrows indicate copy 
number transitions at 18q.   
 
As most 18q chromosomal rearrangements of primary GCs (in published 
reports) were partially karyotyped3
 
, we were hard pressed to design a FISH 
probe assay that would reliably report the 18q breakpoint status. Our initial 
attempt was a paired set of custom-labeled probes comprised of three 18q12 
BAC clones labeled with SpectrumGreen (Vysis, Abbott Molecular Inc.) and 
three 18q21 BAC clones labeled with SpectrumOrange (Vysis, Abbott 















Figure 11-2 Break-apart probes custom labeled with SpectrumGreen (18q12) 
and SpectrumOrange (18q22).   
 
This assay, in theory, could have generated split signals in event of a 
translocation breakpoint either telomeric to 18q12.1 or centromeric to 18q22.3 
(Figure 11-3, arrowheads). In reality, FISH signals were distinctly separated 
even in normal interphase nuclei because of the significant physical distance 









Figure 11-3 Schematic representation of a FISH assay for an 18q2 
translocation. Signals from green probes at 18q12.1 and red probes at 18q22.3 
could be separate in translocations having a breakpoint either telomeric to 
18q12.1 or centromeric to 18q22.3 (green and red arrowheads, respectively). 
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To rectify this design flaw, we supplemented the aforementioned BAC clones 
with a central core of 21 additional BAC clones that mapped to 18q21 (Figure 
11-4). In this expanded probe set, 18q21 and 18q12 probes were labeled with 
SpectrumGreen and 18q22 probes with SpectrumOrange. Using this assay, we 
defined a break-apart pattern as a split between the green (18q12q21) and red 
(18q22) signals. Unlike the initial attempt, hybridization of this expanded 
probe set to normal interphase nuclei showed a barely visible gap between the 
fluorescent signals (Figure 11-4, extreme right panel). We therefore adopted 
this “brute-force” break-apart strategy with the intent of first addressing the 
18q21q22 translocation status of primary GC tumors. It later transpired that 
the larger size of the green probe set was fortuitously advantageous in 
evaluating the break-apart positivity in tumor tissues. 











Figure 11-4 A “brute-force” break-apart probe strategy. 18q12q21 probes 
were SpectrumGreen-labeled and 18q22 probes SpectrumOrange-labeled. The 
right panel shows an interphase nucleus from a section of formalin-fixed 
paraffin-embedded normal stomach epithelium.  
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We predicted several possible signal patterns using this FISH probe assay. 
These are schematically represented in Figure 11-5.  
Predicted signal pattern  Schematic 
representation 
Interpretation 
2G2R: 2 pairs of closely 
juxtaposed green and red 
signals (G/R) 
 Normal 18q in 
interphase nuclei  
1G1R1B: 1 pair of G/R 
and 1 break-apart pair at 
18q21/q22   
 Normal 18q with a  
single break at 
18q21q22  
2G1R: 1 pair of G/R and 
loss of a red signal at 
18q22  
 Normal 18q with 
deletion at 18q22  
1G1R: Only 1 pair of 
G/R 
 Deletion of 
chromosome 18q 
(monosomy 18q) 
nGnR: Multiple pairs of 
G/R and B (break-aparts)  
 Aneuploid nucleus 
with multiple 
copies of normal 




Figure 11-5 Schematic representation of predicted patterns of FISH signals 
using the expanded set of dual-labeled BAC clones. G denotes green signal, R, 
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11.2 TMA construction and FISH assay optimization 
Having adopted the break-apart FISH assay design, our next task was to 
hybridize the customized 18q probes onto a series of primary GC tumors. 
Considering that only 35% of the GC cell lines showed an 18q translocation, it 
was imperative that a sufficiently large number of tumor samples should be 
screened for reliability. To achieve these aims, we accessed de-identified 
archived gastric adenocarcinomas (collected during 2005-2007) from the 
Pathology Department of the Singapore General Hospital. These formalin-
fixed paraffin-embedded (FFPE) tissues were a valuable resource for tissue 
microarray (TMA) construction. Each tumor block was histologically 
confirmed to have a high content (> 90%) of malignant cells by a 
collaborating pathologist before it was cored (0.6 mm diameter) and re-
mounted in a new paraffin block with other tumor-rich cores. The rationale for 
constructing a TMA was that the array format allowed genomic information 
from multiple samples to be acquired in a single hybridization and, at the same 
time, greatly economized on the cost of preparing fluorescently-labeled 
probes. To illustrate this point, a standard FISH hybridization on a single full-
face tissue section required between 8-10 µL of fluorescently-labeled probe 
per reaction. This becomes prohibitively expensive to perform on a large 
number of samples. Our constructed TMA slides had between 60-80 cores 
(equivalent to 30-40 samples spotted in duplicate, Figure 6-1, page 126) over 
an area no larger than 24mm x 24mm over which a similar volume (8-10 µL) 
of probe mixture was sufficient for hybridization . In addition, a high level of 
consistency and standardization could be achieved as slide-to-slide variation, 
11.2.1 Tissue microarrays 
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largely due to pre-treatment and hybridization procedures, was greatly 
reduced.  
However, we realized after pilot experiments of FISH analysis on paraffinized 
tissue sections that variations in tissue fixation and the age of tissue blocks 
could have detrimental effects on sample quality, especially on DNA integrity, 
even to the extent of rendering a substantial proportion of tissue blocks 
completely unsuitable for any FISH analysis. With this experience, we 
routinely pre-screened all tissues by immunostaining with anti-human Ki-67 
antibody which had been found empirically to be reliable in gauging nuclear 
DNA preservation. Tissue blocks that stained weakly for Ki-67 were deemed 
to have significantly degraded DNA and unsuitable for inclusion in TMAs.  
 
After standard de-paraffinization, we evaluated several technical modifications 
to optimize FISH signals. Four crucial variables were selected for 
optimization: a) FFPE section thickness; b) heat pre-treatment; c) pepsin 
digestion; and d) hybridization duration (as detailed in Chapter 6, page 127).  
11.2.2 FISH assay optimization 
 
a) FFPE section thickness 
We performed the thickness optimization using commercial FISH probes 
(Figure 11-6(i) and (ii)). This showed that a section thickness of 2 µM struck 
an optimal balance between excessively high false positive signals and false 
negative patterns from truncation artifacts. Sections thicker than 4 µM 
generated multiple false positive signals because the tissue was examined 
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through several layers of cells. Conversely, 1 µM sections had a high number 
of false negatives because many signals were truncated.  
 
b) Heat pre-treatment 
In optimizing conditions of heat pre-treatment, we discovered that rigorous 
boiling for at least 20 minutes in a microwave oven, allowed better probe 
penetration in gastric tissue sections. Timings shorter than 20 minutes resulted 
in weak signals. In contrast, other tissues (breast and pancreas) were 
adequately heat treated in about 10 minutes. Although it was unclear why 
gastric tissues required harsher heat pre-treatment, all our TMA samples, 
regardless of tissue type, were heat pre-treated for 20 minutes as a standard 
procedure.  
 
c) Pepsin digestion 
Tissue proteins are known to contribute to background fluorescence in FISH 
experiments and were removed with pepsin digestion. We found digestion for 
5 minutes at 37o
 
C gave the best results. 
d) Hybridization duration 
We routinely hybridized labeled probes to tissue sections for more than 48 
hours and were pleased that this did not result in excessively high background 
fluorescence. Doubling this period resulted in only a slight increase in signal 
intensity.  
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To verify that these crucial technical factors had been adequately optimized 
and controlled, we hybridized a commercial BCL2 probe (Vysis, Abbott 
Molecular) to a 2 µM follicular lymphoma FFPE section. This sample was 
previously tested positive for the translocation hallmark, t(14;18)4,5
 
. As a 
validation to our break-apart FISH assay technique (Figure 11-6(iii)), we were 
encouraged to observe that, compared to 1 µM sections, 2 µM thickness did 
not cause a significantly higher proportion of truncation artifacts (< 10 %).  
More importantly, FISH signals from this confirmatory hybridization gave 
visual images of the gap distance we could expect from a break-apart probe 
assay.  
We proceeded to use our custom-labeled 18q probes on three GC cell lines 
whose translocation status was known from SKY analysis: FU97 
(translocation-positive), IM95 and YCC9 (both translocation-negative). From 
our SKY data, FU97 had multiple 18q translocations and was also polysomic 
for chromosome 18. IM95 was diploid and YCC9 was haploid for 
chromosome 18. To emulate similar conditions of treatment and hybridization 
as were performed on primary GC tissue sections, we obtained FFPE sections 
of xenotumors developed from these three GC lines implanted in immuno-
compromised NOD-SCID mice. A 2 µM section of each tumor was hybridized 
to the custom dual-labeled FISH probeset.  In each case, FISH signals 
















Figure 11-6 Optimization and validation of FISH on formalin-fixed paraffin-
embedded tissues. (i) One µM section of normal tonsil tissue hybridized to a 
MYC probe (Dako Denmark A/S) showing strong signal intensities but 
widespread monosomy of chromosome 8 as truncation artifacts. (ii) Two µM 
section of breast cancer tissue hybridized to a BCL2 probe (Vysis, Abbott 
Molecular) showing clear signals and minimal truncation artifacts. (iii) White 
arrows show typical split signals obtained by hybridizing a break-apart BCL2 
probe (Vysis, Abbott Molecular) to a 2 µM section of a case of follicular 
lymphoma known to be positive for t(14;18) using optimized procedures. 
Tumors were developed by implanting cell lines (iv) FU97 (18q21q22 
translocation-positive); (v) IM95 (translocation-negative); and (vi) YCC9 
(translocation negative; 18q monosomy) in NOD-SCID mice. FISH image 
patterns in each case were in agreement with SKY data.  
 
 
A certain number of false positive break-aparts can be expected even in 
normal interphase nuclei due to folding of uncondensed chromosomes. To 
establish the criteria for positive identification of true break-apart status of GC 
tumors, we objectively assessed the performance of the dual-labeled break-
apart probe assay by quantitative measures in histologically benign gastric 
epithelial tissue sections from five human patients as normal controls. We 
determined the frequency of false positive split signals in uncondensed 
11.2.3 Establishing scoring thresholds for break-apart positivity 
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chromatin and false negative signals from truncation artifacts by two observers 
who independently scored FISH signals in > 200 interphase nuclei of each 
normal control (Figure 11-4, right panel). Signals were considered split when 
the distance between them exceeded twice the diameter of the larger green 
signal6. The mean percentages and standard deviations (s.d.) of pooled data are 
shown in the second and third columns of Table 11-1. The cut-off percentage 
(i.e. threshold) for assigning break-apart positive status in primary GCs was 
the presence of break-aparts in > 20% of enumerated nuclei (Table 11-1, 
extreme right column). This threshold was set at 3 standard deviations above 
the mean false positive percentage6
Table 11-1 Scoring thresholds against false positive classification of break-
apart status. The mean percentage of false positive split signals and standard 
deviations (s.d.) were determined from benign gastric epithelial tissues of 5 
patients. The cut-off percentage (i.e. threshold for assigning break-apart and/or 
monosomy status) was set at mean + 3 s.d. 
. By this criterion, for every 100 nuclei 
examined, at least 20 must have a split signal pattern before classifying that 
GC tumor as break-apart positive. Similarly, to rule out truncation artifacts, we 
determined the cut-off percentage by scoring 1000 nuclei from each of 2 
different specimens of benign gastric epithelium. Applying the same rule of 3 
standard deviations above the mean percentage, the threshold for 18q 
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G, SpectrumGreen (green) signals. R, SpectrumOrange (red) signals and B, 
break-apart signals. See Figure 11-7 for representative aberrations. 
 
11.3 18q21q22 break-apart FISH assay in primary gastric adenocarcinomas 
Hybridization of custom-labeled probes to primary GC TMAs was performed 
as detailed in Chapter 6, page 129. Fifty to a hundred nuclei of neoplastic cells 
were scored from each usable sample. Morphologically distinct neoplastic 
nuclei were identified by DAPI staining and confirmed by referencing to 
immediately adjacent hematoxylin and eosin (H&E) stained sections of the 
same TMA block. The cut-off percentages in Table 11-1 were used to assign 
the 18q21q22 break-apart status of each tumor.  
Of a total of ninety-nine GCs analyzed in this manner, thirty-eight cases (38%) 
were break-apart positive at 18q21q22 (Figure 11-7). We observed three 
different break-apart signal patterns: 1) one pair of split signals at 18q21q22 
and one normal pair of unsplit signals (abbreviated 1G1R1B); 2) only one pair 
of split signals at 18q21q22 without a companion pair of unsplit signals (1B); 
and 3) multiple pairs of split and unsplit signals indicating aneuploidy of 
chromosome 18.  
The remaining 61 GC tumors in this series of 99 were break-apart negatives, 
which can be divided into 2 broad subtypes (Figure 11-7): 1) The deletion 
subtype was characterized by an absence of either red signal(s) or green 
signal(s), represented by abbreviations 2G1R, 3G1R, 1G0R. 2) The 
monosomy 18q subtype (1G1R-monosomy) defined as loss of chromosomal 
material spanning 18q12q23, had only one pair of green and red signals 
juxtaposed to each other.  
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To the best of our knowledge, this is the first study to have identified a high 
prevalence of 18q translocations, not least in more than one-third of primary 
GCs. Given the poor quality of G-banded metaphases that can be prepared 
directly from solid tumor tissues, translocations in chromosome 18 are rarely 
reported. However, whole chromosome or partial deletions of 18q had been 
detected. For example, Yamashita et al. reported frequent deletions and 
breakpoints at 18q21 in a SKY analysis of ten GC cell lines and seven samples 
of malignant ascites fluid7. Okada et al.8 reported partial 18q loss using 18q 
paints while Furuya et al. 9 showed whole chromosome loss using alpha 
satellite centromeric FISH analysis on chromosome 18. Here, we also 
observed that 33% of our series of 99 primary GCs had 18q monosomy, 
suggesting the possibility of whole chromosome 18 loss. In addition, 28.3% of 
GCs had loss of 18q22.3q23 (absence of the SpectrumOrange signal). We and 
others10,11 have shown frequent copy number deletions of the terminal regions 
of 18q in GC cell lines and primary tumors. Furthermore, LOH studies have 
also demonstrated the high frequency of genomic loss in 18q, particularly at 





























Figure 11-7 Representative FISH images showing 18q21q22 translocation and 
other chromosome 18 aberrations in primary GCs. Tissue microarrays of 
archived GCs were hybridized to the custom dual-labeled break-apart FISH 
probeset. G denotes SpectrumGreen (green) signal; R, SpectrumOrange (red) 
signal and B, break-apart at 18q21q22. Break-apart-positive GCs showed one 
of 3 patterns: (i) 1G1R1B: one normal 18q and one break-apart in a single 
nucleus; (ii) 1G1R break-apart: loss of one normal 18q and presence of one 
break-apart; (iii) Multiple break-aparts: aneuploid nucleus with several break-
apart signals. Break-apart-negative GCs showed one or more of 4 aberrant 
FISH patterns: (iv) and (v) one normal 18q with supernumerary copies of 
18q12q21 material; (vi) 1G0R: loss of one normal 18q and a partial deletion at 
18q22; and (vii) 1G1R-monosomy 18q: loss of a normal copy of 18q. In total, 
38.4% of 99 primary GCs were break-apart-positive at 18q21q22, 61.6% were 
break-apart-negative. Of which 28.3% had loss of 18q22.3q23 (absence of one 
or more SpectrumOrange signal) and 33.3% were monosomic for 18q. 
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11.4 18q2 break-apart in non-gastric tumors 
We next investigated the occurrence of the same break-apart patterns in a 
panel of non-gastric adenocarcinomas consisting of cancers of the prostate 
(n=20), lung (n=15), breast (n=15), pancreas (n=6), colorectum (n=19) and 
liver (n=8). TMAs were prepared in the same manner (vide supra; also see 
Chapter 6, Page 129). With the exception of prostatic adenocarcinoma cells, 
the other neoplastic nuclei were morphologically distinct from nuclei in their 
corresponding normal epithelium in H&E stained sections. As prostate cancer 
cells are very similar to the surrounding normal prostatic epithelium in stained 
H&E sections, it was necessary to employ immunostaining to identify prostate 
cancer cells. Thus, we performed double immunohistochemical staining with 
anti-human cytokeratin 5/6 (CK5/6) antibody, followed by anti-human alpha-
methylacyl-CoA racemase (AMACR), as detailed in Chapter 6, page 130. 
CK5/6 is expressed in intermediate keratin filaments of prostatic basal cells 
that are absent in prostate cancer. AMACR is selectively expressed in 
neoplastic prostatic epithelium and is therefore a diagnostic marker for 
prostate cancer. AMACR activity and its mRNA (P504S) are over-expressed 
in prostate cancer and are accepted as tissue biomarkers of this disease15,16
 
. 
Thus, only neoplastic nuclei that stained positively for AMACR were scored 
for 18q21q22 break-aparts (Figure 11-8). All double-stained prostatic basal 





















Figure 11-8 Immunostaining and immunofluorescence evaluation of a prostate 
adenocarcinoma. (i) H&E-stained section showing highly similar 
morphological appearance of neoplastic and normal epithelia. (ii) Co-staining 
for AMACR activity (blue arrow) and CK5/6 expression (yellow arrowhead) 
clearly distinguished neoplastic (AMACR-positive) from non-malignant 
(CK5/6-positive) epithelium. Basal cells that were doubly positive for 
AMACR and CK5/6 (inset) were not scored in the break-apart FISH assay. 
(iii) Immunofluorescence of CK5/6 expressing epithelium (red staining). (iv) 
Immunofluorescence of AMACR expression (green staining). (v) Merged 
images of (iii) and (iv).  FISH signals were scored only in AMACR-positive 
cells in green regions (white arrow) without doubly positive cells (yellow 
arrowhead). (vi) 18q monosomy in prostate carcinoma cells.  
 
TMA slides were pre-treated and hybridized with the ‘brute-force’ break-apart 
FISH probeset using the optimized protocols as performed on GC TMAs. 
Identical scoring criteria were applied to enable comparisons to be made 
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across all cancer types examined. The break-apart status at 18q21q22 is shown 















Figure 11-9 Absence of 18q21q22 break-apart in non-gastric cancers. FFPE 
sections of archived non-gastric adenocarcinomas were hybridized with the 
dual-labeled break-apart FISH probeset. Patterns of chromosome 18 
aberrations found in each cancer type are shown in representative images. G 
denotes SpectrumGreen (green) signal; R, SpectrumOrange (red) signal.  
 
Remarkably, none of the non-GCs had break-apart positive patterns that met 
or exceeded the threshold for labeling these tumors as break-apart positive. 
This indicated some degree of gastric specificity of the 18q21q22 
translocation. However, most of the non-GCs examined did have other 18q 
aberrations such as trisomy, tetrasomy and a high frequency of 18q monosomy 
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(Table 11-2). For example, 73.3%, 79% and 100% of lung, colorectal and 
pancreatic cancers, respectively, were monosomic for 18q.   
 
Table 11-2 A summary of 18q21q22 break-aparts in gastric and non-gastric 
cancers. 
The number of each tumor type analyzed is in parentheses. Each aberration is 
expressed as a percentage of its occurrence in the total number of specific 












A similar frequency of 18q loss had been reported in lung cancer17. A recent 
study by Alsop et al. showed 18q11q21 chromosomal loss to be very frequent 
in breast, colorectal and pancreatic cancer cell lines18. These authors further 
reported that 35% of breast cancer cell lines and nearly 12% of colorectal 
cancer lines had chromosomal breakpoints distal to 18q21 identified by 
chromosome 18 cytoband paints. Their results were consistent with our data in 
which 33.3% of breast primary cancers and 21.1% of colorectal cancers had 
18q loss. In the case of pancreatic cancer, frequent deletions of 18q12qter and 
deletion breakpoints at 18q11 have also been reported19
Break-apart positive 
 Break-apart 18q21q22
(1G1R1B, B, multiple B)
         Deletion 
(2G1R/3G2R/1G0R) 
Monosomy 18q 
       (1G1R)               




GC samples (99) 38.4 28.3 33.3 0.0 0.0
Non-GCs
Prostate (20) 0.0 0.0 65.0 15.0 20.0
Lung (15) 0.0 0.0 73.3 0.0 26.7
Breast (15) 0.0 33.3 53.3 6.7 6.7
Pancreatic (6) 0.0 0.0 100.0 0.0 0.0
Colorectal (19) 0.0 21.1 78.9 0.0 0.0
Liver (8) 0.0 0.0 50.0 37.5 12.5
Break-apart negative
. Griffin et al. have 
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more recently confirmed the prevalence of chromosome 18 abnormalities in 
pancreatic cancer. Thus, 93% (14/15) of pancreatic cancer cell lines had 
sustained loss of 18q (5 had a whole chromosomal copy loss, 7 had entire 18q 
and 2 had partial 18q deletions)20
In contrast, chromosome 18 abnormalities were more variable in prostate 
cancers which had either loss (12%) or gain (63%) of chromosome 18
. Our findings are similar i.e. 18q12.1q22.3 
deletion in 100% of primary pancreatic adenocarcinoma.  
21. Our 
data of prostate cancers revealed that 65% showed an 18q loss while 35% 
were either diploid or had a gain of 18q. A FISH study of 20 cases of 
hepatocellular carcinoma using a centromeric chromosome 18 probe showed 8 
to be diploid, 4 monosomic, 5 trisomic and 3 tetrasomic22
 
. Results of our FISH 
analysis of hepatocellular carcinoma were in agreement. 
Taken together, chromosome 18 aberrations, specifically the 18q21q22 
translocation, which was initially identified in GC cell lines, were mirrored in 
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12. Chromosome 18 aberrations and GC histopathology  
 
We have shown that the breakpoint at 18q21q22 was frequent in GC lines and 
primary GCs. This aberration was also reported to have a certain degree of GC 
specificity as other malignancies such as prostate, breast, colon, lung, liver and 
pancreas adenocarcinomas did not harbor this rearrangement. In this Chapter, 
we investigate if 18q21q22 break-apart status has any histopathological 
correlates.  
 
12.1 Clinico-pathological features and 18q21q22 break-apart 
The 18q21q22 break-apart status was correlated to six histopathological 
features assessed by a pathologist (results are detailed in Table 12-1). :  
1) The WHO histological classification1
2) The Laurén classification system
 (Histotypes include tubular, 
papillary, mucinous, signet-ring and other rare variants)  
2
3) Histological grade
 (Two main histotypes: intestinal 
and diffuse. Lesions having features of both intestinal and diffuse GC 
are known as the mixed type) 
1
4) Pathological stage (T: depth and extent of tumor invasion, N: 
lymph node metastasis of GCs. This classification system follows the 
guidelines proposed jointly by the AJCC and the UICC)  
 (Based on the level and extent of glandular 
differentiation) 
5) Lymphovascular invasion (Presence of this feature is known to be 
associated with tumor aggression and poor survival3
6) Perineural invasion (Positive predictor of recurrent disease
) 
4)     
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Table 12-1 Association analysis of primary GCs by their 18q21q22 break-
apart status, histotypes and pathological stage criteria. 18q21q22 break-apart 
positive primary GCs were compared to break-apart negatives by various 
histopathological features. Shown in parentheses are expressed percentages of 
tumors examined for each feature over the total n number of samples from 































1. Histological classification by WHO 0.983
Tubular 27(71%) 16(59.3%) 24(72.7%)
Papillary 3(7.9%) 2(7.4%) 2(6.1%)
Mucinous (>50% mucinous) 0(0%) 1(3.7%) 0(0%)
Signet ring (>50% signet ring) 7(18.4%) 6(22.2%) 7(21.2%)
Others 1(2.6%) 2(7.4%) 0(0%)
2. Histological classification by Lauren's type 0.643
Intestinal 29(76.3%) 20(74.1%) 25(75.8%)
Diffuse 7(18.4%) 6(22.2%) 8(24.2%)
Mixed 2(5.3%) 1(3.7%) 0(0%)
3. Histological grade 0.956
Well (>95% gland forming), G1 4(10.5%) 2(7.4%) 5(15.2%)
Moderate (50-95% gland forming), G2 16(42.1%) 13(48.1%) 14(42.4%)
Poor (5-49% gland forming), G3 18(47.4%) 12(44.4%) 14(42.4%)
4. Extent of invasion 0.116
Early (pT1a, pT1b, pT2a and pT2b) 22(59.5%) 22(78.6%) 24(72.7%)
Late (pT3 and pT4) 15(40.5%) 6(21.4%) 9(27.3%)
5. Lymph node involvement 0.21
No regional lymph node metastasis (N0) 11(28.9%) 12(44.4%) 14(43.8%)
Metastasis in 1-6 perigastric lymph nodes (N1) 12(31.6%) 6(22.2%) 11(34.4%)
Metastasis in 7-15 perigastric lymph nodes (N2) 12(31.6%) 5(18.5%) 4(12.5%)
Metastasis in >15 perigastric lymph nodes (N3) 3(7.9%) 4(14.8%) 4(12.5%)
6. Lymphovascular invasion 0.519
Present 24(64.9%) 17(68.0%) 15(46.9%)
Absent 13(35.1%) 8(32.0%) 17(53.1%)
7. Perineural invasion 0.281
Present 17(48.6%) 17(68.0%) 18(56.3%)
Absent 18(51.4%) 8(32.0%) 14(43.8%)
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Fisher’s exact test was performed to correlate the histopathological data to 
18q21q22 break-apart status (Table 12-1), as recommended by biostatisticians 
from the National Cancer Center, Singapore. Although a significant 
correlation could not be established, we did observe a higher proportion of 
break-apart positive GCs (40.5%) in invasive late-stage tumors (i.e. pT3 and 
pT4) compared to break-apart negative GCs (21.4% and 27.3%; Table 12-1). 
Break-apart positive GCs were more likely to have nodal metastases (N1, N2 
and N3) than with break-apart negative GCs (71.1% versus 55.5% and 
58.4%). On the same note, a fair number of break-apart negative GCs did not 
show metastatic nodal involvement (44.4% and 43.8% versus 28.9%). 
 
In a study of 102 primary GCs, Kimura et al. reported the association of 18q 
loss with pathological stage5. Inoue et al. reported that LOH of 18q22q23 in 
cohesive GC was associated with poor prognosis and tumor progression6. 
These published studies and our data suggest that loss of function of 18q genes 
may influence gastric cancer progression. Furthermore, 18q is known to 




12.2 Chromosome 18 aberrations in metaplasia, dysplasia, early and late 
stage gastric cancers 
One of the most notable hypotheses of gastric carcinogenesis was proposed by 
Correa in 1975 where he advanced a progression model for the intestinal GC 
type11 (Figure 12-1). In this model, a convergence of environmental insults, 
host and bacterial genetic factors incite non-atrophic chronic gastritis that 
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progresses to multifocal atrophic gastritis, intestinal metaplasia (IM), 



















Figure 12-1 Multi-step progression model for the intestinal type of GC. 
(Adapted from ref. 12).  
 
Having shown that 18q21q22 break-aparts tended to be late stage events 
(pT3/pT4 and nodal metastases) while monosomy 18q was a relatively early 
feature, we next investigated chromosome 18q aberrations in a small subset of 
six GC stomach samples (NCC100–NCC105) in which at least two of four 
main stages in GC development (normal, IM, Dys and CA) could be identified 
in each patient. NCC100 and NCC102 had IM and CA stages. NCC101 had 
IM and Dys. NCC103 and NCC105 had IM, Dys and CA. NCC104 had 
normal, low and high grade Dys, and CA (Figure 12-2). We performed break-
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apart FISH assays on these six sample sets. Each slide was histologically 
qualified by a pathologist on H&E stained sections and the immediate adjacent 
section was used for FISH analysis. We also applied similar stringent scoring 
criteria on at least 100 nuclei from each section. Despite having a very small 
sample set (n = 6), the results were quite intriguing. 
We found that as early as the IM stage, there was a propensity to lose 1 copy 
of chromosome 18q. Almost all the samples investigated had monosomy 18q 
in the IM lesions. Interestingly, NCC100 and 102 ‘progressed’ to show an 
18q21q22 break-apart in its cognate carcinoma.  Serving as a positive control, 
all nuclei assessed in normal epithelium within the NCC104 tissue sections 
showed diploid copies of chromosome 18q. This specimen exhibited a distinct 
pattern of progression from 18q monosomy in low grade Dys that evolved to a 
more abnormal pattern of multiple gains of 18q12q21 signals 
(SpectrumGreen) in high grade Dys. This trend appeared to continue as high 
grade Dys was transformed to overt CA that was evidenced by a somewhat 
greater range of chromosome 18 aberrations. Break-apart signals were not 
observed in any sections from NCC104, this being a break-apart negative 
tumor. IM sections of NCC103 and NCC105 showed persistent 18q 
monosomy in their cognate carcinomas.  
Our preliminary results, albeit from a small series of six patients, showed the 
involvement of 18q monosomy and rearrangements from the inception of 
gastric oncogenesis i.e. in IM lesions. Our observations are similar to a 
genome-wide study using chromosomal CGH on twenty archived GCs and ten 
adjacent pre-neoplastic lesions (4 IMs, 1 low-grade Dys and 5 high-grade 
Dys)13 that found multiple similar chromosomal aberrations (e.g. loss of 
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18q12q21; gains of 8q23 and 17q12q21) in high grade Dys as in the cognate 
CA. In this study, low-grade Dys and IM lesions showed relatively few copy 





















Figure 12-2 Chromosome 18 aberrations in pre-malignant gastric lesions. 
Break-apart FISH assay was performed on histologically qualified normal, 
intestinal metaplasia (IM), low/high grade dysplasia (low/high Dys) and 
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Zaky et al. provided evidence recently to support the concept of gastric cancer 
field cancerization14. These authors examined the degree of genetic instability 
in 83 cases of intestinal-type GC that had paired IM lesions distant from the 
GC and compared to 39 cancer-free chronic gastritis cases with IM. Genetic 
instability was assessed by LOH and microsatellite instability of five 
microsatellite loci (Bethesda panel: 2p-BAT26, 4q-BAT25, 2p-DS123, 5q-
D5S346 and 17p-D17S250). Instability was present in 8/39 (20.5%) cases of 
chronic gastritis with IM, 40/83 (48.2%) in GCs with IM and 54/83 (65.0%) 
GCs. There were also significant similarities between GC-IMs and their 
cognate carcinomas. The authors suggested that assessing genetic instability in 
IM may be a useful surrogate marker for GC risk14
A large survey conducted in the Netherlands aimed to establish GC risk of 
92,250 patients with pre-malignant lesions. This survey concluded that 0.1% 
of patients who were diagnosed with atrophic gastritis reportedly developed 
GC within 5 years. In comparison, 0.25% with intestinal metaplasia, 0.6% 




Noffsinger and Waxman supported the view that intestinal metaplasia was the 
start of the sequence of progressive pathogenic changes that culminate in GC. 
They showed that between 15-25% of low-grade dysplasia slowly progressed 
to high-grade dysplasia or carcinoma. Dysplasia was thought to be present in 
all early gastric cancers and close to 80% of advanced cancers. More than 
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Gutiérrez-González and Wright recommended that more intensive 
investigations should be conducted to identify the molecular pathogenic 
factors leading to transformation of benign atrophic gastritis to pre-malignant 
metaplasia and the factors that trigger progression to GC17
Genomic changes in pre-malignant lesions that show increasing complexity of 
DNA copy number aberrations during progression to carcinomas are not 
restricted to GCs, having been documented in oral cancer. Tsui et al.
.  
 
conducted a study involving seventy-one oral pre-malignant lesions versus 
twenty-three oral squamous cell carcinomas using tiling array CGH analysis to 
determine segmental 3p loss18
 
. They showed the recurrent loss of at least six 
shared loci at 3p between high-grade Dys and oral squamous CA.  
Although we have only presented a very small study, we had been intrigued 
by the presence of 18q genomic alterations in the early pre-malignant stages of 
GC development and that it may transpire to more overt aberrations as the 
tumor advances. 18q21q22 break-apart positivity was also found to be more 
common in late stage tumors. Collectively, this suggested that 18q may harbor 
possible pre-malignant molecular markers that may be utilized in patient 
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13. Molecular characterization of 18q21q22 breakpoint genes 
 
Our proceeding chapters emphasized that clinical prevalence of 18q alterations 
in primary GC TMAs. To the best our knowledge, this is the first description 
of a breakpoint within this cytoband in GC. There is therefore little 
information on how this signature breakpoint might alter the expression of 18q 
genes in GC. This chapter attempts to examine the perturbations of 18q 
mRNA and protein expression in relation to the 18q21q22 breakpoint.   
 
13.1 Chromosome 18 mRNA expression profiling in GC lines 
To ascertain an association between perturbed gene expression and 
chromosomal rearrangements in 18q, we first assembled transcriptome 
datasets of 10 GC lines generated on Affymetrix U133 plus 2.0 expression 
arrays. We then sub-classified the cell lines according to their chromosome 18 
aberrant status (Figure 13-1). Three of four lines had a whole chromosomal 
loss of 18. It was noted that the GC lines with an 18q deletion were near-
triploid, with the exception of YCC9. On the other hand, FU97 had as many as 
4 copies of chromosome 18 that were unrearranged by spectral karyotyping, in 



























Figure 13-1 Sub-classification of 10 GC cell lines based on their 18q aberrant 
status.  
 
The expression values of selected probesets on the array that mapped to 18q 
from these 10 lines were analyzed using SAM. A paired analysis was 
performed by grouping break-apart positive lines as class I compared to break-
apart negative lines (class II). A 42-gene profile emerged from this analysis, 
that include genes such as MALT1, BCL2, SMAD4, CDH19 and SERPINB8 
(see full list in Appendix Table 5, page 323). Intriguingly, supervised 
hierarchical clustering using average linkage analysis of the SAM processed 
data showed that this 42-gene profile cleanly classified the 10 GC cell lines by 
Deletion at 18q Breakpoint at 18q11q12 Breakpoint at 18q21q22





-18, -18 YCC3: t(6;18)(p22;q12) MKN7: +t(9;18)(?;q22)x2
YCC9: -18 YCC11: der(18)t(6;18)(?p22;q22) 
YCC1 (3N): +t(7;18)(?;?)
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their 18q aberrant status (Figure 13-2) and compared positively to the 
chromosomal based sub-classification (Figure 13-1). Both reference normal 











Figure 13-2 Supervised hierarchical clustering of 18q transcripts identified by 
SAM segregated GC cell lines by 18q aberrant status. The controls were 
normal human stomach total mRNA (Ambion and Strategene, USA). 
 
13.2 Expression of breakpoint genes by immunohistochemical staining (IHC) 
Having established that mRNA expression of selected genes was strongly 
associated with break-apart status in cell lines, we proceeded to investigate if 
this was also mirrored in primary GC tumors. We immunostained the same 
series of 99 primary GCs on which we showed earlier that 38% were break-
apart positive at 18q21q22. Using the aforementioned 42-gene expression 
profile (Figure 13-2), a total of thirteen genes were mapped to the breakpoint 
region of 18q21.3 and 18q22.2. Our list then whittled down to four genes 
(SERPINB2, SERPINB8, CD226 and SOCS6) where commercial human 
antibodies were available for IHC (Figure 13-3). 







Figure 13-3 Genes within the break-apart locus selected for 
immunohistochemistry.  
 
IHC was performed using antibodies against human Serpin B2, Serpin B8, 
CD226 antigen and SOCS-6 and the staining was scored as detailed in Chapter 
6, page 132-134. Anti-human Ki-67 staining was performed on the same TMA 
series previously used for the break-apart assay, to rule out false negative 
immunostaining due to antigen degradation in the nucleus. All cores were 
shown to stain positively for Ki-67.  
13.2.1 Serpin B8 immunohistochemical staining 
Ninety-eight cases were available for Serpin B8 staining, there being 
insufficient tumor material for one case at this stage of the study. Serpin B8 
expression was predominantly nuclear in all normal gastric epithelia (Figure 
13-4i). The stroma had negligible Serpin B8 expression. Primary GCs showed 
heterogeneous nucleocytoplasmic Serpin B8 expression that was generally 
lower compared to normal gastric controls. Among GCs, break-apart positive 
tumors showed higher nuclear Serpin B8 expression than break-apart negative 
tumors (Figure 13-4ii, iii). A binary scoring system was devised based on the 
nuclear staining intensity and the extent of protein expression in the tissue 
section (detailed in Chapter 6, Page 132). Break-apart positivity correlated 
significantly with intense nuclear Serpin B8 expression (p = 0.0001, Fisher’s 
exact test; Table 13-1).  

















Figure 13-4 Immunohistochemical staining of GC tumor cores using an anti-
human Serpin B8 mAb showed (i) intense nuclear staining in normal gastric 
antral mucosa. (ii) A break-apart positive GC showing similar intense nuclear 
staining, in contrast to (iii) a break-apart negative GC without Serpin B8 
expression. 
 
Table 13-1 Ninety-eight cases were available for Serpin B8 staining. Staining 
intensity was scored as high or low. High Serpin B8 expression was 
significantly associated with break-apart positive GCs (p = 0.0001, Fisher’s 















High expression (2+≥50%, 1+>70%) 22 11
Low expression (2+<50%, 1+≤70%) 15 50
p = 0.0001, Fisher's exact test
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CD226 antigen expression was cytoplasmic in scattered normal gastric 
epithelia (Figure 13-6i). However, we observed varying staining intensities 
among GC samples. To exclude the possibility that weak staining for CD226 
was due to cytoplasmic antigen degradation, anti-human cytokeratin AE1/ 
AE3 immunostaining was performed (Figure 13-5). Weakly-stained samples 
were excluded from the analysis. Of the 95 GC cores immunostained for 
cytokeratin AE1/ AE3 expression, four cores showed weak or no cytoplasmic 
staining and were excluded from further analysis.   
















Figure 13-5 Immunostaining for human pan-cytokeratin AE1/ AE3 to exclude 
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Break-apart positive GCs showed widespread rather than scattered CD226 
antigen expression compared to normal gastric epithelium. Immunostaining 
for CD226 antigen in breakpoint-positive GCs was much more intense 















Figure 13-6 Immunostaining for CD226 antigen expression: (i) Scattered 
cytoplasmic staining in normal antral mucosa. (ii) A break-apart positive GC 
with strong cytoplasmic staining. (iii) A break-apart negative GC with weak 
cytoplasmic staining. 
 
Ninety-one GC cores showed uniform cytoplasmic staining in neoplastic cells. 
Expression was scored as either high or low (Chapter 6, page 134) (Table 13-
2). Break-apart positivity significantly correlated with high CD226 antigen 
expression (p = 0.0001, Fisher’s exact test; Table 13-2). 
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Table 13-2 High CD226 antigen expression was significantly associated with 





Combining data of Serpin B8 and CD226 antigen expression, we showed a 
significant correlation between break-apart positive status and high co-
expression of Serpin B8 and CD226 antigen expression compared to break-
apart negative GCs (Table 13-3). In contrast, expression of Serpin B2 and 
SOCS-6 was similar in all GCs regardless of break-apart status. 
13.2.3 Serpin B8 and CD226 antigen co-expression 
 
Table 13-3 GCs with both high Serpin B8 and high CD226 antigen expression 
correlated significantly with break-apart positivity (p < 0.0001, Fisher’s exact 







Serpins are a large family of serine protease inhibitors that maintain 
homeostasis in the body by removing excess proteases generated 
endogenously by host cells or exogenously produced by microbes1
Break-apart status 
. As 
reviewed by Izuhara et al., human serpin super family are divided into nine 
clades (A-I) and Serpin B8 belongs to one of thirteen members of the human 
ov-serpin/clade B serpin family. Among the members, three are mapped to 
Positive Negative
High expression 22 14
Low expression 11 44
p = 0.0001, Fisher's exact test
Break-apart status 
Positive Negative
High Serpin B8 and high CD226 antigen 12 3
Low Serpin B8 and low CD226 antigen 4 35
p  < 0.0001, Fisher's exact test
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6p25 (SERPINB1, B6 and B9), while all the ten (SERPINB2, B4, B5, B7, B8, 
B10, B11, B12 and B13) incidentally, co-localized to 18q21.3. The clade B 
family members are generally known to target Serine and Cysteine proteases. 
It is interesting to note that SERPINB5 or maspin was reported to be a tumor 
suppressor shown to reduce metastatic activity in tumors in vivo, inhibit cell 
invasion, promote cell apoptosis and inhibit angiogenesis. Furthermore, 
maspin had been documented to be down-regulated in mammary carcinoma 
cell lines (cf. normal mammary epithelial cells). The tumor suppressive 
functions of maspin maybe associated with the fact that it is broadly localized 
in the cell. Although mainly cytoplasmic, maspin is present on the cell surface, 
at secretory vesicles and can be translocated into the nucleus. Nuclear 
localization was predominant in the nucleus of ovarian and lung carcinoma, 
and correlated with a favorable clinico-pathological features1
In our study, we showed serpin B8 to be significantly up-regulated in the 
nucleus of break-apart positives primary GC tumors. In contrast, break-apart 
negatives with whole or partial 18q deletion had significantly lower Serpin B8 
expression. It is unclear what roles Serpin B8 may play in the nuclear over-
expression in break-apart positives or conversely, in the loss of expression in 
break-apart negative GCs. We speculate that a structural rearrangement within 
the break-point region may possibly disrupt the functional capacity of Serpin 
B8.  
.  
Serpin B8 is believed to be involved in many cellular processes including 
coagulation, fibrinolysis, complement fixation, matrix remodeling, and 
apoptosis2. In a recent study, de Koning et al. reported Serpin B8 protein 
expression in normal neuroendocrine cells of several organs such as thyroid, 
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adrenal cortex, colon, and pituitary glands. Intriguingly, Serpin B8 was also 
highly expressed in neuroendocrine tumors of the pancreas3
 
.  
CD226 antigen, a member of the immunoglobulin superfamily, is a 
glycoprotein expressed on the surface of NK cells, platelets, monocytes and a 
subset of T cells. It is believed to be involved in intercellular adhesion, 
lymphocyte signaling, cytotoxicity and lymphokine secretion4. Xu et al. 
presented in a very recent report that high levels of soluble form of CD226 
was detected in multiple tumor types (esophageal, gastric, colorectal, liver, 
breast, cervical/ovarian/endometrial, lung and leukemia/lymphoma).  The 
misexpresion of CD226 in cancer was suggested to be associated with tumor 
invasion and metastasis5. By the method of Sandwich ELISA, the authors 
reported the concentration of soluble CD226 to be significantly higher in 
serum obtained from 259 cancer patients [0.2–60 (median 11.5) ng/mL] 
compared to 129 healthy control subjects [0.1–23 (median 6.3) ng/mL, p < 
0.001]. The authors also showed that gastric cancer patients had the greatest 
difference in serum CD226 expression compared to normals (p = 3.3 x 10-12)5
 
. 
In summary, we showed 18q break-apart status to be associated with a 
characteristic transcriptional pattern of 18q genes and this was further 
confirmed by immunohistochemical evidence in the altered expression of 
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14. Precise determination of translocation breakpoints by 
array painting 
 
Thus far, we showed at least four fusion partners (6p, 8q, 9q and 13q) in the 
18q translocations. High resolution SNP copy number data were useful, to a 
certain extent, in localizing breakpoint regions from copy number transitions 
given that most solid tumor translocations are unbalanced. However, definitive 
identification of the fusion partner(s) is not possible for complex 
rearrangements. A caveat to the SNP analysis was that it measured the sum 
total of genomic alterations in a largely heterogeneous cell population. Hence, 
different rearrangements and/or copy number alterations that occur within 
different copies of the same chromosome will undoubtedly appear as multiple 
regions of copy number transitions. This makes it difficult to determine which 
copy number transition correctly localizes the fusion point in the translocation 
of interest (Figure 10-4, page 233). Given that most GC tumors are highly 
aneuploid, the admixture of normal chromosomal copies and altered segments 
will tend to obscure the exact localization of translocation breakpoints. The 
highly aneuploid GC cell line, FU97, harboring t(8;18) demonstrated how 
determination of the breakpoint is technically challenging in the presence of 

















Figure 14-1 FU97 copy number analysis of chromosome 8. A precise copy 
number transition point cannot be easily determined. 
 
14.1 Chromosome sorting by flow cytometry 
Our interests were to discriminate the fusion points between chromosome 18 
and its multiple partners, and subsequently to determine the likely 
consequences of chromosome fusions. An ideal method would be to isolate or 
enrich the population of translocated chromosomes of interest, thus separating 
it from other “contaminating” chromosomal material. We chose flow 
cytometric chromosome sorting (FACS sorting) as a potential technique for 
isolating pure populations of specific chromosomes. This is the method of 
choice for isolating pure individual chromosomes from human or other species 
in quantity for the development of chromosome paints1. FACS sorting of 
chromosomes is based on principle that chromosomes differ in size (DNA 
content) and DNA base composition2,3. Hoechst 33258 (Ho) preferentially 
binds A-T rich DNA while Chromomycin A3 (CA3) binds GC-rich regions 
more avidly. Thus in a bivariate FACS plot analysis of Ho and CA3 doubly-
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stained normal human chromosomes, a large chromosome having a certain 
average base composition, such as chromosome 1, is well separated from the 
smaller chromosomes (Figure 14-2). With the exception of the similarly sized 
C-group chromosomes (9-12), each of the chromosomes occupies a unique 














Figure 14-2 A flow karyogram of a normal human cell line, GM11321B. Each 
intense spot represents a pure fraction of the isolated chromosomes (identities 
labeled). (Karyogram kindly supplied by B.L. Ng, The Wellcome Trust Sanger 
Institute, U.K.) 
 
With the generous assistance from Dr. Nigel Carter and his team at The 
Welcome Trust Sanger Institute, we successfully analyzed and sorted four GC 
cell lines that had chromosome 18 translocations. The details of this technique 
are presented in Chapter 6, page 135. 
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Successful FACS sorting depends on two main factors, especially crucial in 
highly aneuploid cancer cell lines that are riddled with multiple chromosomal 
rearrangements: 1) Large amounts of pure and un-degraded chromosome 
fractions isolated from highly mitotic cells are required. Preparation of 
chromosomes for flow cytometry needs the careful calibration of pH in 
hypotonic swelling and polyamine isolation buffers, as well as optimization of 
Ho and CA3 staining. 2) An experienced FACS operator to apply precise 
voltages and angles on the deflection plates to separate electrically charged 
chromosomes based on their size and staining pattern. We successfully flow-
sorted chromosomes of four GC cell lines, namely: YCC2, YCC3, MKN7 and 














Figure 14-3 Flow karyogram of YCC2.   


























Figure 14-5 Flow karyogram of MKN7.  















Figure 14-6 Flow karyogram of FU97. 
 
Not only were the flow karyograms of GC cell lines markedly different from 
that of normal diploid human cells, each GC cell line had a unique flow 
karyogram. This meant that it was not possible to match the patterns using the 
normal human cell line as a reference template. The method of choice to 
distinguish the identity of each sorted fraction was reverse FISH analysis. This 
involved labeling and hybridizing isolated fractions of chromosomes (normal 
and/or rearranged) onto metaphase spreads established from normal human 
blood lymphocytes or cell line. The identity of each spot could then be 
characterized and determined.  
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14.2 Reverse FISH analysis 
We devised a systematic nomenclature that designated each spot with an 
Arabic letter (e.g. spot A) followed by a numeric suffix if spots were very 
close together (e.g. A1, A2). Essentially, a minimum of 1000 copies of 
chromosomes from each spot were flow-sorted and prepared for reverse FISH 
analysis as described in Chapter 6, page 137. DNA from each isolate was 
amplified by degenerate oligonucleotide-primed polymerase chain reaction 
(DOP-PCR). An aliquot of the amplified DNA was labeled in a second PCR 
that incorporated a fluorophore such as FITC, Cy3 or Texas Red. Upon 
hybridization onto normal human metaphase spreads, one can determine the 
composition and chromosomal origin(s) of the sorted material.  For example, 
reverse FISH performed using a sorted t(6;18) chromosome spot will give rise 
to fluorescent signals on partial segments of chromosomes 6 and 18 of a 
normal human metaphase (Figure 14-7a).  A caveat to flow cytometric 
chromosome sorting is that different species of chromosomes of similar size 
are not adequately resolved, as in the case of the C-group chromosomes 9-12. 
In such situations, reverse FISH analysis will display hybridization signals in 
multiple chromosome regions (Figure 14-7b), more indicative of a mixed 
population than a pure single fraction. However, complementary spectral 
karyotype data should help to resolve the ambiguity. Here we were able to 
identify translocation partners of chromosome 18 in four cell lines: YCC2, 
YCC3, MKN7 and FU97 [Figures 14-7a) to d)]. Spot E of the YCC3 flow 
karyogram was an example of a spot that was not well resolved by FACS 
sorting as shown by the multiple hybridized chromosomal regions. To date, 
we have completely characterized all spots in all four GC lines by reverse 
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FISH. An example of the complete analysis of YCC2 sorted chromosomes is 
shown in Figure 14-8 where the identity of each isolated spot had been 

























Figure 14-7 Identification of fusion partners in sorted translocated 
chromosomes using reverse FISH analysis. a) spot 3A isolated from YCC2 
showed a der(6)(18qter→18q12::6p24→6qter); b) spot E from YCC3, 
der(6)(18qter→18q12::6p23→6qter), chromosomes 3 and 4; c) spot B from 
MKN7, der(18)(18pter→18q22::9q22→9qter); and d) spot A from FU97, 
der(18)(18pter→18q22::8q21.2→8qter). 
 


























Figure 14-8 Complete characterization of flow-sorted chromosome spots from 
YCC2. 
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14.3 Array painting 
As mentioned, sorted chromosomes are ideal for accurate determination of 
translocation breakpoints and molecular characterization of fusion events. We 
embarked on array painting to map exact fusion points3,4. Array painting 
involved the fluorescence labeling of appropriate amounts of DNA prepared 
from individually sorted chromosomes and hybridization to a DNA 
oligonucleotide array platform. The spatial resolution of the platform 
employed determines the physical precision of breakpoint mapping in the 
absence of ‘contaminating’ chromosomal material. At the time of writing, we 
had performed preliminary experiments on flow-sorted translocated 
chromosome 18 from YCC2. We aimed to address a number of issues in this 
part of the work. The first question we wanted address was the selection of an 
appropriate array platform to be used in array painting. We chose to compare 
the Agilent 244K oligoarrays (Agilent Inc. USA) and the Affymetrix SNP 
mapping 500K arrays (Affymetrix Inc., USA). The next issue was the optimal 
amount of starting DNA material required in each hybridization. The Agilent 
system required a minimum of 1ug DNA versus Affymetrix’s 500ng. Based 
on the estimated size of t(6;18) or spot 3A from YCC2, 1 µg of DNA was 
equivalent to at least 25,000 copies of sorted chromosomes. Hence, the first 
challenge was to generate enough starting material. We first evaluated 
Agilent’s recommended protocol that began with whole genome amplification 
(WGA) using the GenomePlex system (Sigma-Aldrich, USA) on 25,000 
copies of spot 3A. This was followed by a labeling reaction prior to 
hybridization onto Agilent’s 244K oligoarrays. As seen in the analysis 
generated by Agilent DNA Analytics 4.0 software (Agilent Inc., CA, USA), 
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very distinct copy number transitions were determined in both chromosomes 6 
and 18 (Figure 14-9). The chromosome 18 breakpoint was determined at 
18q12.2. In the case of chromosome 6, there was an interstitial deletion at 






















Figure 14-9 DNA copy number analysis of YCC2 spot 3A using Agilent 244K 
oligoarray. Copy number transition points were used to determine the 
translocation breakpoints. Colored regions indicate presence of genomic 
material. The left panel depicts chromosome 6 where a transition was 
identified at 6p24.3 (upper green arrow) and an apparent interstitial deletion at 
6p22.1p22.3 (lower green arrow). The right panel depicts chromosome 18 
with a distinct transition point at 18q12.2 (blue arrow). 
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We next tested if Affymetrix 500K SNP arrays yielded comparable results. 
We made this trial more challenging and informative by performing an 
additional hybridization experiment using DNA from 1000 chromosomes 
flow-sorted from spot 3A and DOP-PCR amplified before fluorescence 










Figure 14-10 DNA copy number analysis of YCC2 spot 3A using Affymetrix 
SNP mapping 500K arrays. Top panel shows data from array painting 25,000 
copies of sorted spot 3A whole genome amplified using GenomePlex (shown 
here as a magnified view of chromosome 18). Bottom panel shows data from a 
parallel experiment in which the starting material was 1000 copies of sorted 
spot 3A (DOP-PCR amplified). 
 
We concluded from these pilot experiments that array painting results were 
not significantly different between the Agilent and Affymetrix platforms as 
both showed sharp and distinct transition points. WGA also relieved the 
limitation of requiring at least 1 µg of starting DNA in Agilent’s protocol. 
More informative to us was that WGA of only 1000 copies of sorted 
chromosomes yielded similar data, albeit at the cost of relatively lower raw 
intensity values. This led us to address the latter issue by exploring another 
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WGA method on 1000 copies of sorted chromosomes. Given the miniscule 
amounts of DNA in 1000 copies (theoretical yield approximately 40ng), we 
needed a technique capable of generating sufficient amplified DNA while at 
the same time not amplifying spurious signals. We chose the GenomiPhi 
system (GE Healthcare, UK) to perform WGA on 1000 copies of sorted spot 
3A from YCC2. We reasoned that if 1000 copies could yield data as reliable 
as 25,000 copies, the demands made on flow sorting would be reduced 
significantly. As shown in Figure 14-11, WGA material using the GenomiPhi 











Figure 14-11 DNA copy number analysis of spot 3A (YCC2) using 
Affymetrix SNP mapping 500K arrays. Shown in the plot is the intensity plot 
of chromosome 18. The sharp transition clearly indicates the translocation 
breakpoint (arrow). Input DNA was generated from GenomiPhi WGA of 1000 
copies of sorted spot 3A.  
 
It was very encouraging that this method did not generate any spurious 
artifacts despite significantly lower amounts of starting DNA. As this was a 
whole genome copy number analysis, only chromosome 6 and 18 (Figure 14-
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11) showed strong intensities. We concluded at this point that 1000 copies of 
sorted chromosomes could be sufficiently amplified (from 40 ng input DNA to 
20 µg amplified product) using the GenomiPhi method, free of artifacts. 
 
To validate the fidelity of array painting data from amplified flow-sorted 
chromosomes vis-à-vis the genomic rearrangements in question, we performed 
gold standard FISH analysis using labeled BAC clones that mapped to the 
copy number transition points determined by Affymetrix 500K SNP arrays 
(vide supra). Dual-labeled probes were hybridized to metaphase spreads 
prepared from YCC2 cell line. The characteristic translocation, t(6;18), was 
clearly confirmed by fusion signals detected in both metaphase chromosomes 














Figure 14-12 Dual-labeled FISH analysis using custom probes hybridized to 
YCC2 metaphase chromosomes and interphase nuclei. BAC clone RP1-90O12 
(6p24.3) was labeled with SpectrumGreen and RP11-318J15 (18q12.2) labeled 
with SpectrumOrange.  
t(6;18) 
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Cumulatively, we have established a sound methodology for determining 
translocation breakpoints at high resolution with greater precision. These data 
facilitated the design of fusion probes to be applied to clinical samples. We are 
currently extending this analysis to three other 18q translocations from the 
remaining flow-sorted GC lines with a view to identifying potential fusion 
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Conclusion and Future Prospects 
 
In conclusion, we have achieved the primary goals of our study. We 
reaffirmed that epithelial tumors such as GC, are more structurally rearranged 
than was initially perceived. Having cytogenetically characterized 17 gastric 
cancer cell lines using an integrated approach, we showed compelling 
evidence of a novel and recurrent translocation breakpoint at 18q21q22, 
initially discovered in GC cell lines, is mirrored in 38% of primary GCs but is 
absent in several common non-gastric cancers. To the best of our knowledge, 
this study is the first to identify a recurrent ‘GC-translocation’ in chromosome 
18.  
Our integrated approach, using a suite of molecular cytogenetic and whole 
genome analyses methods, circumvented major technical hurdles to reveal 
molecular attributes of genomically complex GCs, enabling the identification 
at least forty-five recurrent translocation breakpoints.  
Furthermore, we showed copy number alterations and mRNA misexpression 
segregation patterns that were distinctive of GC when data were compared to 
the NCI-60 panel of non-GC cell lines. These findings have not been reported 
elsewhere, although several significantly dysregulated miRNAs (identified 
from 40 primary GCs and 17 cell lines) have been reported by other 
laboratories in GC and non-GC tumors. Utilizing the most highly aberrant 18q 
arm as a model system, we custom-designed FISH hybridization probes and 
developed a robust TMA break-apart FISH assays that enabled the rapid 
verification of pathologic translocations in archived primary tumor material. 
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Immunohistochemistry performed on the same series of TMAs also showed 
significantly altered expression of breakpoint proteins.  
There is increasing evidence, in other malignancies including solid tumors, 
that chromosomal rearrangements often involved multiple partners. 
Identification of such fusion partner(s) is challenging, not least because it is 
compounded by highly complex and heterogeneous tumor genomes. We 
successfully applied chromosome sorting by flow cytometry to isolate 
individual translocated chromosomes of interest from which fusion 
breakpoints were precisely determined by array painting in YCC2 and three 
other GC cell lines.  
 
Future Prospects 
We envisage that the approaches described in this thesis could form a useful 
general framework for the characterization of other highly recurrent 
translocations that may be pathogenic in GC, and indeed in other solid tumor 
types. Flow cytometry-sorted chromosomes, in the absence of other 
‘contaminating’ DNA species, are ideal templates for detailed molecular 
characterization of fusion events. The methodology will continue to be useful 
in our panel of GC cell lines as well as other malignancies with highly 
complex genomes. We also foresee that this line of investigation is appropriate 
for Next-generation sequencing technologies. Given the significant reduction 
in genomic complexity of sorted chromosomes and a rapid processing time in 
next-generation sequencers, molecular characterization of fusion junctions can 
be performed with greater accuracy and significant cost reductions.  
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Results from Next-generation sequencing could enable the design of highly 
specific DNA FISH probes to be applied to primary GCs, most efficiently 
using tissue microarrays, so that the extent of signature aberrations in clinical 
samples can be known. Disease-associated translocations raise the prospect of 
expressed fusion gene product(s) and exquisitely targeted cancer therapy. 
Recent triumphs of molecularly-directed cancer therapy, such as imatinib, 
suggest that this Holy Grail of clinical oncology may be attained, at least for 
some diseases. The search for possible fusion transcripts will be informed by 
careful bioinformatics analysis, design of gene-specific primers for RT-PCR 
targeting fusion transcripts. Optimized primer sets can be scaled-up to screen 
primary GCs for fusion transcripts.  Chromosomal translocations that do not 
generate pathogenic fusion products may still be clinically useful as prognostic 
indicators to better stratify patients, as exemplified in certain leukemias. In the 
context of the long gestation period of gastric oncogenesis, acquisition of 
signature abnormalities in pre-malignant states offers a further opportunity to 
intervene, interdict progression of oncogenesis and thus help to mitigate the 





















































Balanced Chromosomal Abnormalities 
Band       Abnormality    Cases 
3q21 t(3;5)(q21;q31) 2
5q31 t(3;5)(q21;q31) 2
Unbalanced Chromosomal Abnormalities 
Band Abnormality Cases Band Abnormality Cases 
1p13 add(1)(p13) 2 8q10 i(8)(q10) 11
1p22 del(1)(p22) 5 9p24 add(9)(p24) 2
1p36 add(1)(p36) 2 9q10 i(9)(q10) 3
1q10 i(1)(q10) 2 10q23 del(10)(q23) 2
1q41 del(1)(q41) 2 10q24 del(10)(q24) 2
2q10 i(2)(q10) 3 10q26 add(10)(q26) 2
2q33 del(2)(q33) 2 11p11 add(11)(p11) 2
3p11 add(3)(p11) 3 11p13 add(11)(p13) 2
3p11 del(3)(p11) 3 12p10 i(12)(p10) 2
3p13 del(3)(p13) 3 12p11 add(12)(p11) 4
3p21 add(3)(p21) 2 12p12 del(12)(p12) 4
3p21 del(3)(p21) 7 12p12 der(12)add(12)(p12)del(12)(q24) 2
3p26 add(3)(p26) 3 12p13 add(12)(p13) 3
3q11 del(3)(q11) 2 12q24 del(12)(q24) 2
3q12 del(3)(q12) 2 12q24 der(12)add(12)(p12)del(12)(q24) 2
3q13 add(3)(q13) 2 13p11 add(13)(p11) 2
3q13 del(3)(q13) 2 13q10 der(13;14)(q10;q10) 2
3q21 del(3)(q21) 2 13q10 i(13)(q10) 5
5p10 i(5)(p10) 5 14p11 add(14)(p11) 2
6q15 del(6)(q15) 2 14q10 der(13;14)(q10;q10) 2
6q21 del(6)(q21) 6 15p11 add(15)(p11) 2
6q22 del(6)(q22) 3 17p11 add(17)(p11) 3
6q27 add(6)(q27) 2 17p12 del(17)(p12) 2
7p21 add(7)(p21) 2 17p13 add(17)(p13) 3
7p22 add(7)(p22) 2 17q10 i(17)(q10) 6
7q21 del(7)(q21) 2 18q21 del(18)(q21) 3
7q22 add(7)(q22) 4 21p11 add(21)(p11) 2
7q22 del(7)(q22) 3 22p11 add(22)(p11) 2





























































Abnormality    Cases Abnormality    Cases 
1 6 -1 18
2 9 -2 13
3 8 -3 14
4 4 -4 21
5 9 -5 18
6 8 -6 11
7 20 -7 6
8 29 -8 15
9 12 -9 28
10 6 -10 23
11 7 -11 9
12 11 -12 16
13 13 -13 17
14 6 -14 25
15 3 -15 21
16 10 -16 25
17 5 -17 27
18 3 -18 36
19 5 -19 14
20 26 -20 16
21 9 -21 29
22 9 -22 30
+X 11 -X 25







Appendix Table 2 Copy number gains (205) and loss (158) clusters from 100K 





205 copy number gain 
clusters    
       
Cluster 







1 1 p36.23 8520592 8551967 3 Gain 
2 1 q21.3 149953607 150221854 12 Gain 
3 1 q32.1 200940820 200985598 7 Gain 
4 1 q32.3 210768910 210813740 4 Gain 
5 1 q42.12 223176095 223305091 11 Gain 
6 1 q42.3 233426502 233478671 6 Gain 
7 2 p24.1 23023210 23031558 3 Gain 
8 2 p23.3 26597160 26827788 5 Gain 
9 2 p16.3 48651987 48818526 13 Gain 
10 2 p11.2 85139960 85196635 5 Gain 
11 2 q12.3 108209072 108223937 3 Gain 
12 2 q13 112381102 112460388 3 Gain 
13 2 q14.2 121603296 121614327 4 Gain 
14 2 q21.1 132077943 132179379 3 Gain 
15 2 q32.1 188219586 188451261 10 Gain 
16 2 q35 219228649 219309636 7 Gain 
17 2 q37.3 237807427 237951352 3 Gain 
18 3 p11.1 89604415 89898956 6 Gain 
19 3 q13.12 107976056 108010853 3 Gain 
20 3 q21.3 131151443 131191456 3 Gain 
21 3 q25.2 155697801 155770394 5 Gain 
22 3 q26.1 167781187 167881640 6 Gain 
23 3 q26.32 179116327 179574436 5 Gain 
24 3 q29 196170702 196179309 4 Gain 
25 5 p15.1 17165996 17246633 3 Gain 
26 5 p13.1 42200057 42524789 7 Gain 
27 5 p12 45285361 45512860 3 Gain 
28 5 q11.2 51064217 51077609 3 Gain 
29 5 q11.2 58337160 58387085 9 Gain 
30 5 q21.2 104437659 104562047 12 Gain 
31 5 q31.1 133773297 133816612 4 Gain 
32 5 q31.3 141491844 141609516 8 Gain 
33 5 q35.3 179884180 180003855 5 Gain 
34 6 p21.1 42420353 42430492 4 Gain 
35 7 p22.2 3890182 4018203 4 Gain 
36 7 p22.1p22.2 4408712 5703610 12 Gain 
37 7 p21.3 7511267 7745849 25 Gain 
38 7 p21.3 9327634 9620459 25 Gain 
39 7 p21.3 9862079 9965479 12 Gain 
40 7 p21.3 10353158 10486412 17 Gain 
41 7 p21.3 12155054 12917472 90 Gain 
42 7 p21.2 14314856 14492625 21 Gain 
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43 7 p21.1 15599845 15658675 10 Gain 
44 7 p21.1 16626498 16634559 3 Gain 
45 7 p21.1 17969566 18315422 31 Gain 
46 7 p15.3 20525526 20579321 7 Gain 
47 7 p15.3 21765970 22160144 32 Gain 
48 7 p15.3 22855042 23350222 35 Gain 
49 7 p15.3 23870481 24021536 6 Gain 
50 7 p15.2 25195578 25296053 11 Gain 
51 7 p15.2 25579186 25829614 31 Gain 
52 7 p15.2 27488768 28036836 38 Gain 
53 7 p15.1 28264631 28733403 25 Gain 
54 7 p15.1 29784497 29911394 9 Gain 
55 7 p15.1 30787631 30936325 6 Gain 
56 7 p15.1 31407174 31680492 19 Gain 
57 7 p14.3 32023331 32162747 8 Gain 
58 7 p14.3 32833248 33301917 20 Gain 
59 7 p14.3 33882669 33898350 4 Gain 
60 7 p14.2p14.3 35555738 35672583 10 Gain 
61 7 p14.2 36192880 36309112 5 Gain 
62 7 p14.2 36804574 37091542 21 Gain 
63 7 p14.1 38062259 38157885 13 Gain 
64 7 p14.1 41397331 41491141 15 Gain 
65 7 p14.1 41981689 42199808 19 Gain 
66 7 p14.1 42915299 43061223 13 Gain 
67 7 p13 43345369 43529435 11 Gain 
68 7 p13 45358868 45916095 7 Gain 
69 7 p12.3 46690035 46771438 6 Gain 
70 7 p12.3 47608445 47813366 6 Gain 
71 7 p12.3 48299377 48515795 11 Gain 
72 7 p12.1 51536912 51760920 10 Gain 
73 7 p12.1 53893473 53957996 3 Gain 
74 7 p11.2 54995340 55183403 12 Gain 
75 7 p11.2 56154601 56241393 6 Gain 
76 7 q11.21 62014819 62079435 6 Gain 
77 7 q11.21 63793594 65001791 14 Gain 
78 7 q11.22 68027239 68070065 6 Gain 
79 7 q11.22 68301997 68333009 5 Gain 
80 7 q11.22 70227815 70425245 5 Gain 
81 7 q11.22 70792619 71371987 12 Gain 
82 7 q11.23 74901423 75761928 7 Gain 
83 7 q21.11 80567019 80604343 5 Gain 
84 7 q21.2 90939401 91012199 5 Gain 
85 7 q21.3 93231073 93291923 3 Gain 
86 7 q21.3 97037346 97080190 4 Gain 
87 7 q22.1 97964766 98211585 7 Gain 
88 7 q32.2 129167479 129180577 4 Gain 
89 7 q36.3 156874801 157074432 5 Gain 
90 8 q21.3 89791390 89868632 3 Gain 
91 8 q22.1 97386585 97454149 3 Gain 
92 8 q22.1 98916138 99022252 14 Gain 
93 8 q22.2 99304253 99893673 9 Gain 
94 8 q22.2 101063565 101274956 6 Gain 
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95 8 q22.3 102612941 102854062 8 Gain 
96 8 q23.1 107241060 107319460 6 Gain 
97 8 q23.1 107714747 107899748 8 Gain 
98 8 q23.1 109512244 109632323 9 Gain 
99 8 q23.1 110122659 110203456 5 Gain 
100 8 q23.3 112476554 112711850 7 Gain 
101 8 q23.3 114044747 114206426 18 Gain 
102 8 q23.3 116894719 117309459 27 Gain 
103 8 q24.11 118119913 118410001 30 Gain 
104 8 q24.11 118770631 118844178 10 Gain 
105 8 
q24.11q24.1
2 119057723 119219639 10 Gain 
106 8 q24.12 119361760 119416599 5 Gain 
107 8 q24.12 119729360 120103179 32 Gain 
108 8 q24.12 121015649 121088918 3 Gain 
109 8 q24.13 125661758 126155552 23 Gain 
110 8 q24.21 127463109 127751420 15 Gain 
111 8 q24.21 128194377 128487118 29 Gain 
112 8 q24.21 128759811 129255251 28 Gain 
113 8 q24.21 130070215 130098574 14 Gain 
114 8 q24.22 132488291 132662969 16 Gain 
115 8 q24.22 133426676 133653740 7 Gain 
116 8 q24.22 135205839 135313135 10 Gain 
117 8 q24.22 136121266 136149422 3 Gain 
118 8 q24.23 136768089 137212094 29 Gain 
119 8 q24.23 137459751 138054402 57 Gain 
120 8 q24.23 138436714 138662737 38 Gain 
121 8 q24.23q24.3 139281652 140149271 41 Gain 
122 8 q24.3 142072079 143040511 5 Gain 
123 9 q22.2 91819069 91938626 4 Gain 
124 9 q31.3 111188135 111192977 3 Gain 
125 9 q33.3 128740358 128793172 3 Gain 
126 9 q34.11 130343451 130556659 9 Gain 
127 10 q23.2 88059396 88101610 5 Gain 
128 11 q11 55466760 55516149 3 Gain 
129 11 q12.1 57489108 57725262 13 Gain 
130 11 q13.1 64801562 64803977 3 Gain 
131 11 q13.4 71345252 71433344 8 Gain 
132 11 q13.4 71532141 72397847 11 Gain 
133 11 q13.4q13.5 74375300 75087467 14 Gain 
134 11 q13.5 76175080 76379254 7 Gain 
135 11 q14.3 89034083 89188540 4 Gain 
136 11 q21 93031602 93042994 4 Gain 
137 11 q22.3 107166562 107217046 7 Gain 
138 11 q23.1 111075141 111153208 4 Gain 
139 11 q23.3 119398962 119530453 8 Gain 
140 11 q25 130897898 131004591 4 Gain 
141 12 p13.33 331859 498351 4 Gain 
142 12 p13.31 6264939 6510242 5 Gain 
143 12 p12.3 19035002 19118443 3 Gain 
144 12 q12 43929306 44098347 9 Gain 
145 12 q12 44329880 44378810 3 Gain 
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146 12 q13.13 52752362 52916784 3 Gain 
147 12 q24.11 108031303 108174697 6 Gain 
148 13 q12.12 22963424 23014122 8 Gain 
149 13 q34 109333777 109367385 3 Gain 
150 13 q34 110259218 110377552 3 Gain 
151 14 q11.2 21305730 21395736 12 Gain 
152 14 q24.3 74003876 74189260 3 Gain 
153 14 q24.3 75719885 75857241 4 Gain 
154 14 q24.3 76991628 77191853 7 Gain 
155 14 q32.33 104475429 105832953 3 Gain 
156 15 q25.3 83149176 83180282 4 Gain 
157 16 q22.1 66838812 66922658 3 Gain 
158 17 q11.2 23293052 23333545 3 Gain 
159 17 q11.2 24028830 24185264 3 Gain 
160 17 q12q21.1 34693022 35542587 9 Gain 
161 17 q24.2 62287922 62642504 9 Gain 
162 17 q25.1 68735562 68758486 3 Gain 
163 19 p12 22799189 22945590 9 Gain 
164 19 q13.41 58194918 58837765 7 Gain 
165 19 q13.43 62016152 62189739 5 Gain 
166 20 p13 2542190 3235704 13 Gain 
167 20 p12.3 8768870 9113158 16 Gain 
168 20 p12.1 12064305 12339974 14 Gain 
169 20 p12.1 12983593 13348713 26 Gain 
170 20 p12.1 15848806 15939902 7 Gain 
171 20 p11.23 18598214 18898921 14 Gain 
172 20 p11.23 19398035 19651623 21 Gain 
173 20 p11.23 19982495 20095304 4 Gain 
174 20 p11.23 20483833 20709606 6 Gain 
175 20 p11.22 21514717 21570078 4 Gain 
176 20 
p11.21p11.2
2 22067263 23311989 63 Gain 
177 20 p11.21 24076395 24167041 8 Gain 
178 20 p11.21 24726455 25030256 6 Gain 
179 20 q11.21 29367806 29482515 6 Gain 
180 20 q11.21 30675396 31391022 13 Gain 
181 20 q11.22 32086269 32123851 4 Gain 
182 20 q11.22 32489228 32695151 6 Gain 
183 20 
q11.22q11.2
3 33696692 34224346 10 Gain 
184 20 q11.23 36094246 36539571 17 Gain 
185 20 q11.23 36819791 37230025 12 Gain 
186 20 q12 37613066 40231295 104 Gain 
187 20 q12 40459279 40468399 4 Gain 
188 20 q12q13.11 40778203 41231343 22 Gain 
189 20 q13.12 41886191 42768988 11 Gain 
190 20 q13.12 43268646 43673640 25 Gain 
191 20 q13.12 44210702 44990424 26 Gain 
192 20 q13.13 46496933 47576769 21 Gain 
193 20 q13.13 47709417 47871823 6 Gain 
194 20 q13.2 49387119 49480278 5 Gain 
195 20 q13.2 50189107 50792137 28 Gain 
196 20 q13.2 51308176 51378068 6 Gain 
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197 20 q13.2 52109454 52156350 3 Gain 
198 20 q13.2 52260700 52754311 39 Gain 
199 20 q13.2 53045547 53137100 9 Gain 
200 20 q13.2 53436535 53674399 23 Gain 
201 20 q13.2 53964663 54119424 11 Gain 
202 20 
q13.31q13.3
2 55242287 56004247 16 Gain 
203 20 q13.32 56091721 57096119 26 Gain 
204 20 
q13.32q13.3
3 57464447 59505047 80 Gain 
205 22 q13.31 46193217 46243428 4 Gain 
 
 158 copy number loss clusters    
       
Cluster 





1 1 p36.32 3155127 3329199 7 Loss 
2 1 p36.32 3966540 4073701 4 Loss 
3 1 p36.22 10671784 10755448 3 Loss 
4 1 p36.22 11778965 11976617 3 Loss 
5 1 p36.12p36.13 20271639 20398657 4 Loss 
6 1 p36.12 23324479 23410142 4 Loss 
7 1 p36.11 26194668 26434443 9 Loss 
8 1 p35.3 29042146 29318101 7 Loss 
9 1 p34.1 45131114 45204251 3 Loss 
10 1 p32.3 54590687 54598775 3 Loss 
11 1 p32.3 54959274 54964232 4 Loss 
12 1 p22.1 93172282 93380900 5 Loss 
13 2 p25.3 2854391 2986979 4 Loss 
14 2 p25.1 9066695 9290701 7 Loss 
15 2 p16.3 48441245 48447814 3 Loss 
16 2 q14.3 122233984 122435424 3 Loss 
17 2 q21.1 131806164 131871889 3 Loss 
18 2 q33.1 202873678 202911203 3 Loss 
19 3 p24.3 19122542 19199502 3 Loss 
20 3 p24.1 27301455 27418642 9 Loss 
21 3 p22.1 39440781 39508956 3 Loss 
22 3 p21.2p21.31 51324927 51461610 4 Loss 
23 3 p14.2 59929425 60754812 102 Loss 
24 3 p14.1 67683986 67739439 7 Loss 
25 3 p13 72969412 73009905 5 Loss 
26 3 p12.3 79219920 79280613 3 Loss 
27 4 p16.3 753229 1035323 4 Loss 
28 4 p16.2 3362745 3400993 3 Loss 
29 4 p16.1 5580135 5793496 9 Loss 
30 4 p15.33 11846164 11988416 13 Loss 
31 4 p15.2 24135470 24213874 9 Loss 
32 4 p15.2 25901653 25978818 4 Loss 
33 4 p13 41406619 41469964 4 Loss 
34 4 p12 48150691 48504600 7 Loss 
35 4 q12 53745970 53912256 4 Loss 
36 4 q13.3 72291635 72404454 6 Loss 
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37 4 q21.21 80279231 80412067 7 Loss 
38 4 q22.1 91190768 91307585 7 Loss 
39 4 q22.1 92017061 92189450 16 Loss 
40 4 q22.1 92808933 92889336 5 Loss 
41 4 q25 113599167 113764614 5 Loss 
42 4 q32.1 160911852 160940848 6 Loss 
43 4 q32.2 164187700 164340776 6 Loss 
44 4 q32.3 165788217 166037058 8 Loss 
45 4 q32.3 169684684 169692628 4 Loss 
46 4 q32.3 170308993 170318857 4 Loss 
47 4 q33 171585690 171888556 34 Loss 
48 4 q34.3 180179706 180498192 18 Loss 
49 4 q34.3 181000963 181162034 11 Loss 
50 4 q34.3 181477673 181587029 5 Loss 
51 4 q35.1 182906713 183235320 25 Loss 
52 4 q35.2 188272508 188464945 6 Loss 
53 4 q35.2 189164816 189257342 5 Loss 
54 5 q14.1 80934020 80940689 5 Loss 
55 5 q21.1 100166961 100271404 4 Loss 
56 5 q21.3 105120268 105334799 5 Loss 
57 5 q31.2 138467700 138775359 5 Loss 
58 5 q35.1 171282918 171318906 4 Loss 
59 6 p22.1p21.33 29645954 29908121 9 Loss 
60 6 q25.3 159103550 159104665 3 Loss 
61 6 q27 168654150 168698477 4 Loss 
62 8 p23.2 2291741 2390378 10 Loss 
63 8 p23.1 11612211 11645399 6 Loss 
64 8 p12 35815092 35815353 3 Loss 
65 8 p11.23 39307991 39331612 3 Loss 
66 8 q11.23 54844979 55175649 5 Loss 
67 9 p24.3 1141090 1204563 12 Loss 
68 9 p24.1 5402867 5415109 3 Loss 
69 9 p22.2 17938527 18000485 7 Loss 
70 9 p21.3 21791078 21844199 4 Loss 
71 9 p21.3 22018801 22185820 11 Loss 
72 9 p21.3 22874562 22988880 12 Loss 
73 9 p21.1 31995635 32111628 16 Loss 
74 9 q21.2 79386431 79398945 3 Loss 
75 9 q34.2 135519587 135864199 3 Loss 
76 10 p15.2p15.3 2969651 3180013 7 Loss 
77 10 p14 9560540 9657021 7 Loss 
78 10 p14 11793793 11979487 12 Loss 
79 10 p11.21 35357323 35499982 4 Loss 
80 10 q21.3 69814683 70016746 4 Loss 
81 10 q23.33 96698216 96724572 3 Loss 
82 10 q24.1 98386729 98423551 4 Loss 
83 10 q24.1 99331175 99436415 4 Loss 
84 10 q24.31 102249558 102261569 3 Loss 
85 10 q24.33 105462820 105490847 4 Loss 
86 10 q26.13 126075966 126441375 3 Loss 
87 10 q26.3 132313905 132378860 3 Loss 
88 11 p15.4 6891286 7096779 14 Loss 
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89 11 p15.2 15082661 15264645 17 Loss 
90 11 p11.2 44437547 44539441 6 Loss 
91 11 p11.2 47893595 48121423 5 Loss 
92 11 p11.12 48944115 49070424 3 Loss 
93 12 p13.31 9384549 9422322 9 Loss 
94 12 p12.1 22759432 22774217 5 Loss 
95 12 p11.21 32871284 32871649 3 Loss 
96 13 q13.3 35929396 35931415 3 Loss 
97 14 q32.13 94629611 94761969 4 Loss 
98 15 q25.2 80236961 80256811 3 Loss 
99 16 p12.3 20392371 20452661 3 Loss 
100 16 q12.2 52028579 52120745 8 Loss 
101 16 q23.1 77238804 77312188 5 Loss 
102 17 p13.2 6467489 6545432 7 Loss 
103 17 q21.31 40108332 40203620 3 Loss 
104 17 q25.2 72587259 72587665 3 Loss 
105 18 p11.31 3481981 3529135 4 Loss 
106 18 p11.21 11047865 11076602 3 Loss 
107 18 p11.21 14045454 14366731 3 Loss 
108 18 q11.2 22831048 23078755 21 Loss 
109 18 q12.1 24863396 25073597 14 Loss 
110 18 q12.1 26787999 26882254 11 Loss 
111 18 q12.1 28924019 29032374 7 Loss 
112 18 q12.2 31115275 31540170 13 Loss 
113 18 q12.2 33315195 33343402 3 Loss 
114 18 q12.2 34298724 34478213 23 Loss 
115 18 q12.3 35619727 35754311 5 Loss 
116 18 q12.3 37819950 37868108 6 Loss 
117 18 q12.3 40488186 40757713 21 Loss 
118 18 q21.1 42108479 42164420 3 Loss 
119 18 q21.1 42395949 42511420 12 Loss 
120 18 q21.1 44832424 44856962 3 Loss 
121 18 q21.2 47042462 47215155 6 Loss 
122 18 q21.2 47667460 47696031 9 Loss 
123 18 q21.2 48280650 48441871 23 Loss 
124 18 q21.2 49520564 49631904 7 Loss 
125 18 q21.2 51382311 51580839 4 Loss 
126 18 q21.31 52034647 52168778 9 Loss 
127 18 q21.31 53058117 53109592 4 Loss 
128 18 q21.32 54738782 54968185 6 Loss 
129 18 q21.32 56007912 56088439 5 Loss 
130 18 q21.33 57652168 57751306 8 Loss 
131 18 q21.33 59327546 59355930 5 Loss 
132 18 q22.1 60170704 60372949 5 Loss 
133 18 q22.2 65842500 65888907 3 Loss 
134 18 q22.2 66191637 66354674 8 Loss 
135 18 q22.2 66553842 67024727 23 Loss 
136 18 q22.3 67347147 67822242 41 Loss 
137 18 q22.3 68550968 69397065 44 Loss 
138 18 q22.3 69951244 70266824 23 Loss 
139 18 q22.3 70994152 71016186 4 Loss 
140 18 q22.3 71227937 71838706 54 Loss 
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141 18 q23 72178602 72424285 17 Loss 
142 18 q23 73276885 73561374 7 Loss 
143 18 q23 75586155 76068963 6 Loss 
144 19 q12 33775624 33798612 3 Loss 
145 19 q13.2 44776627 44778481 3 Loss 
146 19 q13.32 51019549 51019773 3 Loss 
147 19 q13.43 61752129 61780662 5 Loss 
148 20 p12.1 14989361 15021680 8 Loss 
149 20 q13.33 61608092 61871587 3 Loss 
150 21 q21.1 16486346 16587460 20 Loss 
151 21 q21.3 26056693 26182624 10 Loss 
152 21 q22.11 32665556 32791634 5 Loss 
153 21 q22.3 42696979 42871733 6 Loss 
154 21 q22.3 43159259 43305949 3 Loss 
155 21 q22.3 44280886 44369022 5 Loss 
156 22 q11.23 24208363 24272670 8 Loss 
157 22 q12.3 35094480 35179861 4 Loss 



































Appendix Table 3 Three hundred and forty-four copy number signature 
clusters comprising of gains (156) and losses (188) from 100K SNP mapping 





156 copy number gain 
clusters    
       
Cluster 







1 1 p36.12 20738915 20739322 3 Gain 
2 1 p34.3 37206210 37286493 3 Gain 
3 1 q42.13 228520666 228534898 5 Gain 
4 2 p25.3 1961809 1973066 3 Gain 
5 2 p25.1 8664645 8704056 3 Gain 
6 2 p25.1 10880978 10881050 3 Gain 
7 2 p24.2 17279050 17318510 3 Gain 
8 2 p16.3 48813041 48818526 4 Gain 
9 2 p16.1 60460075 60461621 3 Gain 
10 2 p11.2 85139960 85140030 3 Gain 
11 2 q21.1 129668043 129730459 3 Gain 
12 2 q31.1 174126434 174151854 3 Gain 
13 2 q32.1 184738190 184738583 3 Gain 
14 2 q33.1 200811696 200812005 3 Gain 
15 2 q33.1 201324390 201324635 3 Gain 
16 2 q35 216538062 216538359 3 Gain 
17 3 p21.33 43800707 43927637 3 Gain 
18 3 q26.2 169925021 169936880 3 Gain 
19 4 p15.32 15348488 15348596 3 Gain 
20 4 p15.31 21407323 21407541 3 Gain 
21 4 p14 38001500 38012269 3 Gain 
22 4 q12 54112431 54122682 3 Gain 
23 4 q13.3 74575464 74666356 4 Gain 
24 4 q13.3 75005492 75054231 3 Gain 
25 4 q21.1 78592907 78597464 3 Gain 
26 4 q21.21 79403302 79403618 4 Gain 
27 4 q22.1 90109807 90110221 3 Gain 
28 4 q24 104431580 104431682 3 Gain 
29 4 q31.23 148426376 148428078 3 Gain 
30 4 q31.23 148955028 148955314 3 Gain 
31 4 q31.3 152398761 152440901 3 Gain 
32 4 q34.3 182586362 182586736 3 Gain 
33 5 p15.31 6776950 6802841 6 Gain 
34 5 p13.2 38227455 38228496 3 Gain 
35 5 q11.2 55865081 55865543 3 Gain 
36 5 q11.2 58337160 58337541 4 Gain 
37 5 q14.3 83343343 83343740 3 Gain 
38 5 q14.3 86439719 86448235 3 Gain 
39 5 q15 95987585 95988173 3 Gain 
40 5 q23.1 116882396 116882974 3 Gain 
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41 5 q32 145904477 145905128 4 Gain 
42 5 q34 166312350 166334875 3 Gain 
43 5 q35.3 179912908 180003855 3 Gain 
44 6 q14.1 76664000 76664374 3 Gain 
45 6 q14.1 77653677 77654354 3 Gain 
46 6 q16.1 93576978 93579206 3 Gain 
47 6 q16.3 103890051 103899825 4 Gain 
48 6 q22.2 117593304 117596029 3 Gain 
49 6 q22.2 117686278 117716222 3 Gain 
50 6 q22.2 117948652 117948822 3 Gain 
51 6 q22.2 118408965 118409533 3 Gain 
52 6 q25.2 153313545 153317018 4 Gain 
53 6 q25.2 154101663 154105599 3 Gain 
54 6 q27 166806486 166837330 3 Gain 
55 7 q11.22 69879234 69882225 3 Gain 
56 7 q11.23 75093569 75761928 3 Gain 
57 7 q21.11 77925692 77930610 4 Gain 
58 8 p23.2 4096472 4097308 3 Gain 
59 8 p23.2 5452120 5454564 4 Gain 
60 8 p23.1 6562926 6586856 4 Gain 
61 8 p23.1 9729951 9771474 3 Gain 
62 8 p23.1 10788398 10997905 3 Gain 
63 8 p22 13893788 13894314 3 Gain 
64 8 p22 15658508 15661232 3 Gain 
65 8 p22 18625487 18631584 5 Gain 
66 8 p22 19086240 19086599 3 Gain 
67 8 p21.3 19621163 19622020 3 Gain 
68 8 p21.3 21079131 21084241 3 Gain 
69 8 p21.3 21545216 21822047 5 Gain 
70 8 p21.2 26659740 26661577 3 Gain 
71 8 p21.2 27212419 27249840 4 Gain 
72 8 q12.1 56222422 56222761 3 Gain 
73 8 q21.11 77616148 77617339 3 Gain 
74 9 p24.3 854834 867871 3 Gain 
75 9 p21.1 30786478 30786759 3 Gain 
76 9 q21.33 89583169 89596368 3 Gain 
77 9 q22.31 93000939 93053838 3 Gain 
78 9 q32 114933308 114939138 3 Gain 
79 9 q32 115195249 115365320 4 Gain 
80 9 q33.2 122686309 122716303 3 Gain 
81 10 p13 12922421 12964665 3 Gain 
82 10 p13 15564168 15584083 4 Gain 
83 10 p12.33 17445147 17446150 3 Gain 
84 10 p12.33 17559724 17560294 3 Gain 
85 10 p12.1 26066521 26117594 4 Gain 
86 10 p11.22 32001828 32002577 3 Gain 
87 10 q11.21 43388564 43519372 3 Gain 
88 10 q11.21 43745581 43776722 3 Gain 
89 10 q21.1 56229725 56284751 3 Gain 
90 10 q21.3 71252461 71302472 3 Gain 
91 10 q23.2 87913935 88064787 5 Gain 
92 10 q25.1 106305233 106417556 3 Gain 
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93 10 q25.2 114722872 114903549 3 Gain 
94 10 q25.3 115140027 115183513 4 Gain 
95 10 q26.13 124204024 124204438 4 Gain 
96 11 p12 36484917 36582180 3 Gain 
97 11 p11.2 44743569 44755210 3 Gain 
98 11 q13.1 65684918 65748920 3 Gain 
99 11 q13.4 71975856 72051144 3 Gain 
100 11 q14.1 77447533 77450102 3 Gain 
101 11 q21 92931547 93032844 4 Gain 
102 11 q21 94590558 94629638 3 Gain 
103 11 q22.3 107179506 107217046 4 Gain 
104 11 q22.3 109474410 109571744 4 Gain 
105 11 q23.2 113544076 113577024 3 Gain 
106 11 q23.2 114299646 114437737 3 Gain 
107 11 q23.3 117462153 117475531 3 Gain 
108 11 q24.1 121454863 121489446 3 Gain 
109 12 p13.33 2369478 2370692 3 Gain 
110 12 q15 68653606 68653898 3 Gain 
111 12 q21.2 77376139 77376497 3 Gain 
112 12 q21.33 89647429 89648686 3 Gain 
113 12 q23.1 97298487 97306233 3 Gain 
114 12 q24.11 108158980 108174697 3 Gain 
115 12 q24.32 124883777 124901304 3 Gain 
116 13 q12.12 24139724 24162037 3 Gain 
117 13 q12.13 24517730 24518426 3 Gain 
118 13 q12.13 25502482 25513614 4 Gain 
119 13 q14.2 48722291 48722637 3 Gain 
120 13 q21.2 60085200 60098067 3 Gain 
121 13 q31.1 84006916 84007088 4 Gain 
122 13 q31.3 93112156 93144491 3 Gain 
123 13 q33.2 104796515 104796673 3 Gain 
124 13 q33.2 105346016 105346881 3 Gain 
125 13 q33.2 105706536 105706936 3 Gain 
126 14 q11.2 19950000 20000915 3 Gain 
127 14 q13.1 31968071 31989530 3 Gain 
128 14 q21.3 46801788 46802461 3 Gain 
129 14 q22.2 53461392 53515693 4 Gain 
130 14 q23.1 61019333 61025684 4 Gain 
131 14 q23.3 64839170 64935983 3 Gain 
132 14 q23.3 65850316 65950544 3 Gain 
133 14 q24.2 70289969 70482093 3 Gain 
134 14 q24.3 75590122 75683431 3 Gain 
135 14 q24.3 77144693 77220089 6 Gain 
136 14 q32.11 90239107 90240579 3 Gain 
137 15 q13.1 27330247 27330484 4 Gain 
138 15 q14 32876724 32878430 3 Gain 
139 15 q21.2 48338192 48339147 3 Gain 
140 15 q25.3 85907453 85915598 3 Gain 
141 15 q26.1 87402313 87434944 3 Gain 
142 16 p12.1 27519162 27853539 3 Gain 
143 16 q23.3 81910433 81910874 3 Gain 
144 16 q23.3 82313716 82313913 3 Gain 
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145 18 q23 71931096 71931615 3 Gain 
146 19 q13.2 46822616 46844069 3 Gain 
147 19 q13.33 56781296 56800742 5 Gain 
148 20 p13 2542190 2542502 3 Gain 
149 20 p12.2 9046090 9059336 3 Gain 
150 21 q22.11 31630312 31631306 3 Gain 
151 21 q22.11 33539599 33539959 4 Gain 
152 22 q11.21 16413199 16442987 3 Gain 
153 22 q12.3 31331354 31438536 5 Gain 
154 22 q12.3 35496620 35626482 3 Gain 
155 22 q13.1 36052836 36232658 3 Gain 




188 copy number loss 
clusters    
       
Cluster 







1 1 p32.3 54961773 54964232 3 Loss 
2 1 p32.3 56088245 56090422 3 Loss 
3 1 p32.2 56591611 56591760 3 Loss 
4 1 p31.1 70108245 70109124 3 Loss 
5 1 p22.1 93252779 93380900 3 Loss 
6 1 p21.2 101695024 101695897 3 Loss 
7 1 p21.1 102600719 102601411 3 Loss 
8 1 p13.3p21.1 106984739 107030604 3 Loss 
9 1 p13.3 107366604 107377922 3 Loss 
10 1 p13.3 107587951 107591031 3 Loss 
11 1 p13.3 107736169 107759809 3 Loss 
12 1 p12 119225550 119262919 3 Loss 
13 1 q21.3 150666679 150675085 3 Loss 
14 1 q23.3 159905154 159953885 3 Loss 
15 1 q23.3 160193803 160196385 3 Loss 
16 1 q24.2 167656477 167656951 3 Loss 
17 1 q24.3 170585922 170610669 3 Loss 
18 1 q25.1 171594944 171781578 3 Loss 
19 1 q25.3 183079885 183080508 3 Loss 
20 1 q31.1 184557144 184559426 3 Loss 
21 1 q31.1 185034615 185035629 4 Loss 
22 1 q31.1 186047074 186047447 3 Loss 
23 1 q31.3 192267576 192290240 3 Loss 
24 1 q31.3 196540984 196581381 3 Loss 
25 1 q32.1 202033018 202036514 3 Loss 
26 1 q43 235218861 235343721 3 Loss 
27 2 p24.1 22606730 22620996 3 Loss 
28 2 p22.3 34418090 34422280 3 Loss 
29 2 p22.3 35626263 35632935 3 Loss 
30 2 p22.1 39068325 39080567 4 Loss 
31 2 p22.1 39761857 39795293 3 Loss 
32 2 p21 44515550 44523280 3 Loss 
33 2 p21 45503401 45522569 3 Loss 
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34 2 p21 45584043 45592047 3 Loss 
35 2 p16.3 49073584 49076652 7 Loss 
36 2 p16.3 50620492 50682535 3 Loss 
37 2 p16.2 54401665 54412518 3 Loss 
38 2 p16.1 55886056 55887839 4 Loss 
39 2 p14 68033567 68044190 3 Loss 
40 2 p14 68423965 68424276 3 Loss 
41 2 p13.2 73627011 73712555 4 Loss 
42 2 p12 79816821 79817082 4 Loss 
43 2 p12 79935726 79973743 3 Loss 
44 2 p12 80665210 80695809 4 Loss 
45 2 p12 81060791 81061153 4 Loss 
46 2 p12 82127678 82161982 3 Loss 
47 2 p11.2 86537153 86693041 4 Loss 
48 2 q11.2 99362597 99383281 3 Loss 
49 2 q11.2 100431642 100455415 4 Loss 
50 2 q14.1 115972968 116000605 3 Loss 
51 2 q14.1 118114972 118115612 3 Loss 
52 2 q21.3q22.1 136526876 136693406 3 Loss 
53 2 q22.1 137594293 137595517 4 Loss 
54 2 q22.1 137606935 137647889 3 Loss 
55 2 q23.3 151206344 151207529 4 Loss 
56 2 q23.3 151211136 151212250 6 Loss 
57 2 q24.3 164694817 164695220 3 Loss 
58 2 q31.1 171503406 171505480 3 Loss 
59 2 q31.1 174245761 174419674 3 Loss 
60 2 q31.1 176998582 177023453 4 Loss 
61 2 q31.2 179077228 179135782 3 Loss 
62 2 q31.3 181111709 181148326 3 Loss 
63 2 q32.1 183383739 183409146 4 Loss 
64 2 q32.1 184203706 184222476 3 Loss 
65 2 q32.1 186375605 186400894 3 Loss 
66 2 q32.3 191875344 191876006 3 Loss 
67 2 q33.1 199875181 199888440 3 Loss 
68 3 p22.1 41805646 41807002 3 Loss 
69 3 p14.2 59881001 59929729 3 Loss 
70 3 p14.2 61227509 61247813 3 Loss 
71 3 p12.3 78021008 78170155 3 Loss 
72 3 q11.2 98415433 98614614 3 Loss 
73 3 q13.11 107384047 107468796 4 Loss 
74 3 q13.13 110954324 110978719 3 Loss 
75 3 q13.2 113964422 113964812 3 Loss 
76 3 q21.3 127802414 128048537 5 Loss 
77 3 q24 145045375 145052742 3 Loss 
78 3 q25.1 150552916 150588416 3 Loss 
79 3 q26.1 163719579 163720363 3 Loss 
80 3 q28 190137289 190144645 3 Loss 
81 3 q28 192463491 192465119 3 Loss 
82 4 p15.2 26864751 26890000 3 Loss 
83 5 p15.32 4587191 4685694 4 Loss 
84 5 p15.31 7959576 7959907 3 Loss 
85 5 p15.2 8226210 8226612 3 Loss 
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86 5 p15.2 8920419 8936365 3 Loss 
87 5 p15.1 15163638 15164809 3 Loss 
88 5 p14.2 23715139 23740353 3 Loss 
89 5 p14.1 25553133 25556718 4 Loss 
90 5 p13.3 29987341 29988931 4 Loss 
91 5 p13.2 37472354 37473605 3 Loss 
92 5 q12.1 62635028 62646270 3 Loss 
93 5 q21.1 100155803 100166961 3 Loss 
94 5 q21.3 109418299 109419129 3 Loss 
95 5 q22.1 110565125 110565496 3 Loss 
96 5 q22.1 111276231 111277509 3 Loss 
97 5 q22.1 111384806 111397791 3 Loss 
98 5 q23.1 115250934 115264589 3 Loss 
99 5 q23.1 115395255 115407541 3 Loss 
100 5 q23.1 116078047 116078486 3 Loss 
101 5 q23.1 121470160 121475977 3 Loss 
102 5 q23.2 124520103 124521223 3 Loss 
103 5 q23.2 124839791 124854142 3 Loss 
104 5 q31.2 138249888 138250893 3 Loss 
105 5 q32 143686326 143765883 4 Loss 
106 5 q33.1 147460749 147461278 3 Loss 
107 5 q33.1 150237584 150278081 3 Loss 
108 5 q34 163557294 163663585 3 Loss 
109 5 q34 163821858 163826956 3 Loss 
110 5 q34 163839299 163841167 4 Loss 
111 5 q34 165587273 165587631 3 Loss 
112 5 q34 166725442 166726164 3 Loss 
113 5 q34 167329617 167330191 3 Loss 
114 5 q35.1 171318279 171318906 3 Loss 
115 6 p24.3 8355535 8362520 3 Loss 
116 6 p24.1 13245751 13255521 3 Loss 
117 6 p23 14707390 14722047 3 Loss 
118 6 p22.3 22223919 22224130 4 Loss 
119 6 p12.1 55299182 55301240 3 Loss 
120 7 p21.3 7868035 7876424 3 Loss 
121 7 p21.3 11881768 11887830 5 Loss 
122 7 p21.3 12191632 12193353 3 Loss 
123 7 p15.3 20404531 20405878 3 Loss 
124 7 p15.3 21233963 21258403 3 Loss 
125 7 p15.3 21720682 21721131 3 Loss 
126 7 p15.3 24319597 24320032 3 Loss 
127 7 p15.2 25579186 25580668 3 Loss 
128 7 q11.21 63477213 63509775 3 Loss 
129 7 q21.11 78409695 78465943 3 Loss 
130 7 q21.11 78586577 78619708 3 Loss 
131 7 q31.1 107710067 107710367 3 Loss 
132 7 q31.1 111347283 111409773 3 Loss 
133 7 q31.32 120900361 120900906 3 Loss 
134 7 q32.3 132190810 132269295 5 Loss 
135 7 q33 135491147 135496333 3 Loss 
136 7 q33 135518370 135529672 3 Loss 
137 7 q33 135662894 135668473 5 Loss 
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138 7 q34 141356163 141357334 3 Loss 
139 7 q34 142424616 142527674 3 Loss 
140 7 q35 144471628 144472464 3 Loss 
141 7 q35 145408676 145413357 3 Loss 
142 7 q35 145688576 145721134 3 Loss 
143 7 q35 145918484 145938758 4 Loss 
144 7 q35 146019876 146020192 4 Loss 
145 7 q35 146704296 146705374 5 Loss 
146 8 q21.3 88516372 88583031 3 Loss 
147 8 q23.1 108295504 108341035 3 Loss 
148 8 q23.2 110893215 110894914 3 Loss 
149 8 q23.3 113182169 113288437 3 Loss 
150 8 q23.3 116030810 116058634 4 Loss 
151 8 q23.3 116588010 116606233 5 Loss 
152 8 q24.12 122109958 122110132 3 Loss 
153 8 q24.21 127309835 127321416 3 Loss 
154 10 p11.21 34666119 34667378 3 Loss 
155 10 q21.2 64395976 64429416 3 Loss 
156 10 q25.1 105719877 105753614 3 Loss 
157 11 p15.4 4882509 4882941 3 Loss 
158 11 p15.1 21149961 21150193 3 Loss 
159 11 p14.2 26738250 26832756 3 Loss 
160 11 q14.2 86029148 86031568 3 Loss 
161 12 p13.33 1095178 1103563 3 Loss 
162 12 p12.3 16760416 16770504 4 Loss 
163 12 p12.3 19802538 19802796 3 Loss 
164 12 p12.1 22246188 22324903 3 Loss 
165 12 q14.3 65442292 65442841 3 Loss 
166 12 q14.3 65548901 65552057 3 Loss 
167 12 q14.3 65583191 65584285 3 Loss 
168 12 q15 68277894 68281593 3 Loss 
169 12 q21.31 80125595 80179992 3 Loss 
170 12 q21.33 87988442 87998934 3 Loss 
171 12 q23.2 101538831 101561177 3 Loss 
172 12 q23.3 106932687 106932975 3 Loss 
173 12 q24.33 129433601 129434280 3 Loss 
174 14 q12 30265621 30266711 3 Loss 
175 15 q11.2 19852868 19915944 3 Loss 
176 15 q21.2 49766074 49767401 3 Loss 
177 15 q21.3 51159739 51173102 5 Loss 
178 15 q21.3 51721345 51725856 3 Loss 
179 15 q25.2 81959475 81992067 3 Loss 
180 16 q21 58228520 58263439 3 Loss 
181 16 q21 62684552 62685068 3 Loss 
182 16 q23.1 73761944 73762403 3 Loss 
183 16 q23.3 80694610 80695143 3 Loss 
184 17 q22 48190536 48225948 3 Loss 
185 17 q24.2 64386865 64413279 3 Loss 
186 18 p11.31 4137742 4172980 3 Loss 
187 19 q12 33008112 33056542 3 Loss 
188 21 q22.2 38827677 38832550 3 Loss 
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Appendix Table 4 Percentage of GC cell lines (n=17) having a misexpression 
in the 63-gene set. Shown in green were down-regulated genes compared to 
NCI-60 panel and in red, up-regulation.   
 
Genes Gene description 
%  
of GCs Cytobands 
GUCY1B3 Guanylate cyclase 1, soluble, beta 3 94.1 4q31.3-q33 
IGFBP5 Insulin-like growth factor binding protein 5 82.4 2q33-q36 
ITGA4 
Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor) 70.6 2q31.3 
LZTS1 Leucine zipper, putative tumor suppressor 1 70.6 8p22 
GAS7 Growth arrest-specific 7 64.7 17p13.1 
GPM6B Glycoprotein M6B 64.7 Xp22.2 
VEGFC Vascular endothelial growth factor C 64.7 4q34.1-q34.3 
HIPK2 Homeodomain interacting protein kinase 2 64.7 7q32-q34 
WASPIP Wiskott-Aldrich syndrome protein interacting protein 58.8 2q31.1 
TRIM9 Tripartite motif-containing 9 58.8 14q22.1 
BNC2 Basonuclin 2 58.8 9p22.3-p22.2 
FOXG1B Forkhead box G1B 52.9 14q12-q13 
DISC1 Disrupted in schizophrenia 1 52.9 1q42.1 
MOXD1 Monooxygenase, DBH-like 1 52.9 6q23.1-23.3 
    
BLCAP Bladder cancer associated protein 88.2 20q11.2-q12 
JUP Junction plakoglobin 82.4 17q21 
RBM25 RNA binding motif protein 25 82.4 14q24.3 
*219881_s_at Unannotated gene 82.4 --- 
CHKA Choline kinase alpha 76.5 11q13.2 
SLC16A5 
Solute carrier family 16 (monocarboxylic acid transporters), 
member 5 76.5 17q25.1 
SFRS7 Splicing factor, arginine/serine-rich 7, 35kDa 76.5 2p22.1 
MARS Methionine-tRNA synthetase 76.5 12q13.2 
PRPF39 PRP39 pre-mRNA processing factor 39 homolog (yeast) 76.5 14q21.3 
CPSF1 Cleavage and polyadenylation specific factor 1, 160kDa 70.6 8q24.23 
MYO6 myosin VI 70.6 6q13 
CNOT3 CCR4-NOT transcription complex, subunit 3 70.6 19q13.4 
ZNF202 zinc finger protein 202 70.6 11q23.3 
C6orf111 chromosome 6 open reading frame 111 70.6 6q16.3 
BAT1 HLA-B associated transcript 1 70.6 6p21.3 
FLJ23322 hypothetical protein FLJ23322 70.6 22q12.3 
RNF41 ring finger protein 41 64.7 
12q13.2-
q13.3 
CREBZF HCF-binding transcription factor Zhangfei 64.7 11q14 
SPTAN1 spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 64.7 9q33-q34 
SUPT6H suppressor of Ty 6 homolog (S. cerevisiae) 64.7 17q11.2 
NCOA3 nuclear receptor coactivator 3 64.7 20q12 
C14orf120 chromosome 14 open reading frame 120 64.7 14q11.2 
FLJ11273 hypothetical protein FLJ11273 64.7 7p21.3 
FLJ21816 hypothetical protein FLJ21816 64.7 16p12.1 
NJMU-R1 protein kinase Njmu-R1 58.8 17q11.2 
CHD1 chromodomain helicase DNA binding protein 1 58.8 5q15-q21 
RAB35 RAB35, member RAS oncogene family 58.8 12q24.31 
PLA2G16 HRAS-like suppressor 3 58.8 
11q12.3-
q13.1 
PRKCI protein kinase C, iota 58.8 3q26.3 
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PNN pinin, desmosome associated protein 58.8 14q21.1 
C6orf111 chromosome 6 open reading frame 111 58.8 6q16.3 
KIAA0776 KIAA0776 58.8 6q16.1 
UCKL1 uridine-cytidine kinase 1-like 1 58.8 20q13.33 
UGCGL2 UDP-glucose ceramide glucosyltransferase-like 2 58.8 13q32.1 
TNFRSF25 tumor necrosis factor receptor superfamily, member 25 58.8 1p36.2 
MGC3329 hypothetical protein MGC3329 58.8 17p13.3 
EPRS glutamyl-prolyl-tRNA synthetase 52.9 1q41-q42 
CYB5-M outer mitochondrial membrane cytochrome b5 52.9 16q22.1 
LDLR 
low density lipoprotein receptor (familial 
hypercholesterolemia) 52.9 19p13.3 
EI24 translokin 52.9 11q21 
CENTG2 centaurin, gamma 2 52.9 2p24.3-p24.1 
ABCC3 
ATP-binding cassette, sub-family C (CFTR/MRP), member 
3 52.9 17q22 
SYNCRIP 
synaptotagmin binding, cytoplasmic RNA interacting 
protein 52.9 6q14-q15 
OGT 
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-
N-acetylglucosamine 52.9 Xq13 
STXBP2 syntaxin binding protein 2 52.9 
19p13.3-
p13.2 
BRAP BRCA1 associated protein 52.9 12q24 
SF1 splicing factor 1 52.9 11q13 
ETEA expressed in T-cells and eosinophils in atopic dermatitis 52.9 5q35.2 
FNBP3 formin binding protein 3 52.9 2q23.3 

































Appendix Table 5 Differentially expressed 42-gene set segregating 10 GC cell 
lines based on their 18q aberrant status. 
 
Genes Cytoband   Genes Cytoband 
CABLES1 chr18q11.2   SERPINB13 
chr18q21.3-
q22 
LAMA3 chr18q11.2   SERPINB3 chr18q21.3 
TAF4B chr18q11.2   SERPINB4 chr18q21.3 
KCTD1 chr18q11.2   SERPINB2 chr18q21.3 
CHST9 chr18q11.2   SERPINB8 chr18q21.3 
DSC3 chr18q12.1   LOC400654 chr18q22.1 
B4GALT6 chr18q11   CDH7 chr18q22-q23 
KLHL14 chr18q12.1   CDH19 chr18q22-q23 
C18orf34 chr18q12.1   DOK6 chr18q22.2 
ZNF396 chr18q12   CD226 chr18q22.3 
LOC284263 chr18q21.1   SOCS6 chr18q22.2 
C18orf25 chr18q21.1   NETO1 chr18q22-q23 
SMAD2 chr18q21.1   LOC400655 chr18q22.3 
SMAD4 chr18q21.1   C18orf55 chr18q22.3 
DCC chr18q21.3   ZADH2 chr18q22.3 
MBD2 chr18q21   MBP chr18q23 
ONECUT2 
chr18q21.1-
q21.2   GALR1 chr18q23 
ATP8B1 chr18q21.31   NFATC1 chr18q23 
NEDD4L chr18q21   ORF1 chr18q23 
ZNF532 chr18q21.32   CTDP1 chr18q23 












































Appendix Figure 1 GC Cell line: AGS  
 
Karyotype: 47-50<2n>, XX[11], der(8)t(1;8)(q12;p22)[11], t(8;10)(?;p13)[5], i(13)(q10)[6], +13[3], +14[8], del(18)(q11.2)[8], -18[3], 




































Appendix Figure 2 GC Cell line: SNU-1 
 




































Appendix Figure 3 GC Cell line: NCI-N87 
 
Karyotype: 42-44<2n>, XYY [8], t(1;5)(p36.1;?)[6], der(3)del(3)(p24)ins(3;8)(p12;?)[10], -4, t(5;19)(p13;?q)[4], 




















Appendix Figure 4 GC Cell line: SNU-5 
 
Karyotype: 68~92<3n>, XX[9], +t(X;15)(p11.2;q10)[9], der(1)(1;5)(p36.1;?)[9], +der(1)(1;5)(p36.1;?)[7], der(1)t(1;8)(p36.1;q23)[10], 
+der(1)t(1;8)(p36.1;q22)[9], +der(2)t(2;3)(p22;q22)x3[10], +3[7], +t(4;13)(q32;q22)x2[9], +der(4)del(4)(q25)ins(4;13)(q12;?)[5], 
+del(5)(p)[10], +5x2[8], del(6)(q24)x2[10], +der(7)t(3;7)(q22;q31)x2[10], +der(7)t(4;7)(q28;q31)x2[10], +7x2[9], +der(8)ins(8;1)(q23;?)[5], 
der(9)t(2;15;9)(?;q10;p12)[9], +10[9], +11x2~3[10], +12x1~2[7], +t(13;18)(q22;q21)[8], +14[8], +t(9;15)(p12;q10)[10], +16x2[10], 



















Appendix Figure 5 GC Cell line: SNU-16 
 
Karyotype: 57~92<4n>, XXX[6], XXXX[3], +1x2[7], +2x2[8], +3[8], +der(4)t(4;21)(p12;q11.2)[10], +der(5)t(5;11;10)(q12;?p;?)[6], 
+i(5)(p10)x1~3[10], +5[3], +der(6)del(p21.1p21.3)del(6)(q22)[3], +6[6], +7x2~4[9], +8[8], +9[9], +del(10)(q21)[10], +del(10)(p10)[2], 
+10[2], +der(11)t(1;11)(p33;p14)[8], +11[8], +del(12)(p11.2)x1~3[10], +der(13)t(8;13)(q11.2;q12)[4], +13[9], +14x1~4[9], +15x1~2[9], 




































Appendix Figure 6 GC cell line: Kato III 
 
Karyotype: 74~84<4n>, XXX[12], +1[8], +del(2)(?)[10], +del(3)(p21)[12], +3x2[12], +4[12], +5[8], +6x2[10], +7x1~3[12], 
+der(7)t(7;11)(q21;q13)[11], +8x2[11], +9x2[11], +10[11], +i(11)(q10)[12], +der(11)hsr(11;10)(q13;q?)[11], +der(12)t(2;12)(q23;q14)[9], 
+12[8], +13x2[12], +14[10], +i(15)(q10)[12], +16x2[12], +dup(17)(q12)[10], +17x2~3[12], +18[8], +19[7], +dup(20)(q13.1qter)[11], 




































Appendix Figure 7 GC Cell line: Hs 746T 
 
Karyotype: 68~73<3n>t(X;10)(p10;p10), t(X;18;2)(q22;q21;?), Y, t(1;2;7)(q10;q10;q32;q31), t(1;5;4;X)(q10;p10;?;?), +t(2;7)(q32;q31), 
t(2;16)(q10;p10), +t(2;17)(p10;p10), +3, t(3;19)(p10;p10), t(3;8)(q10;q10), dic(4;9)(4p15.2;p23)x2, +t(1;4)(q21;q32), +5, t(5;22)(p10;q10), 
t(5;9)(q10;p10), +6, t(6;11)(p21.1;q13)dup(11)(q13), t(7;16)(p10;p10)x2, +t(1;7)(p10;q10)dup(7)(q31), +t(10;7;22)(?;p22;q31;?), 
+t(2;7;11;8)(q31;q32;?;p22), +t(16;20;8)(q22;?;q12), +9, t(3;10)(?;q25)hsr(10)(q24), t(12;11)(p10;q10), t(10;12)(q11.2;p13), 
t(12;16)(p10;q10), t(11;13)(p10;q10), t(14;22)(q10;q10), t(10;22;14)(?;q10;q10), +t(14;22;3)(q10;q10;q13;?), t(6;14)(q10;q10), 





































Appendix Figure 8 GC Cell line: IM95 
 




































Appendix Figure 9 GC Cell line: MKN7 
 
Karyotype: 61~70<3n>, XXY[10], inv(1q12)[11], +3[11], t(3;4)(?;p15.1)[9], t(4;7)(p15.1;?)[10], +5[10], , del(6)(q24)[4], t(1;6)(q25;q25)[11], 
+t(7;15)(q21;q15)[10], t(8;17)(p10;p10)[10], t(8;17)(q10;p10)x3[11], der(9)t(2;9;12)(q21;q21;?)[11], t(20;9;8)(?;q31;?)[10], 
der(11)t(13;11)(q12;p13)ins(11;19)(q13;q13.1qter)[8], +11[11], +11[10], del(12p)x2[11], +i(12p)[11], +t(12;17)(p10;p10)[10], 
t(20;1;13)(?;?;q10)[11], +t(19;14)(q10;q10)x2[11], +14[10], i(15q)[10], -15[3], t(1;16)(?;q12)[9], t(7;16)(?p;q22)[10], t(17;20)(q10;p10)[10], 




































Appendix Figure 10 GC Cell line: FU97 
 
Karyotrype:103~160<5n>, XXx2~4[19], t(X;3)(p10;?)x2[19], t(X;17)(p10;q12)dup(17)(q12)x2[18], t(X;22)(p10;q12)[16], 
+der(3)t(3;12)(q10;p10)x3[19], +der(3)t(3;20)(p10;q10)x3[19], +der(3)t(3;6)(p14;?)ins(3;20)(p12;q11.2)[19], +3[17], +mar(4)x2[17], +4[17], 
+4[17], +4[15], +mar(5)x2[19], +5[19], +5[17], +5[16], +5[8], +6[19], +6[19], +6[18], +6[16], +7[19], +7[19], +7[19], +7[18], +7[16], 
del(8)(q24.1)x4[18], +8[19], +8[9],+9[18], +9[18], +9[13], +mar(10)[18], +10[18], +10[17], +10[17], +10[12], 
+der(11)t(11;15)(p12;q24)x2[16], +der(11)t(11;19)(q10;p10)x2[18], +11[18], +11[17], +der(12)t(12;22)(p10;q10)[17], +12[19], +12[19], 
+12[17], +12[15], +12[13], +13[19], +13[17], +13[17], +13[12], +13[8], +14[17], +14[12], +15[18], +15[18], +15[15], +15[10], 
+der(16)t(11;16)(?;?p13.3)x3[13], +16[19], +16[17], +16[8], +16[6], i(17q10)t(17;3)(q25;?)x2[10], +der(18)t(8;18)(q22;q21)x2[19], +18[18], 





































Appendix Figure 11 GC Cell line: YCC1 
 
Karyotype: 59~66<3n>, X[10], mar(X)[10], +del(1p)(36.1)[10], +der(1)t(1;5)(q10;?)[5], +del(2)(p22)[10], +der(3)t(3;5)(q10;p10)[7], 
+der(3)t(3;12)(p21;?p)[10], der(6)t(6;10)(q24;p13)[9], +dup(7)(q31)[10], +t(6;8)(p10;q10)x2[10], +8[10], del(9)(q21)[10],+mar(9)[9], 
+mar(10)[5], t(8;11)(q22;q23)[10], +t(11;17)(p13;q21)[10], t(10;12)(q10;q10)[10], t(9;13)(q31;q10)[9], +i(13)(q10)t(X;13)(?;q32)[10], 
+t(9;14)(q31;q10)[10], +t(6;15)(?p;q10)[10], +15[5], t(19;16)(?;q10)[5], +t(1;17)(p10;q10)dup(17q21)[10], +t(7;18)(?;?)[9], +19[6], 




































Appendix Figure 12  GC Cell line: YCC2 
 
Karyotype: 81~86<4n>, XX[7], X[3], i(X)(p)[3], i(16p)t(Y;16)(q11.2;q13)[10], +1[9], t(1;2)(q12;p24)[8], +t(2;5)(q12;p12)x2[10], 
+der(2)t(2;19)(q10;p10)x2[10], del(3)(?p)x2[10], +der(3)t(2;3)(?;q10)[10], +der(3)t(21;13;3)(q10;q22;q13.2)[10], +der(3)t(3;10)(q10;p10)[9], 
der(4)t(4;2;8)(q10;q36;?)[10], inv(5)(pterq12)[10], +der(5)t(3;5)(?;p15.1)[10], der(6)t(6;12)(p10;?)x2[9], +der(6)t(6;18)(p22;q21)[10], 
+del(6)(p11.2pter)[5], der(6)t(6;4;5)(q10;q10;?)[10], +der(7)t(7;8)(q36;q22)[10], +der(8)t(4;8)(q25;q24.1)[10], der(8)t(8;13)(q24.1;?)[10], 
del(8)(q24.1)[9], +9[6], +der(10)t(10;14)(q10;?)[8], +del(11)(q23qter)x3[10], der(12)t(22;8;12)(?;?;p13)[9], inv(12)(q14)ins(8;12)(?;q14)[7], 
+13[10], der(13)t(18;19;13)(q10;q10;q31)[8], +14[10], +der(14)t(14;19)(q10;q10)x2[7], der(15)t(7;15)(q10;q10)[10], 
der(15)t(11;15)(q10;q10)x2[10], +der(15)t(12;15)(?p;q10)x3[10], der(16)t(2;16)(?;q21)[10], der(16)t(16;20)(q10;p10)[8], 




































Appendix Figure 13 GC Cell line: YCC3 
 
Karyotype: 61~67<3n>, der(X)t(X;15)(p21;q22)x2[20], +der(1)t(1;6)(p21;?)del(1)(q25)[20], +2[16], +3[20], +3[20], +5[19], 
t(6;18)(p22;q21)[20], t(7;17)(p10;p10)x3[20], t(7;17)(q10;q10)x2[20], +8[18], +del(8)(p21)[19], der(10)t(10;13)(q10;q21)[19], 
+der(10)t(10;19)(p10;q10)[18], +der(11)t(7;11)(?;q23)dup(11)(p14pter)[20], +t(12;13)(q10;q21)[20], i(13)(q10)dup(13)(q21)[20], 
t(13;22)(q10;q10)[20], +14[20], +14[20], der(15)t(13;15)(?;q24)[19], der(16)t(4;16)(q10;q10)del(4)(q32), 





































Appendix Figure 14 GC Cell line: YCC6 
 
Karyotype: 57~71<3n>, XX[10], XXX[3], +t(1;11)(p21.1;q10)x1~2[17], +t(1;13)(q10;q10)x1~2[17], +2[16], +del(3)(p11)[17], 
+del(3)(p11)[14], +del(4)(q28.3)[14], +5[17], +del(5q)(31)[2], +6[15], +der(6)t(1;6)(p10;?q25)[17], +dup(7q)(q21q22)[16], 
+t(7;11)(q10;q10)[16], +9[10], +i(10q)[16], +der(12)t(12;18)(q24.2;?q)[14], +13[10], +der(14)t(21;14;12)(q10;q32;?p)[17], +15[12], +16[11], 




































Appendix Figure 15 GC Cell line: YCC9 
 
Karyotype: 38~41<2n>, X[24], del(3)(p12p24)[22], der(4)t(9;6;4)(p12;?;p15.1)[24], t(4;6)(p15.1;q24)[23], del(7)(q21)[24], 
t(3;7)(?p24;q31)[23], i(8)(q)[22], del(9)(?p12)[23], t(9;Y)(q10;q10)[24], der(14)i(14)(q10)t(3;14)(q13.2;q21)[23], t(17;22)(q24;q12)[24], -




































Appendix Figure 16 GC Cell line: YCC11 
 
Kayotype: 78~91<4n>, XX[11], +del(1)(q25)[9], +der(1)t(1;20)(p13;q12)x2[11], der(1)t(1;20)(p13;q12)dup(1q)[9], 
+der(1)t(1;15)(q44;q12)ins(1)(q12q31)[11], t(2;6)(p22;p12)x2[11], +mar(2)[9], +mar(2)[9], +t(3;7)(q10;q10)[11], +dup(4)(q25)[11], +5[11], 
+5[11], +5[10], t(7;8)(p22;q24.1)[8], t(7;8)(p22;q24.1)x2[11], +der(7)t(7;8;15)(p22;q24.1;q12)[10], +8[10], +8[9], +der(9)t(9;20)(q10;q10)[8], 
+9[11], +9[7], +10[11], +10[11], +11[11], +t(10;12)(p10;q10)del(12)(q22)[9], t(12;21)(q10;q10)[9], der(13)t(2;13)(p10;q10)x2[11], 
+der(13)t(2;13)(p10;q10)inv(13;2)(q22;p13)[9], +14[9], der(15)t(15;7)(pterq12;q33)x2~3[11],+16[11], +16[9], +17[10], +17[6], 




































Appendix Figure 17 GC Cell line: YCC16 
 
Karyotype: 52-58<3n>, XXYY[24], +der(1)t(1;7)(q12;q31)[26], +dic(1;9)(p21;p21)[21], +del(1p)[22], +2[23], +5[5], 
der(7)(t(7;8)(p12;?q24)[25], der(9)t(7;9)(p14;p24)[24], inv(11)(q13)[26], +del(12)(p12pter)[26], +der(14)t(10;14)(q10;q10)[24], +15[25], 
der(16)t(7;16)(q11.2;q11.2)[23], +17[24], +20[20], cp[26] 
 
